close

supply chain

Medical supplies

Over $7 million in medical supplies donated to Ukrainian refugees

Following a request for medical supplies from Moldovan authorities, World Hope International (WHI), Lift Non-Profit Logistics, Globus Relief, Airlink and Flexport.org have teamed up to transport $7 million in humanitarian aid to more than 300,000 Ukrainian refugees.

Supplies were moved from Utah and flown in via a Boeing 747 from Chicago to Amsterdam where Flexport.org then arranged for trucking partners to transport the cargo to Moldova. Responding to the Moldovan authorities’ request for assistance required multi-faceted project coordination and experience in managing complex supply chains. This relief effort required specialized skills to source the requested supplies and transport them from Utah to Moldova via Chicago and Amsterdam.”

“In these difficult times, Moldova is helping Ukrainian refugees with needed shelter and assistance,” said Eugen Caras, Moldova’s Ambassador to the United States. “In this context, we greatly appreciate the efforts that our American friends have made to gather an impressive amount of medical supplies. This support will be used and distributed by the Ministry of Health for Ukrainian refugees in Moldova, and we are very grateful for this. .

“Airlink is thrilled to be part of this coalition of organizations that are using their resources and expertise to provide humanitarian assistance to Moldova for Ukrainian refugees,” said Steven J. Smith, President and CEO of Air link. “There are significant and growing supply chain challenges in the region, so partnership and coordination are essential to ensure that Ukrainian refugees receive the assistance they need.”

Shaimaa Al Wassiti, President of Globus Relief Humanitarian, added: “Globus Relief is equipped to meet the needs of all forms of medical care. are used in first response medical care.”

“The events unfolding in Ukraine and the escalation of violence in the region are beyond tragic on so many levels – and are quickly becoming one of the biggest refugee events of our lifetimes,” said John Lyon, CEO from WHI. “As we look for ways to scale up our support, we hope this week’s effort will have a big impact on those receiving these essential supplies.”

Susy Schöneberg, head of Flexport.org, said, “Humanitarian responses are incredibly complex and require a wide range of coordination from nonprofit organizations. By providing robust air cargo solutions and financial support, we aim to help our nonprofit partners focus on what they do best and respond immediately when disaster strikes.”

The partnership provided over 220,000 pounds of medical supplies to meet a need specifically requested by Moldova’s Ministry of Health.

read more
Medical products

Scoliosis Management Market 2022-2030, by Top Key Players – Aspen Medical Products, Boston Orthotics & Prosthetics, LA Brace, Charleston Bending Brace, Spinal Technology

The Scoliosis Management Market report is a perfect basis for people who are looking for comprehensive study and analysis of the Scoliosis Management Market. This report contains study and miscellaneous information which will help you to understand your niche and focus major market channels in the regional and global Scoliosis Management market. To understand the competition and take action based on your key strengths, market size, current and future years demand, supply chain information, business concerns, competitive analysis and prices as well as supplier information will be presented to you. The report also includes information about the major market players, Scoliosis Management applications, its type, trends and overall market share.

To put your business plan into action based on our detailed report, you will also receive comprehensive and accurate forecasts and projected figures for the future. This will provide an overview of the market and help design solutions to leverage key profitable elements and gain market clarity to develop strategic plans. The data present in the report comes from different publications in our archives as well as many reputable paid databases. Moreover, the data is gathered with the help of dealers, raw material suppliers, and customers to ensure that the end result covers every minute detail regarding the Scoliosis Management market, making it a perfect tool for serious buyers of this study.

Scoliosis Management Market: Competition Landscape

The Scoliosis Management Market report includes information on product launches, sustainability, and outlook from key vendors including: (Aspen Medical Products, Boston Orthotics & Prosthetics, LA Brace, Charleston Bending Brace, Spinal Technology, Inc., Optec USA, Inc., Pro-Tech Orthopedics, DJO Global, UNYQ, Lawall Prosthetics and Orthotics, Chaneco, Trulife, Össur, Ortholutions GmbH & Co. KG, Ottobock)

Click the link for a free sample report @ https://crediblemarkets.com/sample-request/scoliosis-management-market-385291?utm_source=Amruta&utm_medium=SatPR

Scoliosis Management Market: Segmentation

By types

Thoraco-lumbo-sacral orthosis (TLSO)
Sacral Lumbar Thoracic Cervical Orthosis (CTLSO)
Lumbosacral orthosis (OSL)
Scoliosis brace
Others

By apps

Online pharmacies
Hospitals & Clinics
Retail pharmacies

Scoliosis Management Market: Regional Analysis

The whole regional segmentation has been studied based on recent and future trends, and the market is forecast through the forecast period. The countries covered in the regional analysis of the Global Scoliosis Management Market report are USA, Canada & Mexico North America, Germany, France, UK, Russia , Italy, Spain, Turkey, Netherlands, Switzerland, Belgium and the rest of Europe in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, South Korea, Rest of Asia Pacific (APAC) in Asia Pacific (APAC), Saudi Arabia, United Arab Emirates, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as part of the Middle East and Africa (MEA), and Argentina, Brazil and the rest of South America as part of South America.

Key benefits of the report:

  • This study presents the analytical representation of the global Scoliosis Management industry together with current trends and future estimations to determine impending pockets of investment.
  • The report presents information related to key drivers, restraints, and opportunities, along with a detailed analysis of the global Scoliosis Management market share.
  • Current market is quantitatively analyzed from 2021 to 2028 to highlight the growth scenario of the global Scoliosis Management market.
  • Porter’s five forces analysis illustrates the power of buyers and suppliers in the marketplace.
  • The report provides a detailed analysis of the Global Scoliosis Management Market based on the competitive intensity and how the competition will shape in the coming years.

Directly buy this market research report now @ https://crediblemarkets.com/reports/purchase/scoliosis-management-market-385291?license_type=single_user;utm_source=Amruta&utm_medium=SatPR

Main points covered in the table of contents:

Market overview: It includes six sections, research scope, key manufacturers covered, market fragments by type, Scoliosis Management market shares by application, study objectives and years considered.

Market landscape:Here, the global Scoliosis Management market opposition is dissected, by value, revenue, transactions, and pie slice by organization, market rate, fierce circumstances Latest landscape and patterns, consolidation, development, obtaining and parts of the entire industry from top organizations.

Manufacturer Profiles: Here, the driving players of the global Scoliosis Management market are considered dependent on region of deals, key elements, net benefit, revenue, cost, and creation.

Market Status and Outlook by Region: In this segment, the report examines net benefit, transactions, revenue, creation, global industry share, CAGR and market size by region. Here, the Global Scoliosis Management Market is thoroughly examined based on regions and countries like North America, Europe, China, India, Japan, and MEA.

Application or end user: This segment of the exploration study demonstrates how extraordinary end-customer/application sections are added in the global Scoliosis Management market.

Market forecast: Production side : In this part of the report, the creators focused on the conjecture of creation and creation esteem, the gauge of the main manufacturers and the estimation of the creation and creation esteem by type .

Research results and conclusion: This is one of the last segments of the report where the findings of the investigators and the end of the exploratory study are given.

Answers to key questions in the report:

  • What will be the market development pace of the Scoliosis Management market?
  • What are the key factors driving the Global Scoliosis Management Market?
  • Who are the main manufacturers on the market?
  • What are the market openings, market risks and market outline?
  • – What are sales volume, revenue, and price analysis of top manufacturers of Scoliosis Management market?
  • Who are the distributors, traders and dealers of Scoliosis Management Market?
  • What are the Scoliosis Management market opportunities and threats faced by the vendors in the global Scoliosis Management Industries?
  • What are the deals, revenue, and value review by market types and uses?
  • What are the transactions, revenue and value review by business areas?

About Us

Credible Markets is a new era market research company with a firm grip on the pulse of global markets. Credible Markets has become a trusted source for business market research needs in a short period of time. We’ve partnered with leading market intelligence publishers and our report pool coverage spans all key industry verticals and thousands of micro-markets. The massive repository allows our clients to choose from recently released reports from a range of publishers who also provide in-depth analysis by region and country. Moreover, pre-booked research reports are among our best offers.

The collection of market intelligence reports is regularly updated to provide visitors with quick access to the latest market information. We provide round-the-clock support to help you reuse search parameters and benefit from a full range of reserved reports. After all, it’s about helping you make an informed strategic decision on purchasing the right report that meets all your market research demands.

Contact us

Credible market analyzes
99 Wall Street 2124 New York, NY 10005
E-mail: [email protected]

read more
Prescription drugs

Animal Prescription Drugs Market 2022-2030, by Top Key Players – Ourofino Saude Animal, Elanco Animal Health, Vetoquinol, Virbac, Dechra

The Animal Prescription Drugs Market report is a perfect basis for people who are looking for comprehensive study and analysis of the Animal Prescription Drugs Market. This report contains study and miscellaneous information which will help you to understand your niche and focus major market channels in the regional and global Animal Prescription Drugs Market. To understand the competition and take action based on your key strengths, market size, current and future years demand, supply chain information, business concerns, competitive analysis and prices as well as supplier information will be presented to you. The report also includes information about the major market players, Animal Prescription Drug applications, its type, trends and overall market share.

To put your business plan into action based on our detailed report, you will also receive comprehensive and accurate forecasts and projected figures for the future. This will provide an overview of the market and help design solutions to leverage key profitable elements and gain market clarity to develop strategic plans. The data present in the report comes from different publications in our archives as well as many reputable paid databases. Moreover, the data is collated with the help of dealers, raw material suppliers, and clients to ensure that the end result covers every detail regarding the Animal Prescription Drugs market making it a perfect tool for serious buyers of this study.

Animal Prescription Drugs Market: Competition Landscape

The Animal Prescription Drugs Market report includes insights into product launches, sustainability, and outlook from key vendors including: (Ourofino Saude Animal, Elanco Animal Health, Vetoquinol, Virbac, Dechra, MSD Animal Health, Boehringer Ingelheim, Zoetis, Ceva Sante Animale, Animalcare Group)

Click Link to Get Free Sample Copy of Report @ https://crediblemarkets.com/sample-request/animal-prescription-drugs-market-657793?utm_source=Amruta&utm_medium=SatPR

Animal Prescription Drugs Market: Segmentation

By types

oral-type
Smear type
Type of injection
Type of spray

By requests

Pet
Livestock

Animal Prescription Drugs Market: Regional Analysis

The whole regional segmentation has been studied based on recent and future trends, and the market is forecast through the forecast period. The countries covered in the regional analysis of the Global Prescription Animal Drugs Market report are US, Canada & Mexico North America, Germany, France, UK, Russia , Italy, Spain, Turkey, the Netherlands, Switzerland, Belgium and the rest of Europe. in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, South Korea, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Saudi Arabia, United Arab Emirates, South Africa, Egypt, Israel, the rest of the Middle East and Africa (MEA) as part of the Middle East and Africa (MEA), and Argentina, Brazil and the rest of the South America as part of South America.

Key benefits of the report:

  • This study presents the analytical description of the worldwide Animal Prescription Drugs industry together with the current trends and future estimations to determine the impending pockets of investment.
  • The report presents information related to key drivers, restraints, and opportunities, along with a detailed analysis of the global Animal Prescription Drugs market share.
  • Current market is quantitatively analyzed from 2021 to 2028 to highlight the growth scenario of the global Animal Prescription Drugs market.
  • Porter’s Five Forces analysis illustrates the power of buyers and suppliers in the marketplace.
  • The report provides a detailed analysis of the Global Animal Prescription Drugs Market based on the competitive intensity and how the competition will shape in the coming years.

Directly Buy This Market Research Report Now @ https://crediblemarkets.com/reports/purchase/animal-prescription-drugs-market-657793?license_type=single_user;utm_source=Amruta&utm_medium=SatPR

Main points covered in the table of contents:

Market overview: It includes six sections, research scope, key manufacturers covered, market fragments by type, Animal Prescription Drugs market shares by application, study objectives and years considered.

Market landscape:Here, opposition in the global Prescription Animal Drugs market is dissected, by value, revenue, transactions, and pie share by organization, market rate, fierce circumstances Most recent landscape and patterns, consolidation, development, obtaining and industry-wide portions of large organizations.

Manufacturer Profiles: Here, the driving players of the global Animal Prescription Drugs market are considered dependent on region of deals, key elements, net benefit, revenue, cost, and creation.

Market Status and Outlook by Region: In this segment, the report examines net benefit, transactions, revenue, creation, global industry share, CAGR and market size by region. Here, the global Animal Prescription Drugs Market is thoroughly examined based on regions and countries like North America, Europe, China, India, Japan, and MEA.

Application or end user: This segment of the exploration study demonstrates how extraordinary sections of end customers/applications are added to the global Animal Prescription Drugs market.

Market forecast: Production side : In this part of the report, the creators focused on the conjecture of creation and creation esteem, the gauge of the main manufacturers and the estimation of the creation and creation esteem by type .

Research results and conclusion: This is one of the last segments of the report where the findings of the investigators and the end of the exploratory study are given.

Answers to key questions in the report:

  • What will be the pace of market development of the Prescription Drugs for Animals market?
  • What are the key factors driving the global Animal Prescription Drugs market?
  • Who are the main manufacturers on the market?
  • What are the market openings, market risks and market outline?
  • What are sales volume, revenue, and price analysis of top manufacturers of Animal Prescription Drugs market?
  • Who are the distributors, traders and dealers of Animal Prescription Drugs market?
  • What are the Animal Prescription Drugs market opportunities and threats faced by the vendors in the global Animal Prescription Drugs Industries?
  • What are the deals, revenue, and value review by market types and uses?
  • What are the transactions, revenue and value review by business areas?

About Us

Credible Markets is a new era market research company with a firm grip on the pulse of global markets. Credible Markets has become a trusted source for business market research needs in a short period of time. We’ve partnered with leading market intelligence publishers and our report pool coverage spans all key industry verticals and thousands of micro-markets. The massive repository allows our clients to choose from recently released reports from a range of publishers who also provide in-depth analysis by region and country. Moreover, pre-booked research reports are among our best offers.

The collection of market intelligence reports is regularly updated to provide visitors with quick access to the latest market information. We provide round-the-clock support to help you reuse search parameters and benefit from a full range of reserved reports. After all, it’s about helping you make an informed, strategic decision on purchasing the right report that meets all your market research demands.

Contact us

Credible market analyzes
99 Wall Street 2124 New York, NY 10005
E-mail: [email protected]

read more
Medical products

Hot Extrusion Medical Products Market Trends by 2026 with Major Key Players – BASF Pharma, Formex, Omipa, Biogrund, AbbVie and Lubrizol

This global Hot Extrusion Medical Products Market is an attempt to analyze the global opportunities in the field of the global industry, its current capabilities and the potential of selected countries and regions in the market. The report to businesses and companies provides a better understanding of their ability to invest in the market. The report provides the most business-critical issues of the leading organizations in the Global Hot Melt Extrusion Medical Devices Market globally. The report aims to explain to market players the business outlook, key developments and drivers of the global hot melt extrusion medical products market.

The challenges and opportunities of the Hot Melt Extrusion Medical Products market are presented in the report. The report highlights critical value chain destinations of the global hot extrusion medical products market. The report also highlights issues and concerns of local and foreign market players and provides recommendations for policy makers and actions for industrials to grow in the global Medical Hot Melt Extrusion Products market. The report makes projections based on the current global economic scenario. The uncertainties and difficulties faced by the Hot Extrusion Medical Devices market players are included.

Request a sample report: https://www.orbisresearch.com/contacts/request-sample/6239962?utm_source=Sgir

Major Players of Global Hot Extrusion Medical Products Market:

AbbVie
Formex
BASF Pharmaceuticals
omipa
Biogrund
Lubrizol

Points covered in the Hot Melt Extrusion Medical Products Market report:

• Overview of the global hot melt extrusion medical products market by studying different segments.
• The employment contribution of the global hot melt extrusion medical products market to economies around the world.
• The economic contribution of the global hot melt extrusion medical products market to economies around the world.
• Key players’ marketing approaches to attract foreign markets for hot extrusion medical products.
• Domestic and global regulatory constraints faced by the Hot Extrusion Medical Products market players.
• Global and/or regional trends in the medical hot melt extrusion industry in selected countries.
• Financial information and capital market information of hot melt extrusion medical products are provided in the report.

Type of hot extrusion medical products industry includes:

Movies
Taste masking
Drug eluting devices
Others

Hot extrusion medical products industry applications consist of:

Research Laboratory
Contract manufacturing organization
Pharmaceutical companies

This report analyzes the recent Hot Melt Extrusion Medical Devices industry trends along with the production chain, consumption patterns, regional and international level business activities and other industry related fields. The report emphasizes the potential of the global hot extrusion medical products market in developed countries. The data used to study all the factors of the global hot extrusion medical products market uses data from 2010 to 2020 also considering the latest year for performing the analysis. The report compares the growth rates of the strongest segments and consumption and production patterns. The report provides a detailed study of the performance of major Hot Melt Extrusion Medical Products market on the domestic and global fronts. Additionally, the report highlights the countries with the greatest potential for future growth.

Investigate before accessing the report at: https://www.orbisresearch.com/contacts/enquiry-before-buying/6239962?utm_source=Sgir

Why Buy This Hot Melt Extrusion Medical Products Market Report?

• This report helps the Hot Melt Extrusion Medical Products market players to strengthen their market position, improve their business, reach markets and gain competitive advantages.
• The Hot Melt Extrusion Medical Products report focuses on the strategies implemented by manufacturers in their operations, purchasing, and supply chain management.
• The report leverages the capabilities of Hot Melt Extrusion Medical Devices market players to seize new opportunities.
• The report offers supply chain visibility to enable improvisation for Hot Melt Extrusion Medical Devices market players who wish to expand their business into new international markets.
• The Hot Melt Extrusion Medical Products report compares the growth rates of the strongest segments and consumption and production patterns.
• The supply chain visibility provided in this report aids in understanding the drivers of the Global Hot Melt Extrusion Medical Devices Market and helps them maintain their leading position in the Global Hot Melt Extrusion Medical Devices Market over the course of years of forecasting.

About Us:

Orbis Research (orbisresearch.com) is a one-stop-shop for all your market research needs. We have an extensive database of reports from leading publishers and authors around the world. We specialize in delivering customized reports according to our clients’ requirements. We have complete information about our publishers and therefore are sure of the accuracy of the industries and verticals of their specialization. This helps our clients map their needs and we produce the perfect market research required for our clients.

Contact us:

Hector Costello
Senior Manager – Client Engagements
Central Highway 4144N,
Suite 600, Dallas,
Texas – 75204, USA
Telephone number: United States: +1 (972)-362-8199 | IND: +91 895 659 5155
Email ID: [email protected]

Buy the full report at: https://www.orbisresearch.com/contact/purchase-single-user/6239962?utm_source=Sgir

read more
Medical products

This week’s big story: Stop banning medical product exports, report says

A new report from the National Academies of Sciences, Engineering and Medicine in the United States calls for an international treaty to prevent countries from banning exports of medical products, in a bid to prevent supply shortages.

The paper, called Strengthen the resilience of the country’s medical product supply chains, cites the restrictions that a number of countries have imposed on the export of medical products during the pandemic. Many of these still remain, as according to the World Trade Organization (WTO), 45 countries still had more than 70 restrictions in place in 2021, many of which applied to medical products.

The authors of the article go on to warn that export restrictions “can be dangerously counterproductive. What makes sense in an isolated emergency can be seriously detrimental in a global crisis.”

Globalization and the pharmaceutical industry

The pandemic has highlighted how dependent countries have become on imports to ensure they can meet domestic drug demand. China produces most of the active pharmaceutical ingredients (APIs) needed to manufacture common drugs such as penicillin and acetaminophen. India, in turn, relies heavily on imports from China to manufacture drugs for the US market, where it is the largest supplier of generic drugs.

The Russian invasion of Ukraine also raises fears that global supply chains could be disrupted. Russia signed an executive order this week banning exports of medical products from a list of countries it has deemed “unfriendly”, including the UK, EU, Canada, New Zealand, US States, Switzerland and Japan. This ban will apply to products stored in warehouses in Russia, or which pass through customs controls.

The need for collaboration

In the paper, the authors urge the US federal government to consider a multilateral agreement with major exporters of medical products that would be overseen by the World Trade Organization (WTO). They also suggest that the WTO could impose sanctions on countries that have not joined the agreement.

The 336-page document calls for greater international cooperation to prevent supply chain disruptions. It also contains detailed recommendations to prevent national shortages, such as pharmacy teams working with hospitals to inform them of a potential shortage and suggest alternative forms of treatment.

Earlier this year, the US Food and Drug Administration (FDA) made permanent its guidance to prevent supply shortages in the wake of the Covid-19 pandemic. This included requiring manufacturers to submit a notification at least six months before a product is permanently discontinued.

Also in the news:

google launched a new campaign featuring women entrepreneurs in Africa, including the story of Vivian Nwakah who launched Medsaf, a pharmaceutical supply chain solution to help Nigerians access quality pharmaceutical healthcare.
Pharmaceutical Logistics IQ has launched a new survey with SkyCell to get your perspective on the issues facing pharmaceutical supply chains today and the role hybrid container solutions could play. Share your thoughts with us and enter our draw to win a $100 Amazon gift card.

Get exclusive access to articles, reports, videos, interviews, webinars and other members-only premium content from industry experts and thought leaders by signing up for Pharma Logistics IQ here.

read more
Medical products

Stereotactic Biopsy Table Market Size 2022-2029

New Jersey, United States,-Global Stereotactic Biopsy Table Market Size, Status and Forecast 2022-2028. This research report covers key aspects of the Stereotactic Biopsy Table market including drivers, limitations, past and current trends, regulatory scenarios, and technological developments. An in-depth study of industry’s role in the COVID-19 outbreak. A comprehensive risk assessment and industry recommendations have been made for market research reports and industry analysis over a specific period of time. The report compares the market before Corona 19 and after Corona 19. The impact of COVID-19 on the local economy is also considered in the study.

Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=448109

The term Based Stereotactic Biopsy Table market study provides helpful insights such as studying the effects on significant aspects, alternatives, and restraints. Graphical analysis of the Emotion Detection and Recognition demand forecasts for the predicted periods can demonstrate the financial requirements of the global Emotion Detection and Recognition industry. Likewise, the study highlights features which limit demand growth, adequately predict Stereotactic Biopsy Table Market quantities, and have long term effects over the predicted period.

The impact of the Corona 19 outbreak on the global Emotion Sensing and Awareness industry, growth rates, correct supply chain analysis, scale in various scenarios, and responses Corporate critiques of the outbreak are all examined in research on emotion sensing and sensitization. The research focuses on emotion detection and recognition in global markets, particularly in North America, Europe and the Asia-Pacific region, as well as South America, the Middle East and Africa. The study divides the market into four parts: manufacturer, region, type and application.

Major Players Covered in Stereotactic Biopsy Tables Markets:

  • MPI Medical
  • Devicor medical products
  • Siemens
  • Aurora imaging technology
  • Hological
  • Planmeca
  • Metaltronics

Stereotactic Biopsy Tables Market Split By Type:

  • Mechanically operated stereotactic biopsy table
  • Electronically controlled stereotactic biopsy table

Stereotactic Biopsy Tables Market Split By Applications:

  • Hospital
  • diagnostic center
  • Others

The Stereotactic Biopsy Table market report has been segregated into distinct categories such as product type, application, end-user, and region. Each segment is valued based on CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is expected to generate opportunities in the global Stereotactic Biopsy Tables Market in the coming years. This segmental analysis will surely prove to be a useful tool for readers, stakeholders, and market players to get a complete picture of the global Stereotactic Biopsy Tables market and its growth potential in the coming years.

Get | Discount on the purchase of this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=448109

Scope of the Stereotactic Biopsy Tables Market Report

Report attribute Details
Market size available for years 2022 – 2029
Base year considered 2022
Historical data 2019 – 2021
Forecast period 2022 – 2029
Quantitative units Revenue in USD Million and CAGR from 2023 to 2029
Segments Covered Types, applications, end users, and more.
Report cover Revenue Forecast, Business Ranking, Competitive Landscape, Growth Factors and Trends
Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Scope of customization Free report customization (equivalent to up to 8 analyst business days) with purchase. Added or changed country, region and segment scope.
Pricing and purchase options Take advantage of personalized purchasing options to meet your exact research needs. Explore purchase options

Regional Market Analysis Stereotaxic Biopsy Chart can be represented as follows:

Each regional Stereotaxic Biopsy Table sector is carefully researched to understand its current and future growth scenarios. This helps players strengthen their position. Use market research to get a better perspective and understanding of the market and target audience and ensure you stay ahead of the competition.

Based on geography, the global stereotaxic biopsy table market has been segmented as follows:

    • North America includes the United States, Canada and Mexico
    • Europe includes Germany, France, UK, Italy, Spain
    • South America includes Colombia, Argentina, Nigeria and Chile
    • Asia Pacific includes Japan, China, Korea, India, Saudi Arabia and Southeast Asia

For more information or query or customization before buying, visit @ https://www.marketresearchintellect.com/product/global-stereotactic-biopsy-table-market-size-and-forecast/

About Us: Market Research Intellect

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations, in addition to the goal of providing customized and in-depth research studies. range of industries including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. etc Our research studies help our clients to make decisions based on higher data, to admit deep forecasts, to grossly capitalize with opportunities and to optimize efficiency by activating as their belt in crime to adopt a mention precise and essential without compromise. clients, we have provided expert behavior assertion research facilities to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

Contact us:
Mr. Edwyne Fernandes
USA: +1 (650)-781-4080
UK: +44 (753)-715-0008
APAC: +61 (488)-85-9400
US Toll Free: +1 (800)-782-1768

Website: –https://www.marketresearchintellect.com/

read more
Prescription drugs

Non-prescription Drug Consumption Market Size 2022-2029

New Jersey, United States,-Global Non-prescription Drug Consumption Market Size, Status and Forecast 2022-2028. This research report covers key aspects of the Non-Prescription Drug Consumption market, including drivers, limitations, past and current trends, regulatory scenarios, and technological developments. An in-depth study of industry’s role in the COVID-19 outbreak. A comprehensive risk assessment and industry recommendations have been made for market research reports and industry analysis over a specific period of time. The report compares the market before Corona 19 and after Corona 19. The impact of COVID-19 on the local economy is also considered in the study.

Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=419998

The term based Non Prescription Drug Consumption market research provides useful insights such as the study of the effects on important aspects, alternatives, and restraints. Graphical analysis of the Emotion Detection and Recognition demand forecasts for the predicted periods can demonstrate the financial requirements of the global Emotion Detection and Recognition industry. Likewise, the study highlights the features which limit the demand growth, adequately predict the OTC Drug Consumption market quantities and have long term effects over the predicted period.

The impact of the Corona 19 outbreak on the global Emotion Sensing and Awareness industry, growth rates, correct supply chain analysis, scale in various scenarios, and responses Corporate critiques of the outbreak are all examined in research on emotion sensing and sensitization. The research focuses on emotion detection and recognition in global markets, particularly in North America, Europe and the Asia-Pacific region, as well as South America, the Middle East and Africa. The study divides the market into four parts: manufacturer, region, type and application.

Major Players Covered in Non-prescription Drug Consumption Markets:

  • Pfizer
  • rock
  • Sanofi
  • Johnson & Johnson
  • Merck & Co. (MSD)
  • Novartis
  • AbbVie
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Amgen
  • Astra Zeneca
  • Bristol Myers Squibb
  • Eli Lily
  • Suits you
  • Bayer
  • Novo Nordisk
  • Allergan
  • County
  • Boehringer Ingelheim
  • Takeda

Non-Prescription Drug Consumption Market Breakdown by Type:

Non-prescription Drug Consumption Market Split By Application:

The Non-Prescription Drug Consumption Market report has been segregated into distinct categories such as product type, application, end-user, and region. Each segment is valued based on CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is expected to generate opportunities in the global Non-Prescription Drug Consumption Market in the coming years. This segmental analysis will surely prove a useful tool for readers, stakeholders, and market players to get a complete picture of the global Non-Prescription Drug Consumption market and its growth potential in the coming years. .

Get | Discount on the purchase of this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=419998

Scope of Non-Prescription Drug Consumption Market Report

Report attribute Details
Market size available for years 2022 – 2029
Reference year considered 2022
Historical data 2019 – 2021
Forecast period 2022 – 2029
Quantitative units Revenue in USD Million and CAGR from 2023 to 2029
Segments Covered Types, applications, end users, and more.
Report cover Revenue Forecast, Business Ranking, Competitive Landscape, Growth Factors and Trends
Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Scope of customization Free report customization (equivalent to up to 8 analyst business days) with purchase. Added or changed country, region and segment scope.
Pricing and purchase options Take advantage of personalized purchasing options to meet your exact research needs. Explore purchase options

Regional Market Analysis OTC Drug Consumption can be represented as follows:

Each regional Non-Prescription Drug Consumption industry is carefully researched to understand its current and future growth scenarios. This helps players strengthen their position. Use market research to get a better perspective and understanding of the market and target audience and ensure you stay ahead of the competition.

Based on geography, the global non-prescription drug consumption market has been segmented as follows:

    • North America includes the United States, Canada and Mexico
    • Europe includes Germany, France, UK, Italy, Spain
    • South America includes Colombia, Argentina, Nigeria and Chile
    • Asia Pacific includes Japan, China, Korea, India, Saudi Arabia and Southeast Asia

For more information or query or customization before buying, visit @ https://www.marketresearchintellect.com/product/global-non-prescription-drugs-consumption-market-size-and-forecast/

About Us: Market Research Intellect

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations, in addition to the goal of providing customized and in-depth research studies. range of industries including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. etc Our research studies help our clients to make decisions based on higher data, to admit deep forecasts, to grossly capitalize with opportunities and to optimize efficiency by activating as their belt in crime to adopt a mention precise and essential without compromise. clients, we have provided expert behavior assertion research facilities to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

Contact us:
Mr. Edwyne Fernandes
USA: +1 (650)-781-4080
UK: +44 (753)-715-0008
APAC: +61 (488)-85-9400
US toll free: +1 (800)-782-1768

Website: –https://www.marketresearchintellect.com/

read more
Medical supplies

NPMC Acquires GNG Medical Supplies, Another Milestone By NPMC Spokesperson Khaniya Gupta

Dr. Gautam Arora

Dr. Gautam Arora

Dr. Gautam Arora

Dr. Gautam Arora

Dr. Gautam Arora

This would further improve patient care by NPMC Dr Gautam Arora

This would improve patient outcomes and reduce the cost of healthcare”

—Dr. Gautam Arora

MONROE, NJ, USA, February 28, 2022 /EINPresswire.com/ — NPMC, a diversified company founded by Dr. Gautam Arora focused on synergistic acquisitions in critical, fast-growing sectors, acquired a majority stake in medical supplies company GNG. GNG’s primary revenue drivers focus on providing globally sourced heavy duty consumable medical supplies. These include hygiene products, syringes, dressings and sterilization equipment.

Among other elements, the acquisition of GNG brings immediate revenues to NPMC, a high level of operational profitability and an order book of 1.8 Cr for 2021. The company is also engaged in other sales of personal care products. related healthcare and in the development of products that could bear considerable fruit in future quarters.

GNG Medical supply is currently on track to generate revenue of 2.7 Cr in 2022 and is targeting revenue of 3.6 Cr in 2023. In comparison, in 2020 the company generated revenue of 86 Lakhs with an EBITDA of 32.8 Lakhs. Dr. Gautam Arora, MD, CEO, of NPMC commented, “The acquisition of GNG’s medical supply business further strengthens our revenue estimate of Cr3.6 for FY2023. The acquisition provides NPMC a channel to leverage its existing relationships in the medical supply chain to increase GNG’s medical revenue. and global supply chain footprint.”

GNG Medical Supply Background:
Mr. Gavin Kumar founded GNG Medical Supply in 2017 as a sole proprietorship before incorporating in 2019. The company provides the market with globally sourced medical supply products. In addition, it is a financial partner at all stages of enterprise and post-enterprise, private and public – partnership in the sector of biotechnology and sustainable medical equipment.

About NPMC
NPMC started as a clinical practice and is now a diversified company focusing on acquisitions in the following sectors: Healthcare and real estate. NPMC is an acquisition-driven company. The company’s strategy is to acquire majority stakes in undervalued companies and play an active role in improving their performance – accelerating their growth by providing them with both access to capital and management expertise. .

Gautam Arora
NPMC Neurology and Pain Management Clinic
+91 85951 68656
write to us here

read more
Generic drugs

Global Multi-Cancer Generic Drugs Market 2021 Manufacturer Landscape, Revenue and Volume Analysis to 2027 – Business Ethics

The research report MarketQuest.bizto Global market for generic drugs for several cancers reviews important industry and market trends, as well as historical and anticipated market data. The research has implications for the stock market as well as other terms and definitions. Analytics promotes its products by application, sort and location in terms of volume and value.

The market accurately reflected the total sales and marketing volume, maximum production and consumption costs, profit margins, import and export, cost structure analysis, in-depth price analysis , vendor landscapes, and other critical market variables. The research helps identify new marketing opportunities and offers a complete picture of the existing global market for generic drugs for multiple cancers.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/45315

The study is significant for organizations or individuals looking to enter the Generic Drugs for Multiple Cancers industry as it provides detailed qualitative and quantitative insights. It also examines how changing patterns, COVID-19, and inflation are affecting market growth. Additionally, supply chain analysis, profit margin analysis, and price research are all covered in depth to help businesses and give them an estimate of how much money they will need to join this market.

Market segmentation based on region:

  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
  • Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
  • South America (Brazil, Argentina, Colombia and rest of South America)
  • Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, South Africa and Rest of Middle East and Africa)

Player Market Segmentation:

  • Pfizer
  • GlaxoSmithKline
  • Novartis
  • Merck
  • Celgene
  • Teva pharmaceutical
  • Mylan
  • Aurobindo Pharmacy
  • Hikma Pharmaceuticals
  • rock
  • Redsenol

Segment the market by product type:

  • Cytotoxic drug
  • Non-cytotoxic drugs

Market segmentation based on application

  • Hospital pharmacy
  • Retail pharmacies
  • Online pharmacies

ACCESS FULL REPORT: https://www.marketquest.biz/report/45315/global-generic-drugs-for-multiple-cancers-market-2021-by-key-countries-companies-type-and-application

In addition, a framework of study has been created to emphasize future events and possibilities in the global Generic Multiple Cancer Drugs industry in recent years. According to the research study, the market will face a variety of drivers and restraints, opportunities and challenges throughout the forecast period. The report also examines the geographical characteristics of the market, which will impact its growth from 2021 to 2027.

Report customization:

This report can be customized to meet customer requirements. Please contact our sales team ([email protected]), who will ensure that you get a report tailored to your needs. You can also get in touch with our executives at +1-201-465-4211 to share your research needs.

Contact us
mark the stone
Business Development Manager
Call: +1-201-465-4211
E-mail: [email protected]

read more
Medical products

Smith+Nephew appoints new CEO as medical device maker navigates pandemic

Feb 22 (Reuters) – Smith+Nephew (SN.L) on Tuesday appointed Deepak Nath of Siemens Healthineers AG (SHLG.DE) as chief executive to succeed Roland Diggelmann after the medical device maker narrowly missed the analysts’ estimate of annual profit.

Diggelmann was recruited by Smith+Nephew after his former boss left his salary at the end of 2019, and the British company was counting on his more than 20 years of experience in the orthopedic and diagnostic sectors to accelerate the growth of its income.

However, the pandemic hit soon after, forcing hospitals to delay surgeries and elective services to accommodate COVID-19 patients, and slumping demand for hip and knee replacement surgeries. business, while supply chain issues have also weighed it down.

Join now for FREE unlimited access to Reuters.com

Register

The UK company’s revenue rose 10.3% to $5.21 billion in the 12 months to December 31 on an underlying basis, recovering steadily from 2020, while trading profit was $936 million, compared to $683 million the previous year.

Healthcare networks around the world are once again under pressure from the novel coronavirus variant Omicron, and the company is targeting underlying revenue growth in the range of 4.0% to 5.0% for 2022.

“(Deepak Nath) joins us at an inflection point for the business and will bring his drive, experience and expertise to lead the team as we execute on our rapid growth strategy,” said Chairman Roberto. Quarter in a press release.

Analysts had expected a profit of $945 million in 2021 on sales of $5.22 billion at the median, a consensus provided by the company show.

Join now for FREE unlimited access to Reuters.com

Register

Reporting by Pushkala Aripaka in Bengaluru; Editing by Subhranshu Sahu

Our standards: The Thomson Reuters Trust Principles.

read more
Medical supplies

Med Surgical Supplies presents an easy way to buy medical supplies in the USA

Medical and surgical supplies logo

EDISON, NEW JERSEY, USA, February 21, 2022 /EINPresswire.com/ — Healthcare professionals face increasing challenges in their daily work, but solutions exist to help them operate effectively. Medical-surgical suppliesoften called MedsurgicalSupplies.com offers a wide range of supplies and equipment to help ensure top quality patient care. Supplies include everything from surgical instruments and patient reusable products to infection prevention tools and skin care products.

The one-stop-shop program makes ordering supplies easy and convenient! Users can access the entire catalog, including diagnostic and surgical instruments, exam tables and more.

Surgical equipment, plastic surgery fillers, injections, diagnostics, laboratory products, CPAP and oxygen equipment, respiratory therapy products, pharmaceuticals and vaccines all make up the more than 700,000 products available through Med Surgical Supplies.

In-house ordering and inventory tools help nursing homes, laboratories, home health agencies, long term care facilities, nursing homes, healthcare professionals, CHWs, post care -treble with more than just control.

Supply professionals and order nurses can easily track expenses by facility or location, enter purchase orders, approve invoices, access real-time health product information and availability through the Med Surgical Supplies website.

Medical Surgical Supplies is a partner of Pipeline Medical, a market leader in medical technology. Their nationwide delivery network provides 48-hour next-day delivery to 95% of customers with 99.8% order accuracy and also benefits from a personal touch, with account managers assisting with backorder fulfillment.

When you’re in the wholesale industry, you’re looking to be more than just a supplier. You want to be a partner in the success of your customers and provide them with expertise, advice and assistance so that they succeed. It’s not just about delivering their products or services; it’s about making sure they have the resources they need to start their business and keep it running smoothly.

Anyone can sell medical supplies, but it takes an expert in the wholesale medical supplies industry to make sure everything runs smoothly, from the initial sale to any follow-up work. Med Surgical Supplies aims to keep customers healthy and prosperous by providing life-saving products such as equipment, instruments and medications. And of course, working in the regulated healthcare environment, paying attention to the smallest details.

It’s no secret that supply chain has been a major issue in the healthcare industry for the past 18 months. Even as the pandemic itself begins to fade, supply chain issues persist.

Hospitals and health systems are reporting supply issues, and many fear old problems could resurface. The health sector is taking steps to mitigate future disasters and learn from its mistakes, but there are always risks of further disruption.

A recent survey of healthcare executives asked their opinion on the state of supply chain management. Many were confident about what they had learned from the pandemic, but insisted continued vigilance was needed to face future challenges.

Med Surgical Supplies sees itself as part of the solution to providing a quick and efficient way to obtain supplies for all medical and surgical practices.

The website provides a fast and efficient experience for physicians. The site is ideal for the medical supply chain.

Medical-surgical supplies
Medical surgical supplies
write to us here

read more
Medical supplies

2021-2026 Disposable Medical Supplies Market Growth Trend Analysis





In the latest research report on Disposable Medical Supplies Market, researchers and analysts have made optimum use of various multidisciplinary approaches to arrive at the mentioned conclusion and forecast. It offers an in-depth analysis of key opportunities over the forecast years, while simultaneously preparing stakeholders to deal effectively with the threats and challenges of this business domain. Additionally, the authors rigorously assessed the current global Covid-19 crisis for a stronger realization of revenue prospects in the coming years.

Main indicators of the Covid-19 impact assessment:

  • Impact of the Covid-19 pandemic on the global economy.
  • Evolution of supply and demand.
  • Short-term and projected outlook of the Covid-19 pandemic on market compensation.

Request a sample copy of this report @ https://www.getnewsalert.com/request-sample/19505

An overview of the regional analysis:

  • North America, Europe, Asia-Pacific, South America, Middle East & Africa, Southeast Asia are the major regional contributors of the disposable medical supplies market.
  • The study assesses the region’s contribution to the overall growth of the industry.
  • The total sales, net revenue and projected growth rate of each geographic area are listed.

Other Vital Points of the Disposable Medical Supplies Market Report:

  • The report fragments the Disposable Medical Supplies market product terrain into Infusion and Hypodermic Products, Diagnostic Supplies, Dialysis Consumables, Radiology Consumables, Intubation and Ventilation Supplies, Sterilization Consumables, Nonwoven Medical Supplies, Consumables wound care and more.
  • Revenue projections and volume share held by each product type are highlighted.
  • The data supporting the projected market share values, production patterns and growth rate for each product category over the period of analysis are discussed in detail.
  • The report also categorizes the various product offerings based on their scope of application, which is divided into cardiovascular, cerebrovascular, ophthalmology, gynecology, urology, orthopedics, and others.
  • The market share guaranteed by each application segment along with their growth rate on the expected course is also indicated.
  • Medtronic, Teleflex, Terumo Corporation, Baxter, 3M, Ansell, Smiths Group, Novartis, Nitto Medical, Smith & Nephew, Medline, Coloplast, Abbott, Lohmann & Rauscher, ConvaTec, Fresenius, Johnson & Johnson, Boston Scientific, BD, Weigao, B Braun, BSN Medical, Halyard Health and CR Bard are the major players in the disposable medical supplies market.
  • Each competitor’s product portfolio, business profiles, production models, and market compensation are housed in the study.
  • The market share gained by industry leaders, along with their pricing model and gross margins are explained.
  • The latest competition trends are explained in detail.
  • A new project feasibility study leveraging Porter’s Five Forces Analysis and SWOT analysis is contained within the research document.

Main features of the report:

  • Intricate details of each organization.
  • Information regarding market share, product selling price, manufacturing base distribution, total revenue generated and sales.
  • Latest developments from the main players.
  • Sales amassed by each company in relation to their areas of activity.

Report Highlights:

  • Accurate predictions of market size and CAGR for the period 2020-2025
  • Identification and in-depth assessment of growth opportunities in key segments and regions
  • Detailed company profile of the major players of the Global Disposable Medical Supplies Market
  • In-depth research on innovation and other trends in the global disposable medical supplies market
  • Reliable industry value chain and supply chain analysis
  • Comprehensive analysis of significant growth drivers, restraints, challenges and growth prospects

The scope of the report:

The report offers a comprehensive company profile of key players competing in the global market disposable medical supplies market with a focus on market share, gross margin, net profit, sales, product portfolio, new applications, recent developments and several other factors. It also throws light on the vendor landscape to help players realize about the future competitive changes in the global Disposable Medical Supplies market.

Reasons to buy the report:

  • Enhance your market research resources with this comprehensive and accurate report on the Global Disposable Medical Supplies Market
  • Obtain a comprehensive understanding of the general market scenarios and future market situations to prepare for challenges and ensure strong growth
  • The report offers in-depth research and various trends of the global Disposable Medical Supplies market
  • It provides a detailed analysis of changing market trends, current and future technologies utilized, and various strategies adopted by the key players of the global Disposable Medical Supplies market.
  • It offers recommendations and guidance for new entrants in the global Disposable Medical Supplies market and carefully guides established players for future market growth.
  • Along with the hottest technological advancements in the global Disposable Medical Supplies market, it sheds light on the plans of the dominating industry players

Contents:

  • Disposable Medical Supplies Market Industry Overview
  • Industry Chain Analysis of Disposable Medical Supplies Market
  • Disposable Medical Supplies Market Manufacturing Technology
  • Disposable Medical Supplies Market Major Manufacturers Analysis
  • Global Disposable Medical Supplies Market Production, Revenue and Price Analysis by Regions, Manufacturers, Types and Applications
  • Consumption volumes, consumption value, import, export and sales price analysis of Disposable Medical Supplies by Region
  • Gross and Gross Margin Analysis of Disposable Medical Supplies Market
  • Disposable Medical Supplies Market Trader or Distributor Analysis
  • Global and Chinese Economic Impacts on the Disposable Medical Supplies Industry
  • Disposable Medical Supplies Market Development Trend Analysis
  • Disposable Medical Supplies Market Details
  • New Project Investment Feasibility Analysis of Disposable Medical Supplies Market
  • Conclusion of the Global Disposable Medical Supplies Market Industry 2020 Market Research Report

Customization request on this report @ https://www.getnewsalert.com/request-for-customization/19505





read more
Medical products

3 medical products stocks poised to beat this earnings season

Despite the resurgences of COVID-19, so far the fourth quarter reporting cycle has shown improvement for the Medical products companies in the wider medical sector. It should be mentioned that the Medical is expected to be one of the seven fastest growing sectors in earnings in the fourth quarter.

By the last Earnings overview, 33.9% of companies in the medical sector, accounting for nearly 53.7% of the market capitalization of the sector, reported profits through February 2. Profits improved 10% year over year on revenue up 12.1%. A total of 36.8% of corporate earnings and revenue beat Zacks’ consensus estimate.

This dashboard highlights stability in the United States, thanks to the continued economic reopening amid the resurgence of COVID-19 cases. However, this resurgence has led to supply chain disruptions that persist. Additionally, several of the international markets affected by COVID are still suffering due to lower cash flow and difficult economic conditions.

Companies in the medical products sector saw a sequential decline in collective business versus legacy core business in the third quarter. On a positive note, the fourth quarter reporting cycle so far has shown a recovery in these activities despite the resurgence of COVID-19. The substantial increase in vaccination campaigns has helped people gradually return to pre-pandemic normality. This, in turn, has likely resulted in some recovery in hospital visits and core hospital activities in the current reporting cycle, which in turn may have boosted non-COVID legacy activities and electives in the medical sector. Although companies are seeing a sequential recovery in their core business, the improvement in the overall trend is still below pre-COVID levels.

Meanwhile, due to the resurgence of COVID-19 and rising case numbers, manufacturers of tests, vaccines and therapeutics have witnessed massive market uptake of their products and services. of COVID-related healthcare support in the fourth quarter. Diagnostic test stocks have so far seen phenomenal growth, driven by an increase in demand for COVID-19 tests, in line with industry trends. For example, in the fourth trimester, Abbott Laboratories‘ABT’s underlying legacy diagnostic activity continued to improve. This was due to strong sales of ABT’s COVID-19 tests thanks to strong demand for the BinaxNOW, Panbio and ID NOW rapid test platforms. Sales of Abbott’s rapid diagnostics and point-of-care diagnostics both grew organically.

Stocks set to beat fourth-quarter earnings estimates

Given the high degree of diversity in the medical products industry, finding the right stocks with the potential to beat estimates could be quite a task.

However, our proprietary Zacks methodology makes this quite simple.

We focus on actions that combine a positive effect ESP Earnings and a Zacks rank #1 (strong buy), 2 (buy) or 3 (hold). You can see the full list of today’s Zacks #1 Rank stocks here.

Our research shows that for stocks with this combination, the chance of a positive earnings surprise is as high as 70%.

The ESP of earnings provides the percentage difference between the most accurate estimate and the Zacks consensus estimate. You can discover the best stocks to buy or sell before they’re flagged with our Income ESP filter.

Here we feature three stocks that are expected to top earnings estimates in this reporting cycle.

Baxter International, Inc. BAX: Increased demand for acute therapy products due to the COVID-19 pandemic, and continuous renal replacement therapy (CRRT), related devices and consumables are likely to have boosted Acute business performance Baxter’s Therapies in Q4 2021. BAX’s strong product pipeline and expected launch of therapies and products may be reflected in Q4 revenue.

The combination of Baxter’s ESP gains of +3.50% and a Zacks #2 ranking raises the possibility of an earnings surprise in the quarter to report.

The company is expected to release its fourth quarter results on Feb. 17, before the market opens.

Baxter International Inc. Awards and EPS Surprise

Baxter International Inc. price-eps-surprise | Baxter International Inc. Quote

Henry Schein, Inc. HSIC: According to the third quarter 2021 earnings call, the company has seen stronger demand in the global dental and medical markets as practices gradually reopen and global patient traffic has stabilized over the past few months. months, even in countries with stricter lockdown rules. . This recovery trend is expected to have continued through the fourth quarter, boosting the company’s revenue.

HSIC is expected to release its fourth quarter 2021 results on February 15.

Henry Schein has a +1.94% Earnings ESP and a #2 Zacks rank.

Henry Schein, Inc. Awards and EPS Surprise

Henry Schein, Inc. Awards and EPS Surprise

Henry Schein, Inc. price-eps-surprise | Quote from Henry Schein, Inc.

DENTSPLY SIRONA Inc. XRAY: DENTSPLY SIRONA’s Consumables segment is expected to have seen improved revenue in the fourth quarter. The rebound in sales of all product categories may have contributed to the increase. The Technology & Equipment segment may have shown growth in the reportable quarter, driven by recovery across all product categories.

XRAY is expected to report its fourth quarter 2021 results on February 28.

DENTSPLY SIRONA has a Gain ESP of +1.06% and a Zacks Rank #3.

DENTSPLY SIRONA Inc. Price and EPS Surprise

DENTSPLY SIRONA Inc. Price and EPS Surprise

DENTSPLY SIRONA Inc. price-eps-surprise | Quote DENTSPLY SIRONA Inc.

Stay up to date with upcoming results announcements with the Zacks Earnings Schedule.

Just Released: Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know our top 10 buy and hold tickers for all of 2022?

Last year 2021 Zacks Top 10 Stocks the portfolio generated gains as high as +147.7%. Now, a brand new portfolio has been selected from over 4,000 companies covered by the Zacks ranking. Don’t miss your chance to participate in this long term shopping

Access the Top 10 Zacks Stocks for 2022 today >>

Click to get this free report

Abbott Laboratories (ABT): Free Inventory Analysis Report

Baxter International Inc. (BAX): Free Stock Analysis Report

DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report

Henry Schein, Inc. (HSIC): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

read more
Medical products

Hot Melt Extrusion Medical Products Market Growth Analysis 2022, Industry Dynamics 2026

The global Hot Melt Extrusion Medical Devices industry market study provides important insights that can help companies to set priorities, better position their businesses, devise well-thought-out business strategies and make business decisions. investment for the future. The report mainly includes the current status of the Hot Melt Extrusion Medical Products market, products, materials, services and other key aspects of the market. In this research, the report explores the status of the Hot Melt Extrusion Medical Products market in key regions. It includes an overview of how the Hot Extrusion Medical Devices industry fits into the global market landscape, key trends influencing market companies and consumers, and information about what players in the hot extrusion medical products market might want to focus to support and be competitive in the market. Marlet. The report studies the segments that are major contributors to the market and are expected to dominate the hot melt extrusion medical products market in the coming years.

Request a sample report: https://www.orbisresearch.com/contacts/request-sample/6249201?utm_source=SLP

Hot Extrusion Medical Products Market Key Players

AbbVie
Formex
BASF Pharmaceuticals
omipa
Biogrund
Lubrizol

The report studies key parameters of the Medical Hot Melt Extrusion Products industry, including the macroeconomic situation, current status, research and development initiatives, and ongoing merger and acquisition activities. The report studies key indicators of the Hot Melt Extrusion Medical Devices industry defining the current economic situation and financial performance of the market. The major ongoing developments in the industry such as mergers and acquisitions and research and developments locally and globally are highlighted in the report.

Hot Extrusion Medical Products Industry Different product categories include:

Movies
Taste masking
Drug eluting devices
Others

The global hot extrusion medical products industry has a number of end-user applications, including:

Research Laboratory
Contract manufacturing organization
Pharmaceutical companies

The above mentioned activities from 2019 to 2021 are covered in the report with an assessment of pandemic effect on Medical Hot Melt Extrusion Products industry. Additionally, the changes that the pandemic brings to the market, new business models, supply and demand scenario, regulatory framework, technological innovations shaping the market. Then, the report focuses on the key developments that the hot melt extrusion medical products market will witness in 2021 and the developments that occurred in 2020 due to the pandemic. The hot melt extrusion medical products market drivers evident in the market in recent years are studied in the report. This detailed information presented in the report enables market players to make informed decisions and design innovative and sustainable business models.

Investigate before accessing the report at: https://www.orbisresearch.com/contacts/enquiry-before-buying/6249201?utm_source=SLP

What does the Hot Extrusion Medical Products Market report include?

– Factors that may affect future business ventures.
– The future growth rate and expected growth of the Medical Extruders industry and your business.
– The business models and business strategies executed by players of the Hot Melt Extrusion Medical Products market.
– Market, financial and other risks related to local and international commercial activities of hot melt extrusion medical products.
– Global hot extrusion medical products market industry-related revenue.
– The report highlights the opportunities arising from the pandemic for the hot melt extrusion medical products market players over the current and upcoming years.
– The report includes details of revenue and market share losses suffered during the pandemic.
– The report recognizes the drivers of change in the Hot Melt Extrusion Medical Devices industry ahead of 2020.
– The risks and uncertainties that may arise in the Hot Melt Extrusion Medical Devices market are discussed in the report.
– Segments or regions that have extreme growth potential and are expected to witness huge growth in the Hot Melt Extrusion Medical Devices market in the future are detailed in the report.
– The report provides a neutral perspective of the global hot extrusion medical products market and its performance.
– The report explains how players in the hot extrusion medical products market can adapt to the changing market.
– Detailed details of supply chain operations by segment.
– Financial and economic conditions of the Hot Extrusion Medical Products industry market.
– Analysis of revenue growth of all business segments.

About Us:

Orbis Research (orbisresearch.com) is a one-stop-shop for all your market research needs. We have an extensive database of reports from leading publishers and authors around the world. We specialize in delivering customized reports according to our clients’ requirements. We have complete information about our publishers and therefore are sure of the accuracy of the industries and verticals of their specialization. This helps our clients map their needs and we produce the perfect market research required for our clients.

Contact us:

Hector Costello
Senior Manager – Client Engagements
Central Highway 4144N,
Suite 600, Dallas,
Texas – 75204, USA
Telephone number: United States: +1 (972)-362-8199 | IND: +91 895 659 5155
Email ID: [email protected]

Click here to see the full table of contents: https://www.orbisresearch.com/contact/purchase-single-user/6249201?utm_source=SLP



read more
Medical products

Medical Products Stock Earnings Feb. 2: BSX, TMO and More

The last Revenue overview reflects a considerably strong quarterly performance for the Medical sector so far this reporting cycle. According to the sector scorecard, 8.9% of companies in the medical sector, constituting nearly 29.2% of the sector’s market capitalization, reported profits through January 26. Of these, 80% beat earnings estimates and 60% beat the same for revenue. Profits were up 27% year over year on revenue up 12.2%.

This dashboard reflects stability in the United States on continued economic reopening amid the resurgence of COVID-19 cases. However, supply chain disruptions are still significant, thanks to the emergence of the Omicron variant. Additionally, many parts of the COVID-affected international market are still suffering due to lower cash flow and tough economic conditions.

Overall, fourth-quarter profits for the medical sector are expected to rise 18.4% on a 12.2% increase in sales. That compares to reported earnings growth of 29.7% and revenue growth of 15.7% in the third quarter. It is worth mentioning that the medical sector is expected to be one of the seven sectors with the strongest earnings growth in the fourth quarter.

Quarterly summary of medical products

The dynamic nature of the COVID-19 crisis is rapidly transforming the landscape of the medical products industry. Medical products Corporate collective activities (within the broader medical sector) showed a sequential decline in terms of legacy core activity in the third quarter. So far, the fourth quarter reporting cycle has shown a sequential rebound in terms of the companies’ legacy core business despite the emergence of the new Omicron variant. This rebound can be attributed to the fiscal and monetary stimulus measures and the mass vaccination campaign at home and abroad. Although companies are seeing a sequential recovery in basic activity, the improvement in the overall trend is still below the pre-COVID level.

It should be mentioned here that disruptions in the form of the emergence of newer, more infectious variants of COVID-19 have again begun to delay non-COVID-19 elective hospital admissions and procedures. Meanwhile, with resurgences of COVID-19 and rising case numbers, manufacturers of tests, vaccines and therapeutics have witnessed massive market uptake of their products and support services. COVID-related health care in the fourth quarter.

Specifically, fourth-quarter diagnostic test inventory results have so far shown considerable growth, driven by an increase in demand for COVID-19 tests, which had seen a slowdown in demand in the third quarter, a report said. gained momentum in the fourth quarter, in line with industry trends.

Let’s take a look at four Medical Products players who are due to announce their results on February 2.

Boston Scientific Society BSX: In the fourth quarter, within the Urology/Pelvic Health division of Boston Scientific, sales of the Stone, Prostate Health and Pelvic Health franchises are expected to have recorded strong growth. The acquisition of Lumenis (closed in September) should have contributed a full quarter to the company’s sales. The LithoVue, SpaceOAR and Rezum product lines should have performed well. The company continues to expect urology/pelvic health to have one of the fastest potential recovery curves, aided by a higher in-office ASE mix for most elective procedures. (Read more: What do Boston Scientific’s fourth quarter results have in store for us?)

Zacks’ consensus estimate for fourth-quarter earnings per share is pegged at 44 cents and revenue at $3.10 billion.

Boston Scientific Corporation Award and EPS Surprise

Boston Scientific Corporation price-eps-surprise | Boston Scientific Corporation Quote

Boston Scientific doesn’t have the right combination of the two key ingredients – a silver lining ESP Earnings and a Zacks Rank #3 (Hold) or better. BSX has an ESP on gains of 0.00% and carries a Zacks rank of #4 (sell). You can discover the best stocks to buy or sell before they’re flagged with our Income ESP filter.

You can see the full list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Thermo Fisher Scientific Inc. TMO: Thermo Fisher’s Life-Science Solutions segment is expected to have seen strong revenue contributions driven by growing demand for COVID-19 testing with the emergence of the Omicron variant during the fourth quarter. Additionally, vaccine and therapeutics production supplies (recognized in the BioProduction and Biosciences businesses) are expected to have contributed strongly to the company’s growth in the fourth quarter. Thermo Fisher is expected to have seen robust growth in the areas of genetic sciences, biosciences and biomanufacturing thanks to the surge in economic activity globally and the company’s response to the pandemic. (Read more: Increase in COVID testing to boost Thermo Fisher Q4 revenue)

Zacks’ consensus estimate for its fourth-quarter earnings per share is set at $5.22. Revenue is expected to be $9.03 billion.

Thermo Fisher Scientific Inc. Prize and EPS Surprise

Thermo Fisher Scientific Inc. Prize and EPS Surprise

Thermo Fisher Scientific Inc. price-eps-surprise | Quote from Thermo Fisher Scientific Inc.

TMO has a +12.77% win ESP and a #3 Zacks rank.

Hologic, Inc. HOLX: Hologic’s diagnostics business likely experienced robust growth in the first quarter of fiscal 2022 due to increased demand for COVID-19 testing. With that in mind, in November 2021, the company confirmed that its three SARS-CoV-2 tests detect the recently emerged Omicron variant of the coronavirus. This development should have boosted Hologic’s diagnostics revenue in the first fiscal quarter. The same month, Hologic launched the Novodiag system for on-demand molecular testing in Europe. This should have witnessed strong market uptake in the fiscal first quarter as it capitalized on the surge in coronavirus cases induced by the Omicron variant, thus adding to revenue. (Read more: Hologic to Report First Quarter Results: What’s in the Cards?)

Zacks’ consensus estimate for its first-quarter earnings per share is set at $1.21. Revenue is expected to be $1.12 billion.

Hologic, Inc. Price and EPS Surprise

Hologic, Inc. Price and EPS Surprise

Hologic, Inc. price-eps-surprise | Hologic, Inc. Quote

The company has an ESP on Earnings of -1.65% and a #2 Zacks Rank (Buy).

McKesson Corporation MCK: The company’s US pharmaceutical and specialty solutions segment likely acted as a key growth driver in the third quarter of fiscal 2022. The segment should have benefited from market growth and higher volumes of specialties during the quarter to appear. However, brand-to-generic conversions may have weighed on segment performance. The growing demand for COVID-19 testing (due to the resurgence of COVID-19) and improved primary care patient visits have likely positively impacted the company’s medical-surgical solutions segment. (Read more: McKesson to Report Third Quarter Results: What’s in the Cards?).

Zacks’ consensus estimate for its third-quarter earnings per share is set at $5.38. Revenue is expected to be $66.13 billion.

McKesson Corporation and EPS Surprise Award

McKesson Corporation and EPS Surprise Award

McKesson Corporation price-eps-surprise | Quote from McKesson Corporation

MCK has a +1.86% earnings ESP and a #3 Zacks rank.

Stay up to date with upcoming results announcements with the Zacks Earnings Schedule.

7 best stocks for the next 30 days

Just Released: Experts distill 7 elite stocks from the current Zacks No. 1 Ranking 220 Strong Buys list. They consider these tickers “most likely for early price increases.”

Since 1988, the full list has beaten the market more than 2 times with an average gain of +25.3% per year. So be sure to give your immediate attention to these 7 handpicked ones.

Discover them now >>

Click to get this free report

Boston Scientific Corporation (BSX): Free Stock Analysis Report

Thermo Fisher Scientific Inc. (TMO): Free Inventory Analysis Report

McKesson Corporation (MCK): Free Stock Analysis Report

Hologic, Inc. (HOLX): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

read more
Medical supplies

Comprehensive report on Medical Supplies Market predicted to gain significant value by 2026





A latest report titled Global Medical Devices Market, the report has been prepared by expert and knowledgeable market analysts and researchers. They have explored the competitive landscape, segmentation, geographic expansion, and revenue, production, and consumption growth of the global Medical Supplies Market and added in the report. The major key players can use the accurate market facts, figures and analytical studies provided in the report to understand the current and future growth of the global market. The report contains data on the competitive scenario, supply and demand situation, and market growth challenges.

The main objective of the Medical Supplies market report is to predict the performance of the industry for the upcoming years to help the stakeholders to take right decisions and improve their revenue flow. Moreover, key trends and growth opportunities are discussed in detail in the document followed by comprehensive data on the approaches to tackling the challenges faced by the industry. Also, it provides recent updates on the business scenario across the globe along with concise details regarding the revenue outlook post Covid-19 pandemic.

Request a sample copy of this report @ https://www.getnewsalert.com/request-sample/10243

Main highlights of the Covid-19 impact analysis:

  • Impact of Covid-19 on the global economy.
  • Changes in the share of supply and demand.
  • Predictions of the long-term effects of the Covid-19 pandemic on the growth matrix.

An overview of the regional landscape:

  • The medical supplies market is segmented into several regional markets, namely North America, Europe, Asia-Pacific, South America, Middle East and Africa.
  • Each region’s contribution to overall growth is calculated by looking at important metrics like total sales and net income.
  • The growth rate of each regional market over the forecast period is also provided.

Other key takeaways from the Medical Supplies Market report:

  • The report fragments the product scope of the Medical Supplies market into
    • Diagnostic
    • Dialysis
    • Wound care
    • Inhalation
    • infection control
    • Infusion
    • Intubation and PPE

    .

  • Data supporting revenue share and volume estimates for each product category are provided.
  • The study highlights the market share, production model and growth rate of each product type over the forecast period.
  • In terms of scope, the medical supplies market is categorized into
    • Hospital
    • Clinical
    • Rest house
    • Geographically
    • detailed production analysis
    • the trade of the following countries is covered in chapter 4.2
    • 5:
    • United States
    • Europe
    • China
    • Japan and India

    .

  • The market share and growth rate forecasts of each application segment are extensively discussed.
  • Major companies influencing the medical supplies market trends are
    • Baxter International Inc.
    • Thermo Fisher Scientific Inc.
    • Medtronic plc
    • Cardinal Health
    • Inc.
    • Dickinson and company
    • Johnson & Johnson
    • stryker
    • Abbott
    • Boston Scientific Society
    • B. Braun Melsungen AG
    • 3M Company and BD

    .

  • Evaluation of companies based on their production models, product and service portfolio, pricing model, gross margins, market compensation and market share is included.
  • Major competitive trends and their business implications are elaborated.
  • A granular assessment of the industry supply chain, with details on manufacturers, raw material and equipment suppliers, and consumers, is housed in the document.
  • The report also has a dedicated section for determining the feasibility of a new project using various methods such as Porter’s five forces analysis and SWOT analysis.

Contents

  1. Global Medical Supplies Market Research Report
  2. Overview of the global medical supplies market
  3. Global economic impact on the industry
  4. Global Medical Supplies Market Competition by Manufacturer
  5. Global production, revenue by region
  6. Global Market Analysis by Application
  7. Medical Supplies Market Manufacturing Cost Analysis
  8. Marketing Strategy Analysis, Distributors/Traders
  9. Global Medical Supplies Market Forecast
  10. Global Medical Supplies Market competition by players/vendors, revenue, market share, growth rate
  11. Conclusion

Customization request on this report @ https://www.getnewsalert.com/request-for-customization/10243





read more
Medical supplies

Steady growth in the medical supplies market will be witnessed by 2021 to 2028 – The Oxford Spokesman

Global medical supplies market research is an intelligence report with meticulous efforts undertaken to study the correct and valuable information. The data that has been reviewed takes into account both existing top players and upcoming competitors. The business strategies of key players and new industries entering the market are studied in detail. A well-explained SWOT analysis, revenue share and contact information are shared in this report analysis. It also provides market information in terms of development and its capabilities.

MR Accuracy Reports authored the report, titled Global Medical Supplies Market 2021 is a methodical research study based on the Medical Supplies Market analyzing the competitive landscape of the industry across the globe. Using effective analytical tools such as SWOT analysis and Porter’s Five Forces analysis, the report provides a comprehensive assessment of the Medical Supplies market. Our large research team was able to capture all the important chapters of the final report as they strived for it.

Download a free PDF sample report with a full table of contents, figures and graphs (with covid 19 impact analysis): https://www.maccuracyreports.com/report-sample/476944

At the time of this report, official counts of COVID-19 cases and deaths have exceeded 4,000,000 and 280,000. Many governments have announced plans to reopen the national economy, but many countries are still in the process. at the ascent stage. It should be noted that the impact of the epidemic has accelerated the trend of localization, regionalization and decentralization of the global industrial chain and supply chain, so it is inevitable to rebuild the global industrial chain. . Faced with the global industrial mutation of the post-epidemic era, enterprises in different countries need to take precautions.

The chemical and petrochemical industries have noticed the adverse effects of the COVID-19 outbreak. They are in the midst of a two-pronged crisis, besides the impact of COVID-19, another is the oil price war. Oil prices are falling due to the failure of agreements on production cuts between OPEC and Russia in April and the need for chemicals and refined products is slowing due to industrial slowdowns and travel restrictions at the following this global pandemic.

The chemical industry plays an important role in the production of countless products such as plastics, fertilizers, medicines, packaging products, etc., with the spread of the coronavirus, many production facilities of several industries in downstream have been stopped. However, an increase in the demand for packaging materials has been raised to prevent contamination of food, drugs, personal care and medical products, thus creating a large demand for chemicals used in the packaging industry .

In such an environment, XYZ-research has published a comprehensive analysis of key market trends in the global 3160 Medical Supplies Market. It includes discussion of historical trends, current market status, competitive landscape, opportunities for growth and challenges that are supported by factual commentary.

According to MRA analysis, the medical supplies market will reach xx million USD by the end of 2020, growing at a CAGR of xx% during the forecast period 2021-2026, the XX segment of the medical supplies market is expected to reach a market value of xx million USD by 2020 from an initial market value of xx million USD in 2019. The market value of China in 2019 is around xx million USD and the production of medical supplies is xx. The US market value in 2019 is around xx million USD and the production of medical supplies is xx. The market value of Europe in 2019 is around xx million USD and the production of medical supplies is XX.

Regional Segmentation (Value; Revenue, USD Million, 2015 – 2026) of the Medical Supplies Market by MRA Include

China

EU

United States

Japan

India

South East Asia

South America

Competitive analysis; Who are the major players in the Medical Supplies market?

Medtronic (Ireland)

Cardinal Health (USA)

comics (US)

Johnson & Johnson (USA)

B. Braun Melsungen AG (Germany)

Boston Scientific Corporation (USA)

Thermo Fisher Scientific (USA)

Baxter International Inc. (US)

Avanos Medical Inc. (US)

3M (USA)

Smith & Nephew (Ireland)

ConvaTec Group Plc. (UK)

Abbott (USA)

Medical cook (USA)

Merit Medical Systems (USA)

Stryker (USA)

Terumo Corporation (Japan)

Teleflex Incorporated (USA)

Fresenius Medical Care (Germany)

Coloplast Group (Denmark)

Major Types of Medical Supplies Covered in MRA Report:

Diagnostic supplies

Dialysis consumables

Inhalation products

Consumables for wound care

Radiology consumables

Infection control supplies

Infusion products

Intubation and ventilation supplies

Personal Protective Equipment (PPE)

Others

Application segments covered in the ARM market

Urology

Wound care

Radiology

Respiratory

infection control

Cardiology

DIV

Other

For any other requirements, do not hesitate to contact us and we will provide you with a personalized report.

Get an exclusive discount on this report: https://www.maccuracyreports.com/check-discount/476944

Key questions answered by the report include:

  • What will be the market size and growth rate by the end of the forecast period?
  • What are the key trends in the global medical supplies market impacting market growth?
  • What are the potential growth opportunities and threats faced by the major market competitors?
  • What are the key findings of Porter’s Five Forces analysis and SWOT analysis of key players operating in the global medical supplies market?
  • This report gives all the information regarding the industry overview, analysis and revenue of this market.
  • What are the market opportunities and threats faced by the vendors in the global Medical Supplies Market?

If you have any special requirements, please let us know and we will offer the report as you wish.

You can buy the full report @ https://www.maccuracyreports.com/checkout/476944

About Us:

MR Accuracy Reports’ well-researched contributions that encompass areas ranging from IT to healthcare enable our valued clients to capitalize on key growth opportunities and protect against credible threats prevailing in the market in the scenario current and those expected in the near future. Our research reports provide our clients with macro-level insights in various key regions of the world that provide them with a broader perspective to align their strategies to take advantage of lucrative growth opportunities in the market.

Contact us:
MR Accuracy Reports,
USA: +1 804 500 1224
UK: +44 741841 3666
ASIA: +91 747888728100
Email: [email protected]
Website: https://www.maccuracyreports.com

read more
Medical supplies

PNP steps up crackdown on fake COVID-19 test kits and other medical supplies – UNTV News

PNP steps up crackdown on fake COVID-19 test kits and other medical supplies

Robie de Guzman • January 26, 2022 • 19

Manila, Philippines – The Philippine National Police (PNP) announced on Wednesday that it will be stepping up its intelligence network following the seizure of 150 million pesos of fake COVID-19 antigen tests, face masks and drugs used to treat COVID symptoms. -19 in a warehouse in Manila.

In a statement, PNP Police Chief General Dionardo Carlos said he had ordered all police units to further monitor stores and warehouses in their areas of responsibility that sell and store medical supplies. not recorded.

The Bureau of Customs (BOC) announced on Monday that it confiscated thousands of Clungene COVID-19 antigen test kits, counterfeit LianHua Chinese herbal medicines and fake 3M N95 face masks during a raid on a warehouse in San Miguel. last January 21.

The authorities also found that intellectual property rights infringed on goods such as clothing from brands such as Nike, Fila, Converse, Adidas, as well as Louis Vuitton and Gucci bags, wallets, phone accessories, etc. A Chinese national, believed to be the owner of the establishment, was arrested during the operation.

“We want to know the extent of their operation given the large number of confiscated items,” Carlos said.

“If these products have not been regulated by government agencies, we don’t know if they are safe to use,” he added.

The head of the PNP pledged to take more aggressive action to curb the proliferation of these products, under the leadership of the Ministry of Health.

“The PNP will wage a crackdown campaign to curb the proliferation of these fake medical items,” Carlos said.

The public is advised to purchase medical items only from licensed pharmacies and other related outlets.

NCR COVID-19 alert status for Pebrero, possibly lost over weekend – Malakanyang

Manila, Philippines – On Malakanyang Weekend over the weekend, the status of COVID-19 alert level was established in the National Capital Region (NCR) for residents of Pebrero.

In 31 years, Alert Level 3 only applies to the NCR.

Ayon kay Cabinet Secretary Karlo Nograles, Head of the Inter-Agency Task Force for the Management of Emerging Infectious Diseases (IATF-MEID) to talk about the NCR’s alert level in the fight against COVID- 19.

Ayon kay Nograles, sisiyasatin IATF hospital bed utilization rate pati average daily attack rate at two-week growth rate of COVID-19 compared to COVID-19.

Health Secretary Francisco Duque III was unlikely to be on alert at NCR Alert Level 2, with coronavirus infections trending downward.

Hired for the Philippine Medical Association (PMA), he manages the official publication of health protocols and restrictions related to COVID-19 in the NCR.

“The naming of palagis emphasizes the level of alert and respecting minimum health protocols and natin mapatupad…Important pa rin is magpabakuna tayo,” said Dr. Benito Atienza, the best of the PMA.

“Yun po sinasabi natin na sana hindi matulad po yung pagbaba ng alert bago po mag noel at mag new year na talagang pag alert 2 po eh yung mga tao wala na sila pakundangan na makahawa and mahawa kasi dikit dikit ang mga tao kahit sinabi namin nung una pa na kahit an alert level of gawin natin kung hindi naman nasusunod ang patakaran eh ganun pa rin ang mangyayari”, dagdag pa niya.

Maliban in the NCR, established the Pandemic Task Force which deals with the COVID-19 situation within the framework of analysis and control of the disease.

Specially located in CALABARZON, Central Luzon, Ilocos Region, and Cordillera Administrative Region.

Ayon malakanyang, establish the IATF regional working groups which have determined the COVID-19 bed capacities in all capacities necessary to master the challenges of the case.

Many patients with severe and critical cases need to be admitted to hospital in isolation facilities as they are moderate to mild cases of COVID-19.

PNP pockets more than 90 million pesos worth of illegal drugs and nabs 36 suspects in a series of operations

Manila, Philippines – The Philippine National Police (PNP) announced on Wednesday that it had seized more than 90 million pesos worth of illegal drugs in a series of operations this month.

In a statement, the PNP said the week-long Simultaneous Anti-Crime Law Enforcement (SACLEO) operations conducted from January 17 to 23 also resulted in the arrest of 36 prime drug suspects.

These coordinated anti-drug operations included 14 buy-bust operations, 18 service of arrest warrants and two marijuana eradication operations at clandestine cannabis farms in separate locations in different parts of the country, it said. -he adds.

“We scored again in the campaign against illegal drugs. The arrest of drug figures in various parts of the country is a reflection of our intensified strategies to eradicate the supply chain of this illicit activity,” said PNP Police Chief Dionardo Carlos.

The PNP leader also commended the efforts and intelligence gathering of the officers involved in the operation, as well as working with their village counterparts to address the problem of illegal drugs in their community.

“They provided the police with material information so that we could better follow the movements of those who engage in this illegal trade,” Carlos said, referring to an action program called “Double Barrel Finale”.

The PNP said the double barrel finale focuses on drug trafficking and addiction in each barangay. It also seeks to help the community find ways to avoid such a vice and redirect residents’ attention to more productive pursuits.

Carlos pledged to carry out the program during his tenure as head of the PNP.

PH records 3 more deaths among patients with COVID-19 Omicron variant

Manila, Philippines – Three additional deaths among patients who contracted the COVID-19 Omicron variant have been recorded in the country, the Department of Health (DOH) announced on Wednesday.

In a message to reporters, Health Undersecretary Maria Rosario Vergeire said the additional deaths were elderly and all had underlying medical conditions.

The new deaths brought the death toll from the Omicron variant to five.

“Three are elderly and all have comorbidities. One partially vaccinated, one unvaccinated and the other three are still being checked,” Vergeire said.

The DOH said earlier that the highly transmissible variant of Omicron is now prevalent in Metro Manila and other areas, with its BA.1 and BA.2 subvariants detected in the country.

The agency also pointed out that while the Omicron variant primarily presents with asymptomatic and mild disease, the data showed that the elderly, those with comorbidities and unvaccinated people are still most at risk of death.

The first two deaths linked to the Omicron variant also involved elderly people with comorbidities and not vaccinated against COVID-19.

The DOH said there are 535 confirmed cases of Omicron variants in the country.

read more
Medical supplies

Personal perspective: How to strengthen the supply chain of essential medical supplies and medicines

As the COVID-19 pandemic spread across the country, governments and the private sector tore through their stockpiles of personal protective equipment (PPE) and other resources. Several supply chain issues quickly emerged, including lack of visibility into sources of supply, a fragmented approach to ordering and fulfillment, and an overreliance on offshore manufacturing.

While we have made progress in managing aspects of the pandemic, disruptions to the supply chain, including raw materials, manufacturing, shipping, distribution and “last mile” delivery remain. in a system that is not designed for the demands of a pandemic.

With a few targeted strategies, it is possible to reverse these disturbances. For its part, Premier, a health care improvement company uniting 4,400 American hospitals and health systems and partner of the CHAMPS Purchasing group based in northeast Ohio, is concerned with the risk management of the supply chain for years, and we have developed forward-thinking capabilities. to help protect against interference.

To strengthen the supply chain, Premier and CHAMPS are calling for the implementation of key national priorities to meet the growing demand for essential medical supplies and medicines. We need to take a broader approach to creating an end-to-end supply chain that is transparent, diverse and reliable. Beyond quantities, we must also ensure that the United States has established contractual relationships that include contingency plans to increase production as soon as future needs are identified.

Specifically, we need to address the following points.

  • The need for domestic manufacturing: The pandemic has underscored the need for better local access to essential medical supplies, which is why we are advocating for a short-term tax incentive of 30% to support domestic manufacturing. We also believe that the private sector can play a role in promoting change related to the manufacturing of essential goods.

In March 2020, Premier launched a unionized model to ensure a robust and resilient supply chain for essential medical products. The program provides a vehicle through which Premier and its members pool capital to invest in domestic manufacturers who can supply products in short supply, providing initial cash needed to expand production capacity and modernize the plant, as well as long-term purchasing commitments to incentivize innovation. This ensures that providers have a cost-effective national alternative for their patient care needs. Here in Northeast Ohio, CHAMPS Group Purchasing has partnered with JobsOhio to implement agreements with suppliers of PPE and related products as part of our commitment to supporting local national suppliers, diversified and small businesses to advance the region’s economy.

  • The need for an innovative global sourcing strategy: Past situations such as H1N1, Ebola, and Hurricane Maria have highlighted the vulnerabilities associated with over-reliance on a single country for medical supplies and medicines. In response, several organizations (including ours) have diversified PPE production, expanding operations to multiple countries and regions to mitigate ongoing risks of product shortages. As part of this, we must also ensure that suppliers have a say in determining what should be included in the national strategic stock of equipment.
  • Tech-enabling supply chain: Until recently, hospitals were alone in translating local outbreaks of COVID-19 into immediately meaningful information regarding capacity and supplies. Now, providers are using technology to be better informed about how quickly cases are spreading and what supplies they need at any given time. This new technology takes advantage of real-time monitoring capabilities, providing early warnings, predicting surges and helping organizations plan coordinated responses where they are needed most.

Additionally, the federal government needs technology that will provide visibility into what supplies are in inventory, distribution, and hospital inventories during national emergencies. This will allow allocation to places in need and reduce hoarding and the illicit market, issues that have challenged America during the first nine months of the pandemic.

When healthcare providers can predict COVID-19-related hospitalizations and have confidence in the sufficiency of supplies of essential commodities, this creates a positive ripple effect – relieving pressure on supply chains, ensuring more responsive care in communities and helping to keep businesses and schools open and running.

Even as COVID-19 has exposed supply chain flaws and transformed the healthcare landscape, together we continue to show and improve to meet the challenges posed by the pandemic and drive healthcare innovation. health for the future.

We must come together to ensure access to the supplies, data, analysis and intelligence needed to survive and thrive in a challenging environment.

Lane is President and CEO of the Center for Health Affairs and CHAMPS Healthcare. Alkire is President and CEO of Premier Inc.

read more
Prescription drugs

Mark Cuban’s online pharmacy is now open with low-cost prescription drugs

Mark Cuban’s online pharmacy promising affordable prices on prescription drugs is up and running.

The Mark Cuban Cost Plus Drug Company cuts out the middleman and negotiates directly with drug manufacturers and pharmacies to obtain discounts and rebates on behalf of employers, health insurers and government health programs.

It says it offers the lowest direct-to-consumer prices on more than 100 medications, including those commonly prescribed for high cholesterol and blood pressure.

The cholesterol drug Atorvastatin typically costs more than $55, according to the Cuba-backed company’s website. Cost Plus charges $3.60. Prescription amlodipine for high blood pressure usually costs around $50. Cost Plus lists it at $3.30.

Alex Oshmyansky, CEO of the Mark Cuban Cost Plus Drug Company.

“The Mark Cuban Cost Plus Drug Company is trying to reduce drug costs for patients by any means necessary,” said CEO Alex Oshmyansky. “In our online pharmacy, we basically found a category of drugs that are extremely expensive, not really because of the manufacturer’s price, but because of price markups due to intermediaries in the supply chain, mainly pharmaceutical wholesalers. and pharmacy benefits managers.”

The company established its own registered pharmaceutical wholesaler and purchased drugs directly from manufacturers. He then sells the drugs at a fixed markup of 15% and a pharmacist fee of $3.

The pharmacy is cash only at the moment. By next year, Oshmyansky said the company hopes to allow customers to use their insurance.

Wednesday’s launch comes just weeks after the creation of Cuba’s Pharmacy Benefits Management Operation, which works directly with the online pharmacy. Customers can go to the website and order generic versions of drugs to be shipped to their front door.

Mark Cuban Cost Plus Drugs was first launched under a different name in 2018 as a generic drug startup. A year ago, the billionaire owner of the Dallas Mavericks went public with his support.

The company is currently building an $11 million, 22,000 square foot manufacturing facility in Deep Ellum.

Oshmyansky said thousands of people had created accounts when the website launched on Wednesday.

“Our goal is not just to get attention today, but to try to help people every day, so hopefully we can keep the excitement going,” Oshmyansky said.

read more
Generic drugs

Mark Cuban’s drug company launches pharmacy, promising huge savings on generic drugs

Mark Cuban Cost Plus Drug Company (MCCPDC) has launched its online pharmacy as part of an ongoing effort to provide consumers with drugs at low prices.

The pharmacy claims to offer significant savings, with several prescription drugs costing more than half the price of the next most affordable option. For example, imatinib for the treatment of leukemia has a retail price of $9,657 per month, according to the MCCPDC, compared to $120 with a common voucher. Its price through the new company, however, is only $47 per month.

The initial launch of the pharmacy inventory consists of 100 generic drugs.

The MCCDPC aims to circumvent so-called middlemen and markups and boasts of reflecting actual manufacturer prices with a fixed 15% fee. To avoid working with pharmacy benefit managers, the pharmacy will be cash only. The pharmacy is powered by Truepill’s digital health platform and leverages its nationwide pharmaceutical footprint to fill and deliver prescriptions.

“We will do whatever it takes to bring affordable pharmaceuticals to patients,” Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug, said in an announcement. “The mark-up on potentially life-saving medicines that people depend on is an issue that cannot be ignored. It is imperative that we act and help expand access to these medicines for those who need them most.”

RELATED: 2 New PBM Launches Aim to Bring Greater Transparency to the Market

In November, the MCCPDC launched its own Pharmacy Benefits Manager and pledged to be transparent about the costs it pays for drugs with those who work with it. With this venture, he hopes to completely eliminate the traditional PBM model.

The company plans to integrate its pharmacy and wholesaler with its PBM so that PBM customers have access to wholesale pricing through the pharmacy. Its Dallas pharmaceutical plant is expected to be built by the end of this year.

“There are many bad actors in the pharmaceutical supply chain that prevent patients from getting affordable medicines,” Oshmyansky said. “The only way to guarantee affordable prices is to integrate vertically.”

read more
Medical products

FDA Suspends Non-Mission-Critical Domestic and Foreign Inspections – Medical Product Supply Chain Week in Review | Alston and bird

Just before the New Year holidays, the FDA announced it was suspending non-mission-critical domestic and foreign inspection activities. The FDA amended the EUA of the Moderna COVID-19 vaccine recall. The Center for Drug Evaluation and Research has released its annual report. This week, the Senate HELP Committee approved the appointment of Dr. Robert Califf as Commissioner of the FDA. The senators introduced legislation that would require certain foreign establishments to register with the FDA. Please see details of these and other supply chain developments below:

  • On December 29, the FDA implemented changes to its inspection program due to record levels of COVID-19 infections. National mission-critical inspections will continue until January 19, while “some inspection activities” have been temporarily postponed. Mission-critical foreign inspections will continue; however, the agency will reassess feasibility if travel restrictions warrant. The program of priority surveillance foreign inspections which was to begin in February 2022 has been interrupted. It is likely that the FDA will not conduct any uncritical inspections, domestic or foreign, until the United States has passed the peak of the current omicron wave.
  • January 4, HHS amended its declaration under the Public Preparedness and Emergency Preparedness Act (PREP) to include pharmacists and certain pharmacy trainees as “qualified persons” who can administer flu vaccines in states where they are not not authorized or certified. The PREP Act allows the Secretary of HHS to issue a statement and grant immunity from liability to such individuals.
  • On January 5, White House Press Secretary Jen Psaki and Port Envoy to the White House Supply Chain Task Force John Porcari tenuous a briefing on the progress of supply chain improvements and new actions to come. Porcari reported that consumers received 97% to 99% of their packages on time or with minimal delays during the holiday season. Porcari added that the ports of Los Angeles and Long Beach are imposing a new tax on long-lived empty containers. Porcari stressed that procedures are in place to prioritize the distribution of medical supplies. One such procedure is to “bulk stow” medical supplies on ships for easy identification and retrieval. He also discussed the impact of the omicron variant on operations and the procedures in place to deal with any disruptions.
  • On January 7, the FDA amended the EUA of the Moderna COVID-19 vaccine recall. The agency authorized the administration of the booster dose five months (previously six months) after the primary vaccination of the vaccine.
  • On January 10, the FDA Posted draft guidance, “Notification to the FDA of a Permanently Discontinuing or Discontinuing Manufacture of a Device Under 506J of the FD&C Act”. These draft guidelines, authorized under the CARES Act of 2020, are intended to prevent shortages of medical devices before and during a public health emergency and to provide a mechanism by which manufacturers notify the FDA of their intention to cease or suspend production. The draft guidelines apply to “devices essential to public health during a public health emergency, including those that are essential to life, sustaining life or intended for use in the medical care of emergency or during surgery” or “devices for which the FDA determines information about possible significant supply disruptions are needed during or before a public health emergency. Comments are due no later than March 11, 2022.
  • On January 10, Senators Gary Peters (D-MI) and Susan Collins (R-ME) introduced S. 3449, a bill that would require foreign drug and device establishments to register with the FDA whether or not the drug or device undergoes further processing at a separate facility outside the United States. States before being imported into the United States. The goal is to give the FDA greater regulatory oversight authority to not only monitor products entering the supply chain and determine shortages, but also ensure that products are safe for the public. The Bill has been referred to the Health, Education, Labor and Pensions (HELP) Committee.
  • On January 13, the Senate HELP committee vote 13 to 8 to advance the President’s nominee for FDA Commissioner Dr. Robert Califf. His confirmation hearing took place on December 14, 2021. The nomination now goes to the Senate for a final vote and confirmation.
  • FDA Center for Drug Evaluation and Research (CDER) published its annual report, “Advancing Health Through Innovation: New Drug Therapy Approvals”. The report highlights CDER approvals of new therapies, biosimilars, and new indications for approved products. A post-marketing safety surveillance review is also included. The number of products approved (50) was above average despite the pandemic-related challenges, with more than half (27) being first-line drugs. CDER also met its action targets under the Prescription Drug User Fees Act for 49 of the 50 submissions.

[View source.]

read more
Medical products

Monetizing healthcare with disposable medical products – Hunter Women’s Chronicle

Reading time:3 minutes, 13 seconds

This report analyzes the single-use endoscope market, with the United States being the largest. The monetization of healthcare with disposable medical devices and recurring revenue from monitoring, a smaller and lighter product, creates new opportunities for broader consumer and commercial markets. Improving product quality, reducing costs and profitable growth are the keys to dominating this lucrative market. However, poor design and prototype design can be linked to several challenges. Technological innovation, integrated services and reduced R&D costs could significantly increase a company’s revenue.

Click on the tab below to benefit from the sample copy of the report

Sample request

Introduction to Single Use Endoscopes Market

Strict government regulations make it difficult for doctors, hospitals and large corporations to raise capital in the current economic climate. There has been a shift in the way pharmaceutical organizations have approached the development of disposable medical products. Pharmaceutical companies are now offering their services and expertise in this area to medical device manufacturers without costly milestone payments to third parties.

Global Endoscope Explosion

Slowing economic growth and rising import tariffs have led to a slowdown in global healthcare spending, which presents a unique opportunity for the disposable medical products market. This can be attributed in particular to the greatly increased use of endoscopes in recent years. According to Global Industry Analysts (GIA) Inc., one of the leading research companies, there were around 1 billion daisies installed globally across the globe in 2020 alone.

Defining the key players in the single use endoscopes market

The pharmaceutical industry is striving to develop and introduce more disposable products, which makes the single-use endoscope market an attractive area for new investment. A few years ago, only knives and needles were included in the disposable medical market as antibacterials. The discovery of a new way to use endoscopes, which includes test strips to determine the appropriate medications that could be prescribed without harming patients while they undergo medical tests, has increasingly served to increase the number of observers included in this market.

An analysis of the low, medium, high and technological platform; their role in product development

In March 2020, the American Society of Gastroenterology declared that endoscopes are writable and disposable. This means that with proper treatment and monitoring, these devices can last up to six months, providing a frictionless revenue stream with negligible cost to hospitals. For insights into a new market segment and the opportunities ahead, download the report Single-Use Endoscopes Market: Monetizing Healthcare with Disposable Medical Products today.

Regulations and cost variables in the preparation of single-use endoscopes

The use of disposable medical instruments, such as endoscopes, is increasing rapidly. This is due to government regulations and regulatory requirements that reduce costs for outsourced healthcare providers. Additionally, the demand for more flexible options in disposable medical devices is pushing manufacturers towards more specialized instruments with various functionalities.

Click on the tab below for the instant purchase of the report with a flat rate discount of $500

Instant Buy Request

Supply chain approach for manufacturer pharmaceutical process for disposable medical products

Due to stringent government regulations and increasing attention to patient safety and human factor issues, the healthcare industry is moving towards a system where the emphasis is on the quality life cycle. Patient safety issues leading to contaminated supply chains pose a major challenge to manufacturers. Reports show that healthcare interventions are highly dependent on the use of home medical products, but it has been difficult from a business perspective to effectively plan for a market with multiple users of these products. Manufacturers are required to closely monitor the demand for single-use endoscopes for the development of replacement products. A supply chain approach will be more effective in achieving affordability and meeting regulatory requirements unlike other methods that manufacturers have tried in the past.

happy

happy


0 %

Sad

Sad


0 %

Excited

Excited


0 %

Sleepy

Sleepy


0 %

Angry

Angry


0 %

Surprise

Surprise


0 %

read more
Generic drugs

Generic Drugs Market Segmentation, Analysis by Recent Trends, Development by Region to 2030 Abbott Laboratories, Allergan, Inc., Alvion Pharmaceuticals PC, Amneal Pharmaceuticals, Inc

The Global Generic Drugs Market Report is a compilation of in-depth research studies on various aspects of the Generic Drugs Market. With precise data and highly authentic information, it brilliantly attempts to deliver a real and transparent picture about the current and future situations of the global Generic Drugs Market. Market players can use this powerful tool to create effective business plans or make significant changes to their strategies. The report discusses the growth of global and regional markets. It also sheds light on the high growth segments of the global generic drugs market and their development in the coming years.

Key players operating in the global generic drugs market include: Abbott Laboratories, Allergan, Inc., Alvion Pharmaceuticals PC, Amneal Pharmaceuticals, Inc., Aspen Pharmacare Holdings Limited., AstraZeneca plc., Cipla Inc., Dr. Reddy’s Laboratories Ltd., Egis Group, Eli Lilly and Company, Endo International plc , Fresenius Kabi Kabi SwissBioSim GmbH, Gedeon Richter Ltd, Gilead Sciences, Inc., GlaxoSmithKline Plc., Lupine Pharmaceuticals, Inc., Mylan NV, Novartis International AG, Pfizer Inc., STADA Arzneimittel AG, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd .

Request a sample PDF copy of this report from: https://www.absolutemarketsinsights.com/request_sample.php?id=603

Global Generic Drugs Market was valued at USD 284.56 Billion in 2018 and is projected to reach USD 472.32 Billion by 2027, growing at a CAGR of 5.8% over the forecast period.

The study of the generic drugs market follows a combination of in-depth research and structured methodology. These methods probe the market from different angles to find suitable analyses. However, on a general scale, data is gathered from a variety of trusted sources such as vendor listing, product and research papers, manufacturer processes, and many more. Every market research is given the exact same careful shadow that makes it valuable reading.

The Generic Drugs market report categorized the market into segments comprising product type and application. Each segment is assessed based on its share and growth rate. In addition, analysts have studied potential regions that could prove valuable for manufacturers in the years to come. The regional analysis includes reliable forecasts of value and volume, helping market players to gain in-depth knowledge about the entire industry. In addition, the Generic Drugs market study revolves around the development of regional trends, preferred marketing channels, long-term stability, and environmental analysis. It also contains product capabilities, price, earnings status, demand, production and market growth and a trajectory of future forecasts.

If you have any questions/requests, ask our expert: https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=603

Impact of COVID-19:

This study presents insights into COVID-19 in consumer behavior and changing demand, buying habits, supply chain reorganization, market force dynamics, and substantial involvement of the government. The new research provides insights, analysis, estimates and forecasts considering the effect of COVID-19 on the markets.

Reasons to buy the report:

  • The study details the generic drugs market with a detailed market breakdown in terms of volume, size and value across all sectors.
  • A comprehensive breakdown of the Generic Drugs market supported by graphs, pie charts, and figures aids understanding.
  • A projected forecast of the generic drugs market is expected to be extracted from real-time data points which are a compilation of 2016 to current data.

Customization request: https://www.absolutemarketsinsights.com/request_for_customization.php?id=603

Global Generic Drugs Market Segmentation:

By type

  • Prescription products
  • Over-the-counter (OTC) products

By app

  • Respiratory
  • Dermatology
  • Oncology
  • Diabetes
  • Infectious diseases
  • Ophthalmology
  • women’s health
  • Central nervous system (CNS)
  • Cardiovascular
  • Urology
  • Others (pain management, etc.)

By form

  • Tablets
  • capsules
  • Injectables
  • Topical creams
  • Others

By distribution channel

  • Retail pharmacy
  • Hospital pharmacy

By region:

  • North America [U.S., Canada, Mexico]
  • Europe [Germany, UK, France, Italy, Rest of Europe]
  • Asia Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
  • South America [Brazil, Argentina, Rest of Latin America]
  • Middle East and Africa [GCC, North Africa, South Africa, Rest of the Middle East and Africa]

For more information, click on: https://www.absolutemarketsinsights.com/reports/Generic-Drugs-Market-2019-2027-603

Contact us:

Company: Absolute Markets Insights
Email ID: [email protected]
Phone: IN +91-740-024-2424, US +1-510-420-1213
Contact Name: Shreyas Tanna
Website: www.absolutemarketsinsights.com/

read more
Medical products

FDA suspends non-mission-critical domestic and foreign inspections – Medical Products Supply Chain Week in Review – Food, Drugs, Healthcare, Life Sciences

United States: FDA suspends non-mission-critical domestic and foreign inspections – Medical Product Supply Chain Week in Review

To print this article, all you need to do is be registered or log in to Mondaq.com.

Just before the New Year holidays, the FDA announced it was suspending non-mission-critical domestic and foreign inspection activities. The FDA amended the EUA of the Moderna COVID-19 vaccine recall. The Center for Drug Evaluation and Research has released its annual report. This week, the Senate HELP Committee approved the appointment of Dr. Robert Califf as Commissioner of the FDA. The senators introduced legislation that would require certain foreign establishments to register with the FDA. Please see details of these and other supply chain developments below:

  • On December 29, the FDA implemented changes to its inspection program due to record levels of COVID-19 infections. National mission-critical inspections will continue until January 19, while “some inspection activities” have been temporarily postponed. Mission-critical foreign inspections will continue; however, the agency will reassess feasibility if travel restrictions warrant. The program of priority surveillance foreign inspections which was to begin in February 2022 has been interrupted. It is likely that the FDA will not perform any uncritical inspections, domestic or foreign, until the United States has passed the peak of the current omicron wave.
  • January 4, HHS amended its declaration under the Public Preparedness and Emergency Preparedness Act (PREP) to include pharmacists and certain pharmacy trainees as “qualified persons” who can administer flu vaccines in states where they are not not authorized or certified. The PREP Act allows the Secretary of HHS to issue a statement and grant immunity from liability to such individuals.
  • On January 5, White House Press Secretary Jen Psaki and Port Envoy to the White House Supply Chain Task Force John Porcari tenuous a briefing on the progress of supply chain improvements and new actions to come. Porcari reported that consumers received 97% to 99% of their packages on time or with minimal delays during the holiday season. Porcari added that the ports of Los Angeles and Long Beach are imposing a new tax on long-lived empty containers. Porcari stressed that procedures are in place to prioritize the distribution of medical supplies. One such procedure is to “bulk stow” medical supplies on ships for easy identification and removal. He also discussed the impact of the omicron variant on operations and the procedures in place to deal with any disruptions.
  • On January 7, the FDA amended the EUA of the Moderna COVID-19 vaccine recall. The agency authorized the administration of the booster dose five months (previously six months) after the primary vaccination of the vaccine.
  • On January 10, the FDA Posted draft guidance, “Notification to the FDA of a Permanently Discontinuing or Discontinuing Manufacture of a Device Under 506J of the FD&C Act.” These draft guidelines, authorized under the CARES Act of 2020, are intended to prevent shortages of medical devices before and during a public health emergency and to provide a mechanism by which manufacturers notify the FDA of their intention to cease or suspend production. The draft guidelines apply to “devices essential to public health during a public health emergency, including those that are essential to life, sustaining life or intended for use in the medical care of emergency or during surgery” or “devices for which the FDA determines information about possible significant supply disruptions are needed during or before a public health emergency.” Comments are due by March 11, 2022.
  • On January 10, Senators Gary Peters (D-MI) and Susan Collins (R-ME) introduced S. 3449, a bill that would require foreign drug and device establishments to register with the FDA whether or not the drug or device undergoes further processing at a separate facility outside the United States. States before being imported into the United States. The goal is to give the FDA greater regulatory oversight authority to not only monitor products entering the supply chain and determine shortages, but also ensure that products are safe for the public. The Bill has been referred to the Health, Education, Labor and Pensions (HELP) Committee.
  • On January 13, the Senate HELP committee vote 13 to 8 to advance the President’s nominee for FDA Commissioner Dr. Robert Califf. His confirmation hearing took place on December 14, 2021. The nomination now goes to the Senate for a final vote and confirmation.
  • FDA Center for Drug Evaluation and Research (CDER) published its annual report, “Advancing Health Through Innovation: Approvals of New Drug Therapies”. The report highlights CDER approvals of new therapies, biosimilars, and new indications for approved products. A post-marketing safety surveillance review is also included. The number of products approved (50) was above average despite pandemic-related challenges, with more than half (27) being first-line drugs. CDER also met its action targets under the Prescription Drug User Fees Act for 49 of the 50 submissions.

The content of this article is intended to provide a general guide on the subject. Specialist advice should be sought regarding your particular situation.

POPULAR ARTICLES ON: US Food, Drugs, Healthcare, Life Sciences

read more
Prescription drugs

This is why prescription drugs are so expensive

Oligopoly: a state of limited competition, in which a market is shared by a small number of producers or sellers.

SALT LAKE CITY — Why are prescription drugs so expensive? An advocate for open access, transparency and competitive markets in the pharmaceutical industry shares his mind-blowing insights into the prescription drug industry and how insiders, whose job it is to watch over consumers, rake in a fortune.

Welcome to the show

Heather Kelly, host of Money Making Sense, talks with Antonio Ciaccia, president of 3 Axis Advisors, about pharmacy benefit managers and their role in controlling prescription drug costs.

“How do prescription drugs get to our pharmacies? asked Kelly.

In simple terms, Ciaccia explained the main pillars of the prescription drug supply chain:

  • A drug manufacturer sells to a drug wholesaler, such as McKesson, Cardinal Health, or AmerisourceBergen.
  • The wholesaler then sells the medicine to pharmacies, hospitals and medical practices.
  • And with each step, the price of the drug increases for the end consumer.

PBMs administer prescription drug benefits on behalf of health insurers, Medicare Part D drug plans, large employers and other payers.

By negotiating with drug manufacturers and pharmacies to control drug spending, PBMs have a significant behind-the-scenes impact on determining total drug costs for insurers, patient access to drugs, and provider compensation. pharmacies, according to the Commonwealth Fund.

“Keep these discounts to themselves”

“They’re not doing a great job, especially for my mom,” Kelly said, explaining that her mom, who is on Medicare, pays $250 out of pocket every month for a drug she needs. “She still has to buy four or five more. So these PBMs don’t do a great job. I’m just telling you now.

“Unfortunately, the system was supposed to work much better,” Ciaccia said.

He added that PBMs were designed to counterbalance the drugmaker, wholesalers and pharmacies and negotiate greater discounts for consumers.

“The problem is that PBMs are really good at negotiating these discounts, but they’re even better at keeping these discounts to themselves, often forcing the patient to pay the full list price when they’ve negotiated a price themselves. far different and better for himself,” he said.

Ciaccia said PBMs used to be just claims processors, but have since landed on the list of America’s biggest and richest companies.

The top 10 Fortune 500 companies in the United States include:

  • CVS Health, owner of CVS Pharmacy, a chain of retail pharmacies; CVS Caremark, a pharmaceutical benefits manager;
    UnitedHealthGroup, which offers healthcare products and insurance services;
    McKesson, which distributes pharmaceuticals and provides health information technology, medical supplies and care management tools; and
    AmerisourceBergen, a wholesale drug company.

Who watches the watchdog?

“They’re bigger than the pharmaceutical companies and drugmakers they were hired to police in the first place,” Ciaccia said.

He said PBMs ended up making prescription drug pricing more complicated and expensive.

“The PBM uses all of us as individuals to negotiate deep discounts that they get at the end of the transaction. But they don’t pass them on to us as a patient,” Ciaccia said.

Heather said her blood was starting to boil “a little bit right now”.

No one knows the price of drugs

Ciaccia said if you walked into a grocery store and it cost $20 for a gallon of milk, you’d know right away you were being ripped off. You would take your money to another grocery store where the price of milk would match market expectations.

It’s “what ultimately holds quality and price accountable in your grocery store. Nobody knows what the prices of thousands of different drugs are or what they should be,” he said.

Ciaccia said that due to the “enormous” lack of transparency, the pharmaceutical market is ripe for exploitation.

“Let’s be clear, PBMs aren’t the only villains in the drug supply chain, but they’re the only ones whose existence is predicated on trying to save us money,” he said. declared.

Related:

read more
Medical products

2022 Emergency Oxygen Kits Market Analysis by Major Key Players

New Jersey, United States,-

A new report titled “(Emergency Oxygen Kits Market)” by Market Research Intellect sheds light on the industry dynamics and current and future trends that play a key role in determining the expansion of the market. ‘business. The report also highlights the key driving factors and restraints affecting the growth. For a comprehensive understanding, experts reviewed regulatory scenarios, market entry strategies, industry best practices, pricing strategies, technology and consumer environment, sales and demand outlook . It also included growth estimates to provide users with accurate statistics and facts. The report will provide readers with a broader and more transparent picture of the overall scenario.

Corona impact outlook 19

This section of the report shows the impact of the global Corona outbreak on businesses. The report describes the impact on manufacturing activity, production, demand, supply chain, logistics management and distribution networks. The analysts have highlighted the measures or strategies taken by the company to combat the impact of Corona 19. In addition, they have identified a major opportunity to emerge after Corona 19. This will help players take advantage of the opportunity to recover losses and stabilize the activity.

Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=559836

Additionally, market revenue based on region and country is provided in the Emergency Oxygen Kits report. The authors of the report also shed light on common business tactics adopted by players. Key players of the global Emergency Oxygen Kits market and their comprehensive profiles are included in the report. Additionally, investment opportunities, recommendations, and current trends in the global Emergency Oxygen Kits market are mapped by the report. Using this report, key players in the global Emergency Oxygen Kits Market will be able to make sound decisions and plan their strategies accordingly to stay ahead.

The competitive landscape is an essential aspect that every key player must know. The report highlights the competitive scenario of the Global Emergency Oxygen Kits Market to know the competition at country and global level. Market experts have also provided an outline of each major player in the global Emergency Oxygen Kits market, considering key aspects such as business areas, production, and product portfolio. Additionally, the companies in the report are studied based on key factors such as company size, market share, market growth, revenue, production volume, and profit.

Major Players Covered by Emergency Oxygen Kits Markets:

  • Mada Medical Products
  • Inc.
  • Marine Medical Antibes
  • Corporate Life
  • FERNO
  • Allied Health Care
  • Mega medical

Emergency Oxygen Kits Market Split By Type:

Emergency Oxygen Kits Market Split By Application:

  • Hospitals and Clinics
  • Industrial and factories
  • Public facilities

The Emergency Oxygen Kits Market report has been segregated into distinct categories such as product type, application, end-user, and region. Each segment is valued based on CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is expected to generate opportunities in the Global Emergency Oxygen Kits Market in the coming years. This segmental analysis will surely prove to be a helpful tool for readers, stakeholders, and market players to get a complete picture of the global Emergency Oxygen Kits market and its growth potential in the years future.

Get | Discount on the purchase of this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=559836

Scope of the Emergency Oxygen Kits Market Report

Report attribute Details
Market size available for years 2021 – 2028
Reference year considered 2021
Historical data 2015 – 2019
Forecast period 2021 – 2028
Quantitative units Revenue in USD Million and CAGR from 2021 to 2027
Segments Covered Types, applications, end users, and more.
Report cover Revenue Forecast, Business Ranking, Competitive Landscape, Growth Factors and Trends
Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Scope of customization Free report customization (equivalent to up to 8 analyst business days) with purchase. Added or changed country, region and segment scope.
Pricing and purchase options Take advantage of personalized purchasing options to meet your exact research needs. Explore purchase options

Regional Analysis of the Emergency Oxygen Kits Market can be represented as follows:

Each regional Emergency Oxygen Kits industry is carefully researched to understand its current and future growth scenarios. This helps players strengthen their position. Use market research to get a better perspective and understanding of the market and target audience and ensure you stay ahead of the competition.

Based on geography, the global emergency oxygen kit market has been segmented as follows:

    • North America includes the United States, Canada and Mexico
    • Europe includes Germany, France, UK, Italy, Spain
    • South America includes Colombia, Argentina, Nigeria and Chile
    • Asia Pacific includes Japan, China, Korea, India, Saudi Arabia and Southeast Asia

Answers to key questions in the report:

  • What is the growth potential of the Emergency Oxygen Kits markets?
  • Which product segment will take the lion’s share?
  • Which regional market will impose itself as a precursor in the years to come?
  • Which application segment will grow at a rapid pace?
  • What are the growth opportunities that may emerge in the Lock Washers industry in the coming years?
  • What are the major challenges that the global emergency oxygen kit markets may face in the future?
  • Who are the leading companies in the Global Emergency Oxygen Kits Market?
  • What are the key trends that are positively impacting market growth?
  • What are the growth strategies considered by the players to maintain their hold in the global emergency oxygen kits market?

For more information or query or customization before buying, visit @ https://www.marketresearchintellect.com/product/global-emergency-oxygen-kits-market-size-forecast/

The study thoroughly explores the profiles of major market players and their major financial aspects. This comprehensive business analyst report is useful for all existing and new entrants when designing their business strategies. This report covers the Emergency Oxygen Kits market production, revenue, market share and growth rate for each key company, and covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Historical failure data of emergency oxygen kits from 2016 to 2020 and forecast to 2021-2029.

About Us: Market Research Intellect

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations, in addition to the goal of providing customized and in-depth research studies. range of industries including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. etc Our research studies help our clients to make decisions based on higher data, to admit deep forecasts, to grossly capitalize with opportunities and to optimize efficiency by activating as their belt in crime to adopt a mention precise and essential without compromise. customers, we have provided expert behavior assertion research facilities to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

Contact us:
Mr. Edwyne Fernandes
USA: +1 (650)-781-4080
UK: +44 (753)-715-0008
APAC: +61 (488)-85-9400
US toll free: +1 (800)-782-1768

Website: –https://www.marketresearchintellect.com/

read more
Medical products

Alimed, Bioseal, Cypress Medical Products, Deroyal, Dukal Corporation, Dynarex Corporation – Industrial Computing

The global tourniquet market 2021 The report is a collection of details related to each market related parameter. Each aspect is studied in detail in the analysis report. The market analysis report provides a comprehensive analysis of all financial topics associated with the Tourniquet industry. The growth pattern observed in the Turnstile industry performance over time is studied in the market report. The study helps provide an in-depth understanding of fundamental changes in the state of the market over time. The analysis report also provides an in-depth discussion about all the aspects that are likely to impact on the performance of the Tourniquet market.

The report profiles the following companies, which include

  • Alimed
  • Bioseal
  • Cypress Medical Products
  • Deroyal
  • Dukal Corporation
  • Dynarex Company
  • Graham-Field Inc
  • Integrated Life Sciences
  • Medline
  • Cardinal Health
  • Patterson Medical
  • Stryker
  • Tetra Medical Supply Corp
  • VBM
  • Zimmer
  • Longtai
  • Lantian

The industry report analyzes the set of deliberate movements in the Tourniquet industry on a global level. The research includes an in-depth study of the growth and development activities taking place in the Tourniquet industry. The research based on the global Turnstiles market provides details associated with fundamental events and investments made in the market. The research provides details related to popular trends widely accepted by entities in the Tourniquet market. The industry analysis report includes an in-depth discussion of several industry analysis strategies used by researchers while documenting the research.

Download a free sample at: https://courant.biz/report/global-tourniquet-market/61152/

Global Tourniquets Market: Product Segment Analysis

  • Non-inflatable tourniquets (electronic tourniquet systems connected to inflatable armbands.)
  • Pneumatic tourniquets, the cuffs of which are inflated by compressed gas.

Global Tourniquets Market: Application Segment Analysis

  • Surgical framework
  • Emergency use

Global Tourniquet Market: Regional Segment Analysis

  • United States
  • Europe
  • Japan
  • China
  • India
  • South East Asia

Research includes the analysis of all deliberate movements, policies, technological developments, discoveries, trends, tools, products, development plans, news, etc. The analysis of the global Tourniquet market covers detailed data about the anticipated growth rate for the anticipated era. In addition, a detailed discussion about the future scope of the Turnstile market is also included in the study report. The report on the global Tourniquet industry focuses on the expansion of the market in the coming times. It offers readers detailed data on several strategies and development plans implemented by market entities across the world. The report aims to provide a 360 degree view of the tourniquet industry.

The content of the study topics includes a total of 10 chapters:

  1. About Tourniquet Industry (Industry Definition, Types, Main Market Activities)
  2. Global Market Competition Landscape (Markets by Regions, Market Revenue (M USD), Market Sales and Growth Rate 2016-2021, Major Players Revenue by Regions)
  3. Global Tourniquet Market Share (Production and Revenue Market Share by Regions and Players)
  4. Supply chain (raw material analysis, raw material market analysis, cost of production, manufacturing equipment and end user analysis)
  5. Company Profiles (Company Details, Product Info, Revenue, Profit Analysis)
  6. Globalization and commerce (business locations, supply channels, marketing strategy, etc.)
  7. Distributors and customers (Information on the main distributors and customers by region)
  8. Import, export, consumption and consumption value by major countries
  9. Global Tourniquet Market Forecast to 2026 (Demand, Price Revenue, Regions, Types, Applications)
  10. Key success factors and market overview

Access the full report here:https://courant.biz/report/global-tourniquet-market/61152/

Customization of the report:

This report can be customized to meet customer requirements. Please connect with our sales team ([email protected]), which will make sure you get a report that’s right for you. You can also contact our leaders at +1 (210) 807 3402 to share your research needs.

Contact us:
Nancy smith
Business sales specialist
[email protected]
Phone number: United States: +1 (210) 807 3402
current.biz

read more
Medical products

Greenrise Global’s medical cannabis subsidiary, AMP Alternative Medical Products GmbH, announces the start of dronabinol sales in Germany

Dronabinol is pure tetrahydrocannabinol (THC) and is registered as an active pharmaceutical ingredient (API) and has been registered for sale with the competent authorities in Germany. Doctors and pharmacists can find more information about the product or order on the AMP website: https://amp-eu.com/doccheck-login/

AMP and Eurox have entered into a non-exclusive agreement for the marketing and distribution of Dronabinol for sale in pharmacies from February 2022. In preparation for the launch of pharmacy sales, AMP trained its national sales team on the benefits of Dronabinol for patients to physicians and preparation methods for pharmacists.

Eurox was one of the first medical cannabis companies to produce Dronabinol made in Germany to one of Europe largest GMP facilities located in Hesse, Germany and controls the entire supply chain, from cultivation, production to distribution, ensuring a stable and efficient supply to its customers.

Neil Smith, the President of Eurox commented: “If you believe in ‘Made in Germany‘, it means Eurox. AMP’s focus on serving German patients and its national sales coverage make it an ideal partner for us.”

dr. Stefan Feuerstein, President and Director of Greenrise Global and Managing Director of AMP, “The German market is gravitating towards pharmaceuticals as health authorities tighten their regulatory oversight to ensure patient safety. Dronabinol is a well-established product in the Germany, and we expect it to be one of our best-selling products this year.”

About Eurox Pharma

Eurox Pharma is one of Europe leading medical cannabis companies. Eurox is vertically integrated, with:

  • Fully owned German subsidiaries responsible for product development and intellectual property.
  • Manufactured to EU GMP in Germany with a German pharmaceutical partner.
  • A cultivation facility at Portugal ensure vertical integration and independence of supply.
  • A significant minority stake in Integro Medical Clinics, a UK-registered medical cannabis clinic.
  • Various high caliber distribution partnerships in Germany and other European countries and its own sales team.

For more information on Eurox, please visit www.eurox-pharma.com

About Greenrise Global Brands

Greenrise Global helps people realize the beneficial properties of cannabis. Greenrise Global is a publicly traded Canadian company with two German operating subsidiaries: Greenrise GmbH (“Greenrise Wellbeing”) and AMP Alternative Medical Products GmbH (“AMP”). Greenrise Wellbeing is a CBD wellness company based in Hamburg, with brands such as Herbify and CANAVEX® in his wallet.

AMP is based in Erfurt and supplies medical cannabis products to pharmacies across Germany, including the medical cannabis brands of Aphria, Bedrocan, Small green pharmacy and GPAof the branded product line and sold through its national sales team. AMP complies with the German Narcotics Act (BtMG) and the regulatory requirements of the Free State of Thuringia, ensuring that products imported from around the world and sold in Germany Meet the European Union Good Manufacturing Practice (EU-GMP) standard.

For more information about Greenrise Global, please visit https://greenriseglobal.com/

FOLLOW US ON:

Twitter: https://twitter.com/GreenriseGlobal
LinkedIn: https://linkedin.com/company/greenriseglobal/
Instagram: https://www.instagram.com/greenriseglobal/

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This press release contains forward-looking statements based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and their calendar. Although the Company believes that the expectations expressed in these forward-looking statements are based on reasonable assumptions, these statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Accordingly, actual results may differ materially from those expressed in such forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless the otherwise required by law.

SOURCE Greenrise Global Brands Inc.

For further information: GREENRISE CONTACT: Hendrik Knopp, Director, [email protected], +1 236-833-1602; Media inquiries: Valeria Bravo, Corporate Communications and Media, [email protected], +1 604-689-7533; AMP CONTACT: Dr. Stefan Feuerstein, President, Greenrise Global Inc., Managing Director, AMP Alternative Medical Products GmbH, [email protected], +49 151 7284 4643; EUROX CONTACT: Jessica Smith, International Director of Public Relations and Marketing, [email protected]

read more
Generic drugs

Fitch, Health News, ET HealthWorld

India will become the world’s largest production hub for general Covid-19 antiviral drugs after the Drugs Controller granted emergency use authorization to several pharmaceutical companies in the country to manufacture and market generic versions of molnupiravir, said Fitch Solutions on Friday.

Increased access to molnupiravir will keep hospitalizations and deaths in India manageable as Omicron infections rise, Fitch Solutions said in a report.

Those that have obtained clearance from the Drugs Controller General of India (DCGI) include Dr. Reddy’s Laboratories, Torrent Pharmaceuticals, Cipla, Sun Pharma, Natco Pharma, Viatris, Hetero Drugs and Mankind Pharma.

Lagevrio (Molnupiravir) was developed by Merck and Ridgeback Biotherapeutics, and it is the first-ever oral antiviral drug for the treatment of high-risk adults with mild to moderate Covid-19.

Following clearance, Cipla, Sun Pharma and Dr. Reddy’s Laboratories are expected to market molnupiravir capsules in the coming weeks, with other companies to follow.

“This will make India the world’s largest hub for the production of generic Covid-19 antiviral drugs,” he said. “Efficacy of molnupiravir during its Phase III MOVe-OUT trial has been broadly promising, with a 50% reduction in hospitalizations and deaths in early-stage infections.” However, safety concerns remain over its risk of inducing harmful mutagenesis if the drug is prescribed worldwide, creating the potential for new strains of Covid-19.

The second wave of Covid-19 in India peaked in April and May 2021 when daily average cases exceeded 4 lakh. The number of cases has fallen significantly since then, with the national tally remaining below 10,000 cases per day for the rest of the year.

However, in recent days there has been an increase in daily cases of Covid-19 driven by the Omicron variant which is expected to overtake Delta as the dominant variant.

On January 6, 2022, Covid-19 cases rose to 1,17,100, with 3,007 cases confirmed to be the Omicron variant, according to the Union Health Ministry.

“Additionally, India continues to lag behind in its Covid-19 vaccine rollout target as 44.5% of the population has been fully vaccinated,” Fitch Solutions quoted Our World In Data as saying. “Therefore, given the slow pace of vaccination and the recent sharp increase in Covid-19 cases, generic versions of molnupiravir could significantly reduce the risk of hospitalization or death.”

Generic molnupiravir will increase access in India and other low- and middle-income (LMIC) countries, while simplifying current supply chain barriers, he said.

A full five-day course of molnupiravir in the United States costs around US$712 (Rs. 52,909). Generic versions of the drug will cost between $18.79 (about Rs. 1,400) and $21.48 (about Rs. 1,600) for a five-day course, which is significantly lower, according to Fitch Solutions.

For example, Dr. Reddy has priced his generic version of molnupiravir, molflu, at US$0.4693 (Rs. 35) per capsule and US$18.79 (Rs. 1,400) for a five-day course of 40 capsules. .

“With this relatively low cost, we expect generic versions of molnupiravir to significantly increase access in India and other LRICs after regulatory approvals,” he said.

Additionally, these oral antiviral drugs will result in lower transportation and distribution costs compared to intravenous Covid-19 antivirals such as Ronapreve (casirivimab/imdevimab) or Veklury (remdesivir).

Having a solid and compact shape, oral medications do not require glass vial containment requirement and the tablets can be packed tightly without risk of breakage. Likewise, more of the drug can be contained in a defined space, increasing the rate at which the drug can be dispensed, he added.

read more
Generic drugs

Drug covid: India will become a hub for generic antiviral drugs Covid-19: Fitch

India will become the world’s largest general production center of Covid-19 antiviral drugs after the drug controller granted emergency use authorization to several pharmaceutical companies in the country to manufacture and market generic versions of molnupiravir, Fitch Solutions said Friday.

Increased access to molnupiravir will keep hospitalizations and deaths in India manageable as Omicron infections increase, Fitch Solutions said in a report.

Those who have obtained authorization from the Drugs Controller General of India (DCGI) include Dr. Reddy’s, Torrent Pharmaceuticals, Cipla, Sun Pharma, Natco Pharma, Viatris, Hetero Drugs and Mankind Pharma laboratories.

Lagevrio (Molnupiravir) was developed by Merck and Ridgeback Biotherapeutics, and it is the first-ever oral antiviral drug for the treatment of high-risk adults with mild to moderate Covid-19.

Following the clearance, Cipla, Sun Pharma and Dr Reddy’s labs are expected to launch molnupiravir capsules in the coming weeks, with the other companies to follow.

“This will make India the world’s largest production center for generic Covid-19 antiviral drugs,” he said. “The efficacy of molnupiravir during its phase III MOVe-OUT trial has been broadly promising, with a 50% reduction in hospitalizations and deaths in early-stage infections.” However, safety concerns remain about its risk of inducing harmful mutagenesis if the drug is prescribed globally, creating potential for new strains of Covid-19.

The second wave of Covid-19 in India peaked in April and May 2021, when the daily average of cases exceeded 4 lakh. The number of cases has declined significantly since then, with the national tally remaining below 10,000 cases per day for the rest of the year.

However, in recent days there has been an increase in daily cases of Covid-19 driven by the Omicron variant which is expected to overtake Delta as the dominant variant.

On January 6, 2022, Covid-19 cases rose to 1,17,100, of which 3,007 were confirmed to be the Omicron variant, according to the Union Ministry of Health.

“Additionally, India continues to lag behind in its Covid-19 vaccine deployment target, as 44.5% of the population has been fully vaccinated,” Fitch Solutions said citing Our World In Data. “Therefore, given the slow pace of vaccination and the recent sharp increase in Covid-19 cases, generic versions of molnupiravir could significantly reduce the risk of hospitalization or death. ”

Generic molnupiravir will increase access in India and other low and middle income countries (LMICs), while simplifying current supply chain barriers, he said.

A full five-day treatment with molnupiravir in the US costs around $ 712 (around Rs. 52,909). Generic versions of the drug will cost between $ 18.79 (around Rs 1,400) and $ 21.48 (around Rs 1,600). ) for a five-day course, which is significantly lower, according to Fitch Solutions.

For example, Dr Reddy priced his generic version of molnupiravir, molflu, at $ 0.4693 (Rs 35) per capsule and $ 18.79 (Rs 1,400) for a five-day course of 40 capsules. .

“With this relatively low cost, we expect generic versions of molnupiravir to dramatically increase access in India and other LMICs following regulatory approvals,” he said.

Additionally, these oral antivirals will lead to lower transportation and distribution costs compared to Covid-19 intravenous antivirals such as Ronapreve (casirivimab / imdevimab) or Veklury (remdesivir).

Having a solid and compact form, oral medications do not require confinement of the glass vials and the tablets can be packaged tightly without risk of breakage. Likewise, a larger amount of the drug can be contained in a defined space, increasing the speed at which the drug can be dispensed, he added.

read more
Generic drugs

India to become hub for generic Covid-19 antiviral drugs: Fitch

India will become the world’s largest production hub for general Covid-19 antiviral drugs after the drug controller granted emergency use authorization to several pharmaceutical companies in the country to manufacture and market generic versions of molnupiravir, said Fitch Solutions on Friday.

Increased access to molnupiravir will keep hospitalizations and deaths in India manageable as Omicron infections rise, Fitch Solutions said in a report.

Those that have obtained clearance from the Drugs Controller General of India (DCGI) include Dr. Reddy’s Laboratories, Torrent Pharmaceuticals, Cipla, Sun Pharma, Natco Pharma, Viatris, Hetero Drugs and Mankind Pharma.

Lagevrio (Molnupiravir) was developed by Merck and Ridgeback Biotherapeutics, and it is the first-ever oral antiviral drug for the treatment of high-risk adults with mild to moderate Covid-19.

Following clearance, Cipla, Sun Pharma and Dr. Reddy’s Laboratories are expected to market molnupiravir capsules in the coming weeks, with other companies to follow.

“This will make India the world’s largest hub for the production of generic Covid-19 antiviral drugs,” he said. “Efficacy of molnupiravir during its Phase III MOVe-OUT trial has been broadly promising, with a 50% reduction in hospitalizations and deaths in early-stage infections.” However, safety concerns remain over its risk of inducing harmful mutagenesis if the drug is prescribed globally, creating the potential for new strains of Covid-19.

The second wave of Covid-19 in India peaked in April and May 2021 when daily average cases exceeded 4 lakh. The number of cases has fallen significantly since then, with the national tally remaining below 10,000 cases per day for the rest of the year.

However, in recent days there has been an increase in daily cases of Covid-19 driven by the Omicron variant which is expected to overtake Delta as the dominant variant.

On January 6, 2022, Covid-19 cases rose to 117,100, with 3,007 cases confirmed to be the Omicron variant, according to the Union Health Ministry.

“Additionally, India continues to lag behind in its Covid-19 vaccine rollout target as 44.5% of the population has been fully vaccinated,” Fitch Solutions quoted Our World In Data as saying. “Therefore, given the slow pace of vaccination and the recent sharp increase in Covid-19 cases, generic versions of molnupiravir could significantly reduce the risk of hospitalization or death.”

Generic molnupiravir will increase access in India and other low- and middle-income (LMIC) countries, while simplifying current supply chain barriers, he said.

A full five-day course of molnupiravir in the US costs around $712 ( 52,909). Generic versions of the drug will cost between 18.79 USD (approximately 1,400) at $21.48 (approx. 1,600) for a five-day course, which is significantly lower, according to Fitch Solutions.

For example, Dr. Reddy priced his generic version of molnupiravir, molflu, at $0.4693 ( 35) per capsule and $18.79 ( 1,400) for a five-day course of 40 capsules.

“With this relatively low cost, we expect generic versions of molnupiravir to significantly increase access in India and other LRICs after regulatory approvals,” he said.

Additionally, these oral antiviral drugs will result in lower transportation and distribution costs compared to intravenous Covid-19 antivirals such as Ronapreve (casirivimab/imdevimab) or Veklury (remdesivir).

Having a solid and compact shape, oral medications do not require glass vial containment requirement and the tablets can be packed tightly without risk of breakage. Likewise, more drug can be contained in a defined space, increasing the rate at which the drug can be dispensed, he added.

To subscribe to Mint Bulletins

* Enter a valid email address

* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint. Download our app now!!

read more
Medical products

FDA Approves Booster Dose for Teens – Medical Products Supply Chain Weekly Review | Alston & Bird

During the holidays, the CDC updated its recommendations for quarantine and post-exposure masking. The FDA has cleared the booster dose of Pfizer vaccine for adolescents 12 to 15 years old and for immunocompromised children 5 to 11 years old. The FDA has released draft guidelines for manufacturers of medical devices marketed under EUA or enforcement discretion policies to help them transition to traditional approvals at the end of the health emergency. public. The Administration has convened the Supply Chain Disruption Working Group for an update on its progress. The FDA has issued guidance for lab staff and manufacturers on technical considerations for new strains in developing COVID-19 tests and reading current test results. Please see details of these and other supply chain developments below:

  • On December 22, the President convened a meeting of the Supply Chain Disruption Task Force with stakeholders from the business sector. The implementation of the recommendations of the Working Group has led to drastic improvements in the flow of goods in the main ports. Dwell times in the ports of Long Beach and Los Angeles have been reduced from 12 to 5 days and from 9 to 4 days, respectively. The Port of Savannah with the Georgia Ports Authority has set up inland pop-up container sites that are accessible by truck and train, speeding up the movement of containers to these locations. The involvement of commercial carriers has also accelerated the movement of goods through the supply chain. The ports of Long Beach and Los Angeles are still operating towards 24/7 operation.
  • On December 22, administration officials met with EU officials on COVID-19 and global health security to assess each country’s progress towards the goal of the partnership cemented in September to defeat the global pandemic . Increasing the global production of vaccines and supplies is a major component of the initiative. The meeting also focused on developing strategies for future actions, including establishing a source of funding for such efforts.
  • On December 22, the FDA Center for Device and Radiological Health (CDRH) released a draft guidance document “Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUA) During Coronavirus Disease 2019 (COVID-19) Public health emergency ”and“ Transition plan for medical devices that fall under enforcement policies during the public health emergency of coronavirus disease 2019 (COVID-19). These proposed transition plans are guided by the principles of ensuring continued access of patients, providers and consumers to quality products; adequately prepare manufacturers and other stakeholders for the transition; and avoid supply chain disruptions. The plans would provide guidance on the requirements and timelines for marketing presentations. Assessment methods would include a risk-based approach that takes into account the intended uses, regulatory history and the level of risk of the device. A notice will be published for manufacturers 180 days before the expiration date of the EUA declaration. An EUA declaration is separate from a public health emergency declaration. Once an EUA declaration is terminated, all EUAs authorized under the EUA declaration are also terminated. Manufacturers must notify the FDA if they intend to continue marketing their products. The FDA intends to apply a phased approach to products marketed under discretionary enforcement policies that allow manufacturers to prepare for new requirements to avoid disruption. Comments on these draft guidelines are expected by March 23, 2022. We recommend that stakeholders carefully review the documents, submit comments if necessary, and start preparing for transitions early.
  • On December 22, the FDA released a draft guideline, “Digital Health Technologies for Remote Data Acquisition in Clinical Investigations,” to provide sponsors and other stakeholders with guidance on how to assess digital health technology (DHT) used in their clinical investigations. The draft guidance includes how to assess a DHT as suitable for use. When evaluating a product, sponsors and stakeholders should consider the rationale for using the product and its descriptions. Sponsors and stakeholders should also consider whether the product can offer verification, validation and usability information. In addition, investigators should determine whether DHT would provide data permitting an appropriate assessment of clinical parameters from the data from any statistical analysis. The draft guidance also emphasizes that risk considerations regarding clinical risks, confidentiality and informed consent should be considered. Comments are due by March 22, 2022.
  • On December 23, the FDA released a revised guideline, “SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests,” which contains specific information regarding the omicron variant. The agency asks labs to be aware that some molecular tests fail to detect omicron and that there are other tests that detect modified omicron. Tests that do not detect omicron should not be used. Laboratories that use tests with multiple genetic targets should be aware that omicron demonstrates genetic abandonment in the results. Although this result may indicate the presence of omicron, it is not definitive. In light of this, the FDA advises labs to consider genetic sequencing if available.
  • On December 27, the CDC announced that it was recommending a five-day window for isolation and the use of masks for asymptomatic people with positive COVID-19 results. The CDC has also changed its recommendations for people exposed to someone with COVID-19 in isolation with strict mask use for five days after exposure for those exposed who are not vaccinated or have been vaccinated more. six months previously (two months for Johnson & Johnson). For those who have received a booster, isolation is not required; however, the use of a mask for five days followed by a test on the fifth day is recommended.
  • On December 29, the Center for Devices and Radiological Health (CDRH) issued an EUA for CLINITEST, a rapid self-test of the COVID-19 antigen from Siemens. This EUA is particularly important because the validation data was collected through the FDA’s collaboration with the National Institutes of Health (ITAP) Independent Testing Assessment Program. SD Biosensor Inc. has also been granted EUA for its home COVID-19 test.
  • On January 3, the FDA announced changes to the EUA for the Pfizer vaccine. The agency decided to allow a booster dose for adolescents 12 to 15 years old and to shorten the recommended time between the primary vaccination and the booster dose to five months, instead of six months. The decision was made on the basis of actual data from Israel which showed no additional security concerns. The decision to reduce the time between the primary series and the booster is taken in response to the prevalence of the more transmissible omicron variant and the need to strengthen the immune response of the population. The FDA has also cleared a third dose of Pfizer vaccine for immunocompromised children 5 to 11 years old. The agency defines immunocompromised as those who have undergone a solid organ transplant or similar conditions that compromise their immune system. The aim is to strengthen their immune response to “enable these children to obtain the maximum potential benefit from the vaccination”.

[View source.]

read more
Medical products

FDA Cleared Booster Dose for Teens – Medical Products Supply Chain Weekly Review – Food, Drugs, Healthcare, Life Sciences

United States: FDA Approves Booster Dose for Teens – Medical Products Supply Chain Weekly Review

To print this article, simply register or connect to Mondaq.com.

During the holidays, the CDC updated its recommendations for quarantine and post-exposure masking. The FDA has cleared the booster dose of Pfizer vaccine for adolescents 12 to 15 years old and for immunocompromised children 5 to 11 years old. The FDA has released draft guidelines for manufacturers of medical devices marketed under EUA or enforcement discretion policies to help them transition to traditional approvals at the end of the health emergency. public. The Administration has convened the Supply Chain Disruption Working Group for an update on its progress. The FDA has issued guidance for lab staff and manufacturers on technical considerations for new strains in developing COVID-19 tests and reading current test results. Please see details of these and other supply chain developments below:

  • On December 22, the President convened a meeting of the Supply Chain Disruption Task Force with stakeholders from the business sector. The implementation of the recommendations of the Working Group has led to drastic improvements in the flow of goods in the main ports. Dwell times in the ports of Long Beach and Los Angeles have been reduced from 12 to 5 days and from 9 to 4 days, respectively. The Port of Savannah with the Georgia Ports Authority has set up inland pop-up container sites that are accessible by truck and train, speeding up the movement of containers to these locations. The involvement of commercial carriers has also accelerated the movement of goods through the supply chain. The ports of Long Beach and Los Angeles are still operating towards 24/7 operation.
  • On December 22, administration officials met with EU officials on COVID-19 and global health security to assess each country’s progress towards the goal of the partnership cemented in September to defeat the global pandemic . Increasing the global production of vaccines and supplies is a major component of the initiative. The meeting also focused on developing strategies for future actions, including establishing a source of funding for such efforts.
  • On December 22, the FDA Center for Device and Radiological Health (CDRH) released a draft guidance document “Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUA) During Coronavirus Disease 2019 (COVID-19) Public health emergency ”and“ Transition plan for medical devices that fall under enforcement policies during the public health emergency of coronavirus disease 2019 (COVID-19). These proposed transition plans are guided by the principles of ensuring continued access of patients, providers and consumers to quality products; adequately prepare manufacturers and other stakeholders for the transition; and avoid supply chain disruptions. The plans would provide guidance on the requirements and timelines for marketing presentations. Assessment methods would include a risk-based approach that takes into account the intended uses, regulatory history and the level of risk of the device. A notice will be published for manufacturers 180 days before the expiration date of the EUA declaration. An EUA declaration is separate from a public health emergency declaration. Once an EUA declaration is terminated, all EUAs authorized under the EUA declaration are also terminated. Manufacturers must notify the FDA if they intend to continue marketing their products. The FDA intends to apply a phased approach to products marketed under discretionary enforcement policies that allow manufacturers to prepare for new requirements to avoid disruption. Comments on these draft guidelines are expected by March 23, 2022. We recommend that stakeholders carefully review the documents, submit comments if necessary, and start preparing for transitions early.
  • On December 22, the FDA released a draft guideline, “Digital Health Technologies for Remote Data Acquisition in Clinical Investigations,” to provide sponsors and other stakeholders with guidance on how to assess digital health technology (DHT) used in their clinical investigations. The draft guidance includes how to assess a DHT as suitable for use. When evaluating a product, sponsors and stakeholders should consider the rationale for using the product and its descriptions. Sponsors and stakeholders should also consider whether the product can offer verification, validation and usability information. In addition, investigators should determine whether DHT would provide data permitting an appropriate assessment of clinical parameters from the data from any statistical analysis. The draft guidance also emphasizes that risk considerations regarding clinical risks, confidentiality and informed consent should be considered. Comments are due by March 22, 2022.
  • On December 23, the FDA released a revised guideline, “SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests,” which contains specific information regarding the omicron variant. The agency asks labs to be aware that some molecular tests fail to detect omicron and that there are other tests that detect modified omicron. Tests that do not detect omicron should not be used. Laboratories that use tests with multiple genetic targets should be aware that omicron demonstrates genetic abandonment in the results. Although this result may indicate the presence of omicron, it is not definitive. In light of this, the FDA advises labs to consider genetic sequencing if available.
  • On December 27, the CDC announced that it was recommending a five-day window for isolation and the use of masks for asymptomatic people with positive COVID-19 results. The CDC has also changed its recommendations for people exposed to someone with COVID-19 in isolation with strict mask use for five days after exposure for those exposed who are not vaccinated or have been vaccinated more. six months previously (two months for Johnson & Johnson). For those who have received a booster, isolation is not required; however, the use of a mask for five days followed by a test on the fifth day is recommended.
  • On December 29, the Center for Devices and Radiological Health (CDRH) issued an EUA for CLINITEST, a rapid self-test of the COVID-19 antigen from Siemens. This EUA is particularly important because the validation data was collected through the FDA’s collaboration with the National Institutes of Health (ITAP) Independent Testing Assessment Program. SD Biosensor Inc. has also been granted EUA for its home COVID-19 test.
  • On January 3, the FDA announced changes to the EUA for the Pfizer vaccine. The agency decided to allow a booster dose for adolescents 12 to 15 years old and to shorten the recommended time between the primary vaccination and the booster dose to five months, instead of six months. The decision was made on the basis of actual data from Israel which showed no additional security concerns. The decision to reduce the time between the primary series and the booster is taken in response to the prevalence of the more transmissible omicron variant and the need to strengthen the immune response of the population. The FDA has also cleared a third dose of Pfizer vaccine for immunocompromised children 5 to 11 years old. The agency defines immunocompromised as those who have undergone a solid organ transplant or similar conditions that compromise their immune system. The aim is to strengthen their immune response to “enable these children to obtain the maximum potential benefit from the vaccination”.

The content of this article is intended to provide a general guide on the subject. Specialist advice should be sought regarding your particular situation.

POPULAR ARTICLES ON: Food, Medicines, Health Care, Life Sciences of the United States

Alston and Birds Health Care Week in Review, December 17, 2021

Alston & Bird

Below is Alston & Bird’s Healthcare Week review, which provides a summary of the latest healthcare regulatory news, advice and guidance; federal legislation and the work of congressional committees; reports, studies and analyzes; and other health policy news.

read more
Medical products

FDA clears two oral drugs for COVID-19 – Medical Products Supply Chain Weekly Review – Food, Drugs, Healthcare, Life Sciences

United States: FDA clears two oral drugs for COVID-19 – Medical products supply chain review of the week

To print this article, simply register or connect to Mondaq.com.

Last week, the FDA cleared oral antivirals from Pfizer and Merck for the treatment of COVID-19. The Biden-Harris administration released the trucking action plan. The CDC approved the ACIP preference recommendation for the Pfizer-BioNTech and Moderna vaccine boosts. The new recommended Tris vaccine buffer leads to greater stability and does not require dilution. Please see details of these and other supply chain developments below:

  • On December 15, the FDA approved Eagle Pharmaceuticals’ Abbreviated New Drug Application (ANDA) for injection of vasopressin (20 units / ml in multidose vials), a product that has grown in demand during the COVID-pandemic. 19. The FDA said that this approval, the first approval from an ANDA for this product, represents the agency’s commitment “to facilitate access to medical products to help meet the critical needs of the American public.”
  • On December 16, the Authority released its Trucking Action Plan to help reduce supply chain disruption as part of initiatives promoted by the Chain Disruption Task Force. supply. Globally, the plan aims to implement measures to reduce barriers to the issuance of commercial driver’s licenses (CDLs); accelerate the learning of trucking; recruit veterans, especially those with previous trucking experience, into the industry; and schedule listening sessions with the current workforce to implement improvement strategies. In order to promote immediate implementation, the plan also includes specific actions for 30, 60 and 90 days to implement the objectives of the plan.
  • On December 16, the FDA approved the use of Tris buffer for the manufacture of Pfizer-BioNTech’s Comirnaty COVID-19 vaccine. This new formulation offers two key advantages to vaccinators: (1) it increases the stability of the vaccine longer at refrigerated temperatures; and (2) it does not require dilution by the supplier before use.
  • On December 16, the CDC approved the Advisory Committee on Immunization Practices (ACIP) recommendations that the Pfizer-BioNTech and Moderna vaccines are preferred for booster use over the Johnson & Johnson vaccine. ACIP met earlier today and based its decision on data including a review of efficacy and adverse events.
  • On December 17, the FDA announced that it was considering a program that would impose sterilization changes to the master file pilot program for 510 (k) approved medical devices. The change applies to the established Category B or to new sterilization methods. In addition to manufacturers in the innovation challenge, current 510 (k) holders can also participate in two previous programs where the FDA (1) has challenged manufacturers to develop new ways to develop alternatives to the ethylene oxide; and (2) reduce emissions of ethylene oxide. If changes are made to sterilization methods when ethylene oxide is used, participants can now refer to their master files instead of submitting a new 510 (k).
  • On December 20, Moderna announced that it was continuing to advance clinical trials to develop an omicron-specific vaccine for use as a booster. He also noted that the antibodies from his 50mcg and 100mcg booster doses demonstrated a 37- and 83-fold increase in antibody levels. Clinical trials of vaccines targeting both omicron and delta are underway.
  • On December 21, the Center for Devices and Radiological Health (CDRH) released a plan for how the CDRH intends to manage reviewer workload in 2022 based on the increase in the total number of submissions. In 2021, the CDRH saw an increase in medical device submissions for approval through the traditional processes, namely the PMA, 510 (k) and Q-sub processes, which it addressed through the implementation of new approaches to review, including triage of cases, reallocation of staff and resources to COVID-19 products, use of contractors and overtime. Despite these approaches, some issues related to meeting review deadlines still need to be addressed. For devices other than in vitro diagnostics, the CDRH expects to be able to comply with the review deadlines of the Medical Device User Fee Agreement (MDUFA) in 2022 despite the influx of medical products subject to review. For in vitro diagnostic products, the CDRH will also try to meet the deadlines promised by the MDUFA. Non-COVID products that were not prioritized during the pandemic will require extended review times. In addition, the pre-submission request program will be reinstated as of January 1, 2022.
  • On December 22, the FDA cleared Pfizer’s oral antiviral drug, Paxlovid, for the treatment of mild to moderate COVID-19 in adults and children 12 years of age or older (weighing 40 kg or more). This is the first oral antiviral treatment for COVID-19 to receive emergency use authorization. The clearance was based on data from the EPIC-HR trial, which demonstrated that Paxlovid significantly reduced hospitalizations and deaths from all causes in the study population compared to those randomized to receive a placebo. Paxlovid is a combination of nirmatrelvir and ritonavir – the former inhibits the replication of SARS-CoV-2 and the latter slows down the breakdown of nirmatrelvir in the body. The FDA will continue to monitor clinical trial data for the safety and effectiveness of the drug.
  • On December 23, the FDA cleared Merck’s oral antiviral drug, molnupiravir, for the treatment of mild to moderate COVID-19 in adults at high risk of progression to severe COVID-19 and for whom options for Alternative treatment to COVID-19 is not available. accessible or clinically appropriate.

The content of this article is intended to provide a general guide on the subject. Specialist advice should be sought regarding your particular situation.

POPULAR ARTICLES ON: Food, Medicines, Health Care, Life Sciences of the United States

read more
Medical products

FDA Approves Two Oral COVID-19 Drugs – Medical Products Supply Chain Weekly Review | Alston & Bird

Last week, the FDA cleared oral antivirals from Pfizer and Merck for the treatment of COVID-19. The Biden-Harris administration released the trucking action plan. The CDC approved the ACIP preference recommendation for the Pfizer-BioNTech and Moderna vaccine boosts. The new recommended Tris vaccine buffer leads to greater stability and does not require dilution. Please see details of these and other supply chain developments below:

  • On December 15, the FDA approved Eagle Pharmaceuticals’ Abbreviated New Drug Application (ANDA) for injection of vasopressin (20 units / ml in multidose vials), a product that has grown in demand during the COVID-pandemic. 19. The FDA said that this approval – the first approval from an ANDA for this product – represents the agency’s commitment “to facilitate access to medical products to help meet the critical needs of the American public.”
  • On December 16, the Authority released its Trucking Action Plan to help reduce supply chain disruption as part of initiatives encouraged by the Chain Disruption Task Force. supply. Globally, the plan aims to implement measures to reduce barriers to the issuance of commercial driver’s licenses (CDLs); accelerate the learning of trucking; recruit veterans, especially those with previous trucking experience, into the industry; and schedule listening sessions with the current workforce to implement improvement strategies. In order to promote immediate implementation, the plan also includes specific actions for 30, 60 and 90 days to implement the objectives of the plan.
  • On December 16, the FDA approved the use of Tris buffer for the manufacture of Pfizer-BioNTech’s Comirnaty COVID-19 vaccine. This new formulation offers two key advantages to vaccinators: (1) it increases the stability of the vaccine longer at refrigerated temperatures; and (2) it does not require dilution by the supplier before use.
  • On December 16, the CDC approved the Advisory Committee on Immunization Practices (ACIP) recommendations that the Pfizer-BioNTech and Moderna vaccines are preferred for booster use over the Johnson & Johnson vaccine. ACIP met earlier today and based its decision on data including a review of efficacy and adverse events.
  • On December 17, the FDA announced that it was considering a program that would impose sterilization changes to the master file pilot program for 510 (k) approved medical devices. The change applies to the established Category B or to new sterilization methods. In addition to manufacturers in the innovation challenge, current 510 (k) holders can also participate in two previous programs where the FDA (1) has challenged manufacturers to develop new ways to develop alternatives to it. ethylene oxide; and (2) reduce emissions of ethylene oxide. If changes are made to sterilization methods when ethylene oxide is used, participants can now refer to their master files instead of submitting a new 510 (k).
  • On December 20, Moderna announced that it was continuing to advance clinical trials to develop an omicron-specific vaccine for use as a booster. He also noted that the antibodies from his 50mcg and 100mcg booster doses demonstrated a 37- and 83-fold increase in antibody levels. Clinical trials of vaccines targeting both omicron and delta are underway.
  • On December 21, the Center for Devices and Radiological Health (CDRH) released a plan for how the CDRH intends to manage reviewer workload in 2022 based on the increase in the total number of submissions. In 2021, the CDRH saw an increase in medical device submissions for approval through the traditional processes, namely the PMA, 510 (k) and Q-sub processes, which it addressed through the implementation of new approaches to review, including triage of cases, reallocation of staff and resources to COVID-19 products, use of contractors and overtime. Despite these approaches, some issues related to meeting review deadlines still need to be resolved. For devices other than in vitro diagnostics, the CDRH expects to be able to meet the review deadlines of the Medical Device User Fee Agreement (MDUFA) in 2022 despite the influx of medical products subject to review. For in vitro diagnostic products, the CDRH will also try to meet the deadlines promised by the MDUFA. Non-COVID products that were not prioritized during the pandemic will require extended review times. In addition, the pre-submission request program will be reinstated as of January 1, 2022.
  • On December 22, the FDA cleared Pfizer’s oral antiviral drug, Paxlovid, for the treatment of mild to moderate COVID-19 in adults and children 12 years of age or older (weighing 40 kg or more). This is the first oral antiviral treatment for COVID-19 to receive emergency use authorization. The clearance was based on data from the EPIC-HR trial, which demonstrated that Paxlovid significantly reduced hospitalizations and deaths from any cause in the study population compared to those randomized to receive a placebo. Paxlovid is a combination of nirmatrelvir and ritonavir – the former inhibits the replication of SARS-CoV-2 and the latter slows down the breakdown of nirmatrelvir in the body. The FDA will continue to monitor clinical trial data for the safety and effectiveness of the drug.
  • On December 23, the FDA cleared Merck’s oral antiviral drug, molnupiravir, for the treatment of mild to moderate COVID-19 in adults at high risk of progression to severe COVID-19 and for whom options for Alternative treatment to COVID-19 is not available. accessible or clinically appropriate.

[View source.]

read more
Generic drugs

Generic Inhalation and Nasal Spray Market $ 6.87 Billion by Indication, Age Group, Class, Route, Distribution Channel and Region

Dublin, December 23, 2021 (GLOBE NEWSWIRE) – The ‘Generic Inhalation Drugs and Nasal Sprays Market Research Report by Indication, Age Group, Class, Route, Distribution Channel and Region – Global Forecast to 2026 – Cumulative impact of COVID- Report 19 “has been added to ResearchAndMarkets.com offer.

The global generic inhalation and nasal spray market size was estimated to be USD 6,392.52 million in 2020, is expected to reach USD 6,879.55 million in 2021, and is expected to grow at a CAGR of 7.95% to reach 10,119 , 95 million USD by 2026.

Market statistics
The report provides market size and forecast in five major currencies: USD, EUR GBP, JPY, and AUD. It helps organizational leaders make better decisions when currency data is readily available. In this report, the years 2018 and 2019 are considered as historical years, 2020 as the base year, 2021 as the estimated year and the years 2022 to 2026 are considered as the forecast period.

Market segmentation and coverage

This research report categorizes Generic Inhalation Drugs and Nasal Sprays to forecast revenue and analyze trends in each of the following submarkets:

  • Based on the indication, the market has been investigated for allergic rhinitis, asthma and COPD.

  • Based on age group, the market has been researched among adults, children 2-5 years old, and children 6-12 years old.

  • Based on the class, the market has been studied for allergy blockers, anticholinergics, antihistamines, decongestants, mast cell inhibitors, and nasal steroids.

  • Based on Route, the market has been investigated for inhalation, nasal spray, and tropical lotion.

  • Based on the distribution channel, the market has been studied in hospital medical stores, online pharmacies and retail pharmacies.

  • Based on the region, the market has been studied in the Americas, Asia-Pacific and Europe, Middle East and Africa. The Americas are studied in more detail in Argentina, Brazil, Canada, Mexico and the United States. The United States is studied in more detail in California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. Asia-Pacific is further explored in Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, the Middle East and Africa are studied in more detail in France, Germany, Italy, the Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates and United Kingdom.

Companies mentioned

  • Allergan plc

  • Altaire Pharmaceuticals inc.

  • Beximco Pharmaceuticals Ltd.

  • Catalent Pharma Solutions

  • Cipla Limited

  • Hikma Pharmaceuticals PLC

  • Mylan NV

  • Navajo Manufacturing Company Inc.

  • Pharmaceutical company Nephron

  • Perrigo Company plc

  • Preferred Pharmaceuticals Inc.

  • Sandoz International GmbH

  • Sheffield Pharmaceuticals LLC

  • Sun Pharmaceutical Industries Ltd.

  • Teva Pharmaceutical Industries Ltd.

Cumulative impact of COVID-19
COVID-19 is an incomparable global public health emergency that has affected nearly all industries, and the long-term effects are expected to impact the growth of the industry during the forecast period. The analyst’s ongoing research is amplifying their research framework to ensure the inclusion of the underlying issues of COVID-19 and potential avenues to follow. The report provides insights on COVID-19 given changes in consumer behavior and demand, purchasing patterns, supply chain diversion, dynamics of current market forces, and significant government interventions. . The updated study provides information, analysis, estimates and forecasts, considering the impact of COVID-19 on the market.

Competitive strategic window
The Competitive Strategy Window analyzes the competitive landscape in terms of markets, applications and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for suppliers to adopt successive strategies of merger and acquisition, geographic expansion, research and development, and new product introduction strategies to continue the expansion and growth of the business during a forecast period.

FPNV positioning matrix
The FPNV Positioning Matrix assesses and ranks vendors in the Generic Inhalation and Nasal Spray market based on business strategy (company growth, industry coverage, financial viability, and channel support) and product satisfaction (value for money, ease of use, product features) and customer support) which helps businesses make better decisions and better understand the competitive landscape.

Market share analysis
The market share analysis offers the analysis of the suppliers considering their contribution to the overall market. It provides the idea of ​​its revenue generation in the overall market compared to other space providers. It provides insight into the performance of vendors in terms of revenue generation and customer base compared to others. Knowing the market share gives an idea of ​​the size and competitiveness of the suppliers for the base year. It reveals the characteristics of the market in terms of traits of accumulation, fragmentation, dominance and fusion.

Competitive scenario
The competitive scenario provides a outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section delivers valuable insights at different stages while staying up to date with the business and engaging stakeholders in the economic debate. The competitive scenario represents press releases or news from companies categorized as M&A, Agreement, Collaboration and Partnership, New Product Launch and Improvement, Investment and Funding, and Reward, Recognition and Expansion. All the news gathered helps the supplier understand the market gaps and the strengths and weaknesses of competitors, thus providing information to improve products and services.

Main topics covered:

1. Preface
1.1. Objectives of the study
1.2. Market segmentation and coverage
1.3. Years taken into account for the study
1.4. Currency and price
1.5. Language
1.6. Limits
1.7. Hypotheses
1.8. Stakeholders

2. Research methodology

3. Executive summary

4. Market overview
4.1. introduction
4.2. Cumulative impact of COVID-19

5. Market dynamics
5.1. introduction
5.2. Conductors
5.2.1. Low cost associated with generic prescription drugs
5.2.2. Increased prevalence of asthma and COPD disorders
5.2.3. High cost of health care in developed regions
5.3. Constraints
5.3.1. Strict regulations for generic drugs
5.4. Opportunities
5.4.1. Successful drug patents expire and FDA approvals increased
5.4.2. Trend towards generic drugs in developed countries due to rising cost of health care
5.5. Challenges
5.5.1. Pressure on prices due to the presence of several players in the segment

6. Generic Inhalation and Nasal Sprays Market, by Indication
6.1. introduction
6.2. Allergic rhinitis
6.3. Asthma
6.4. COPD

7. Generic Inhalation Nasal Spray Drugs Market, By Age Group
7.1. introduction
7.2. Adults
7.3. Children 2 to 5
7.4. Children 6 to 12

8. Generic Inhalation and Nasal Spray Drugs Market, By Class
8.1. introduction
8.2. Allergy blocker
8.3. Anticholinergic
8.4. Antihistamine
8.5. decongestant
8.6. Mast cell inhibitor
8.7. Nasal steroid

9. Generic inhalation and nasal sprays market, by road
9.1. introduction
9.2. Inhalation
9.3. Nasal spray
9.4. Tropical Lotion

10. Generic inhalation and nasal sprays market, by distribution channel
10.1. introduction
10.2. Hospital medical store
10.3. Online pharmacy
10.4. Retail pharmacy

11. America Generic Inhalation and Nasal Spray Market

12. Asia-Pacific Generic Inhalation and Nasal Spray Market

13. Europe, Middle East & Africa Generic Inhalation Drugs and Nasal Sprays Market

14. Competitive landscape
14.1. FPNV positioning matrix
14.1.1. Quadrants
14.1.2. Business strategy
14.1.3. Product satisfaction
14.2. Market ranking analysis
14.3. Market share analysis, by key player
14.4. Competitive scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, collaboration and partnership
14.4.3. New product launch and improvement
14.4.4. Investment and financing
14.4.5. Awards, recognition and expansion

15. Company usability profiles

For more information on this report visit https://www.researchandmarkets.com/r/374c1l

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
read more
Medical supplies

Transportation congestion causing long delays for medical supplies

Hospitals and other providers are experiencing delays in delivering 8,000 to 12,000 containers of essential medical supplies and equipment, a setback that could negatively impact patient care and public health.

Healthcare resources are delayed on average for up to 37 days across the U.S. transportation system due to supply chain congestion, according to a study by the Health Industry Distributors Association.

Medical shipments are held in US ports for approximately 17 days. The ports of Long Beach and Los Angeles in California have the highest number of delayed medical containers on the West Coast. The port of Savannah, Georgia, is the most congested on the east coast, reports the association.

A shipping container contains approximately 190,000 medical gowns, 360,000 syringes and 3.5 million surgical gloves, according to HIDA estimates. These containers are delayed an average of 11 days per train and nine days per truck, according to the group of distributors.

The association currently represents 111 members, who manage logistics, provide customer service and deliver medical products and supplies, including 51 billion units of personal protective equipment last year.

Because unprecedented transportation disruptions have restricted the reliable and rapid movement of medical products, the Health Industry Distributors Association is working with several port associations and leaders to provide healthcare professionals and frontline workers with equipment faster and more. effectively, according to the group.

“HIDA recommends a rapid transit system to prioritize essential medical supplies via ports, rail and truck for expedited delivery to the front lines of healthcare,” said Matthew Rowan, President and CEO of HIDA, in a press release. “Rules and regulations that hamper the rapid and efficient movement of essential medical supplies must be relaxed during a public health emergency.”

read more
Medical products

FTC to Survey Big Business Supply Chain Problems – Medical Products Supply Chain Weekly Review | Alston & Bird

Over the past two weeks, the Federal Trade Commission (FTC) has ordered major U.S. companies to provide information on problems and solutions in their supply chain. The FDA has issued an Emergency Use Clearance (EUA) for monoclonal therapy to include all children. An independent survey of pharmacies indicates that they still face supply chain issues. Please see details of these and other supply chain developments below:

  • On November 29, the FTC ordered nine major U.S. companies to provide the government with information about their supply chain operations. Specifically, the FTC is conducting an investigation to determine the reason for the delays. The FTC has asked companies to provide information on the main drivers of disruption in their supply chain and what they have done to address the issues. Companies have 45 days to respond.
  • On November 30, the FDA released a statement that discusses its omicron variant surveillance plan. The plan includes ongoing reporting by stakeholders of the impact of the variant on testing, vaccines and treatments. Currently, the FDA expects the variant to have a low impact on testing capabilities and infrastructure. The information will be released to the public as soon as it becomes available.
  • On December 3, the FDA expanded the EUA for two monoclonal antibodies – bamlanivimab and etesevimab (used in combination) – to include treatment of all pediatric patients, including newborns, who test positive for the COVID test -19 and are at high risk of progression to severe COVID-19. The combination drug is now also authorized for post-exposure prophylaxis for the prevention of COVID-19 in all pediatric patients, including newborns, at high risk of progression to severe COVID-19. The move comes after the FDA evaluated the results of clinical trials that showed the therapy to be safe and effective.
  • On December 3, the Federal Reserve released a note based on a textual analysis of earnings calls to account for the effects of the supply chain bottleneck on prices. Call SMS messages won from the S&P Global Market Intelligence database were searched for certain terms and were classified as positive impact or negative impact. Additionally, the authors used a regression model to analyze the impact of supply bottlenecks on concerns. The authors’ findings suggest that the global container shortage is the primary concern of most industries, and that the automotive sector suffers the most negative impacts. In an analysis of companies facing large supply chain disruptions versus low disruptions, those that experienced large disruption experienced statistically significant price increases. Overall, stronger global demand, supply bottlenecks and chip shortages had the biggest effect on prices. It is important to note that capacity issues and shipping bottlenecks have not resulted in price increases due to the increase in mentions in calls.
  • On December 8, the FDA issued an EUA for AstraZeneca’s Evusheld, an injectable drug combined with monoclonal antibodies. The authorization is for use in adults and adolescents 12 years of age and older who also have moderately to severely compromised immune systems or whose vaccination is not recommended due to serious side effects. Data from a clinical trial have shown a 77% reduction in the risk of contracting COVID-19 after treatment, with efficacy lasting up to six months.
  • On December 8, the FDA released a draft guideline titled “Considerations for Using Real Data and Evidence to Support Regulatory Decision Making for Drugs and Biologics”. The goal of the guidance, which would meet a mandate under the 21st Century Cures Act of 2016, is to facilitate increased efficiency in the approval of new indications for legally marketed drugs. Sponsors are encouraged to contact the FDA to discuss their draft study protocol and statistical analysis plan for review and comment before finalizing the documents. Additionally, sponsors need to consider and address data privacy concerns using real world data.
  • On December 9, the Treasury Department’s Office of Foreign Assets Control (OFAC) imposed sanctions on foreign government officials and entities on the International Anti-Corruption Day. The initiative targets, among others, heads of state and entities that have participated in acts of corruption in the context of “COVID-19 purchases”. Specifically, officials who have engaged in bribery programs, inflation in the prices of medical devices and PPE, and improper awarding of contracts are subject to sanctions. Government officials and their families have also faced sanctions for US visas.
  • On December 9, at the Food and Drug Law Institute’s Enforcement, Litigation and Compliance conference, Elizabeth Miller of the FDA, deputy commissioner for medical products and tobacco operations in the Office of Regulatory Affairs, spoke revealed that the agency is planning a pilot program to conduct unannounced inspections in India and expand the program to China.
  • On December 10, the Department of Transportation announced that the agency had awarded $ 12.6 million in America’s Marine Highway (AMHP) grants to nine maritime highways to help deal with disruption in the water supply chain. supply and movement of goods. AMHP, which operates as a public-private partnership, seeks to reduce land congestion, support transport options and improve the performance of the transport system. Some specific projects mentioned include funding for a New York / New Jersey barge project to increase trailer transportation, increasing the operational capacity of the Richmond, Virginia marine terminal, and upgrading ship equipment. a marine terminal in North Carolina.
  • On December 10, the Center for Devices and Radiological Health released a discussion paper titled “Point-of-Care 3D Printing of Medical Devices.” The paper provides background, an overview of how these devices might be approved for point-of-care use, and the challenges of this approach. The authors also ask 16 questions on which they would like to receive comments. Public comments are expected on February 8, 2022.
  • On December 16, the FDA released a draft guideline, “Inspection of Injectables for Visible Particles: Draft Guidance for Industry.” The guidelines aim to provide industry with risk-based procedures to “assess, correct and prevent the risk of visible particulate contamination”. Serious adverse events have been observed following injectables contaminated with visible particles. Manufacturers performing risk assessments and implementing mitigation strategies for injectables containing visible particles should consider the type of particles, container components and closure systems, and quality assurance procedures, among other factors. Comments are due by February 14, 2022.
  • The International Coalition of Drug Regulators has published an article from its COVID-19 Working Group, “Remote PCB and GMP Regulatory Oversight Inspections”. The document provides an assessment of how regulators provided remote monitoring during the pandemic, the challenges of implementation, and the success of the programs. The Working Group noted that while the possibilities offered by remote monitoring facilitate new monitoring methods, they should not replace traditional inspections. However, there is room for supplementation with these new tools.
  • The National Community Pharmacists Association has released the results of a survey showing that supply chain issues continue to plague 60% of independent pharmacies. In addition to these disruptions, independent pharmacies continue to flag staff, low reimbursement rates and market forces as reasons for their concern. Supply chain disruptions have increased consumer wait times for prescriptions. Overall, 41% of respondents felt that the state of the industry can be classified from bad to very bad.
  • Amazon has invested in a private supply chain network that has helped the company bypass supply chain issues. The company uses charter freighters, its own shipping containers, ships that bypass the busiest ports of Los Angeles and Long Beach, and planes that bypass ports completely. By serving as its own shipping provider, Amazon can use less busy ports for deliveries and is not dependent on container availability and access by third-party shipping companies. Amazon is now estimated to ship 72% of its merchandise. In addition, Amazon has increased the number of vacation rentals by 50% and increased the number of new installations.

[View source.]

read more
Medical supplies

HIDA: Millions of essential medical supplies delayed at congested ports

Congestion at ports is creating a crisis for the country’s medical providers. The Health Industry Distributors Association (HIDA) told American Shipper that between 8,000 and 12,000 containers filled with millions of essential medical supplies are being delayed.

According to HIDA, these containers are on average 37 days late.

“COVID is always with us and it is difficult to predict the evolution of particular variants and their impact on supplies,” said HIDA President and CEO Matthew J. Rowan. “So the best strategy is for the supply chain to maintain readiness and for distributors and manufacturers to continue to get medical supplies to suppliers. “

Federal Maritime Commissioner Carl Bentzel told American Shipper he had received letters and held follow-up meetings with representatives from HIDA, the Advanced Medical Technology Association (AdvaMed) and the International Safety Equipment Association (ISEA), all highlighting the need shipping abroad and begging for help. for port managers to identify and prioritize medical supply containers for quick pickup.

“Although the CMF does not have the legal authority to prioritize freight, these containers contain essential products for the health, safety and well-being of our country’s frontline medical workers, as well as patients.” , said Bentzel. “President [Daniel] Maffei realizes this and we at the CMF have had several meetings on the issue and are committed to doing what we can to help healthcare providers receive these vital products.

“The Biden administration has also helped, and we are in contact with John Porcari [port envoy to the White House Supply Chain Disruptions Task Force] on the project to ensure the delivery of essential health products to American hospitals ”

Bentzel said he contacted Port of Los Angeles Executive Director Gene Seroka and Port of Long Beach Executive Director Mario Cordero, as well as SSA Marine, the second largest container terminal operator in the Americas, to find means of prioritizing the cargo and accelerating its movement inland.

In March 2020, Seroka was chosen by Los Angeles Mayor Eric Garcetti to be responsible for City of Los Angeles logistics and he oversaw the Logistics Victory Los Angeles (LoVLA) response effort which assisted obtain essential personal protective equipment (PPE) and emergency services. supplies to healthcare and supply chain workers.

“These port managers were the first to identify and move containers full of PPE and other health care and disinfection supplies at the onset of the pandemic,” Bentzel said. “Gene and Mario immediately agreed to help and set up teams at the port to move the product. They are in the process of identifying the containers. SSA is in the process of labeling the containers and using peel piles for expedited pickup.

Seroka told American Shipper, “These supplies are more vital than ever as the omicron variant spreads across the country. HIDA has contacted us to identify the containers to be shipped. We use our digital system to identify these containers so that we can move them as quickly as possible.

“Unfortunately, these boxes are mixed with the thousands of import containers arriving at the port. The sooner we know when these containers are arriving, the more effective we can be in fending off these valuable imports. “

Cordero said: “Since the start of the pandemic, the Port of Long Beach, in partnership with the marine terminal operators and the stevedoring workforce, has been able to expedite shipments of PPE, supplies medical and medical equipment. Everyone has worked together to help these life-saving shipments get to hospitals and healthcare professionals as quickly as possible. This remains a priority for the entire port community.

One of the terminals playing a key role in this supply chain mission, according to Bentzel, is SSA Marine Terminals.

Sal Ferrigno, vice president of SSA Marine Terminals, explained that the terminals electronic platform is used to identify containers.

“In an effort to ensure the availability of essential supplies for our country, we have prioritized medical supplies at our terminals,” Ferrigno said. “The solution is simple with the help of eModal. We are able to identify containers with medical equipment before they arrive.

“Once unloaded from a ship, the containers are given a priority appointment where, once they leave the gate, they will be taken to their destination. The process is safe, efficient, and fast, especially when you consider the omicron virus outbreak and the need for medical supplies. “

According to the HIDA transit analysis, congestion along the east coast is also hampering the logistical efforts of medical providers. HIDA told American Shipper that Savannah, Georgia had the most delays, followed by New York and New Jersey.

“We spoke with Sam Ruda from the Port of New York / New Jersey and Griff Lynch from the Port of Savannah and warned them something like this was going to happen to them,” said Bentzel. “We are in the early stages of these ports. “

Bentzel also communicated with the World Shipping Council on this logistics mission.

“I plan to do a presentation to their members on our need for their assistance in the accelerated movement of this essential cargo,” said Bentzel. “In this insistence, we do not have adequate levels of US flag vessels under ultimate government control to assist, but I am asking for support for the delivery of this cargo.

“The success of this initiative must involve the World Shipping Council and potentially other US coastal ports such as Savannah and New York / New Jersey. At first, they were responsive, and hopefully progress on the West Coast can lead to a heightened national effort. HIDA says hospitals urgently need these products. All facets of the maritime community should work together on this medical logistics mission. “

read more
Medical supplies

HIDA: Millions of critical medical supplies delayed in congested ports

Congestion at ports is creating a crisis for the country’s medical providers. The Health Industry Distributors Association (HIDA) told American Shipper that between 8,000 and 12,000 containers filled with millions of essential medical supplies are being delayed.

According to HIDA, these containers are on average 37 days late.

“COVID is always with us and it is difficult to predict the evolution of particular variants and their impact on supplies,” said HIDA President and CEO Matthew J. Rowan. “So the best strategy is for the supply chain to keep readiness and for distributors and manufacturers to keep medical supplies moving to suppliers.”

Special FREE Masterclass! How to get started in trading in 2022 with Matt Maley! Register now!

Federal Maritime Commissioner Carl Bentzel told American Shipper he had received letters and held follow-up meetings with representatives from HIDA, the Advanced Medical Technology Association (AdvaMed) and the International Safety Equipment Association (ISEA), all highlighting the need shipping abroad and begging for help. for port managers to identify and prioritize medical supply containers for quick pickup.

“Although the CMF does not have the legal authority to prioritize freight, these containers contain essential products for the health, safety and well-being of our country’s frontline medical workers, as well as patients.” , said Bentzel. “President [Daniel] Maffei realizes this and we at the CMF have had several meetings on the issue and are committed to doing what we can to help healthcare providers receive these vital products.

“The Biden administration has also helped, and we are in contact with John Porcari [port envoy to the White House Supply Chain Disruptions Task Force] on the project to ensure the delivery of essential health products to American hospitals “

Bentzel said he contacted Port of Los Angeles Executive Director Gene Seroka and Port of Long Beach Executive Director Mario Cordero, as well as SSA Marine, the second largest container terminal operator in the Americas, to find means of prioritizing the cargo and accelerating its movement inland.

In March 2020, Seroka was chosen by Los Angeles Mayor Eric Garcetti to be responsible for City of Los Angeles logistics and he oversaw the Logistics Victory Los Angeles (LoVLA) response effort which assisted obtain essential personal protective equipment (PPE) and emergency services. supplies to healthcare and supply chain workers.

“These port managers were the first to identify and move containers full of PPE and other health care and disinfection supplies at the onset of the pandemic,” Bentzel said. “Gene and Mario immediately agreed to help and set up teams at the port to move the product. They are in the process of identifying the containers. SSA is in the process of labeling the containers and using peel piles for expedited pickup. “

Seroka told American Shipper, “These supplies are more vital than ever as the omicron variant spreads across the country. HIDA has contacted us to identify the containers that need to be shipped. We use our digital system to identify these containers so that we can move them. get out as quickly as possible.

“Unfortunately, these boxes are mixed in with the thousands of import containers arriving at the port. The sooner we know when these containers are arriving, the more effective we can be in fending off these valuable imports.”

Cordero said: “Since the start of the pandemic, the Port of Long Beach, in partnership with the marine terminal operators and the stevedoring workforce, has been able to expedite shipments of PPE, supplies medical and medical equipment. Everyone has worked together to help these vital shipments reach the hands of hospitals and healthcare professionals as quickly as possible. This remains a priority for the entire port community.

One of the terminals playing a key role in this supply chain mission, according to Bentzel, is SSA Marine Terminals.

Sal Ferrigno, vice president of SSA Marine Terminals, explained that the terminals electronic platform is used to identify containers.

“In order to ensure the availability of essential supplies for our country, we have prioritized medical supplies at our terminals,” Ferrigno said. “The solution is simple with the help of eModal. We are able to identify containers with medical equipment before they arrive.

“Once unloaded from a ship, containers are given a priority appointment where once out of the gate they will be taken to their destination. The process is safe, efficient and fast, especially considering the omicron virus outbreak and the need for medical equipment. “

According to the HIDA transit analysis, congestion along the east coast is also hampering the logistical efforts of medical providers. HIDA told American Shipper that Savannah, Georgia had the most delays, followed by New York and New Jersey.

“We spoke with Sam Ruda from the Port of New York / New Jersey and Griff Lynch from the Port of Savannah and warned them something like this was going to happen to them,” Rowan said. “We are in the early stages of these ports.”

Bentzel also communicated with the World Shipping Council on this logistics mission.

“I plan to do a presentation to their members on our need for their assistance in the accelerated movement of this essential cargo,” said Bentzel. “In this insistence, we do not have adequate levels of US flagged ships under ultimate government control to help, but I am asking for support for the delivery of this cargo.

“The success of this initiative must involve the World Shipping Council and potentially other US coastal ports such as Savannah and New York / New Jersey. Beforehand, they have been responsive and hopefully progress on the West Coast can lead to increased national effort HIDA says hospitals urgently need these products All facets of the maritime community should work together on this medical logistics mission.

Image from Pixabay

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

read more
Generic drugs

Global Generic Inhalation and Nasal Spray Market Expected to Reach Over $ 10 Billion by 2026 – ResearchAndMarkets.com

DUBLIN – (COMMERCIAL THREAD) – The report “Generic Inhalation Drugs and Nasal Sprays Market Research Report by Indication, Age Group, Class, Route, Distribution Channel and Region – Global Forecast to 2026 – Cumulative Impact of COVID -19 “has been added to ResearchAndMarkets.com offer.

The global generic inhalation and nasal spray market size was estimated to be USD 6,392.52 million in 2020, is expected to reach USD 6,879.55 million in 2021, and is expected to grow at a CAGR of 7.95% to reach 10,119 , 95 million USD by 2026.

Market statistics

The report provides market size and forecast in five major currencies: USD, EUR GBP, JPY, and AUD. It helps organizational leaders make better decisions when currency data is readily available. In this report, the years 2018 and 2019 are considered as historical years, 2020 as the base year, 2021 as the estimated year and the years 2022 to 2026 are considered as the forecast period.

Market segmentation and coverage

This research report categorizes Generic Inhalation Drugs and Nasal Sprays to forecast revenue and analyze trends in each of the following submarkets:

  • Based on the indication, the market has been investigated for allergic rhinitis, asthma and COPD.

  • Based on age group, the market has been researched among adults, children 2-5 years old, and children 6-12 years old.

  • Based on the class, the market has been studied for allergy blockers, anticholinergics, antihistamines, decongestants, mast cell inhibitors, and nasal steroids.

  • Based on Route, the market has been investigated for inhalation, nasal spray, and tropical lotion.

  • Based on the distribution channel, the market has been studied in hospital medical stores, online pharmacies and retail pharmacies.

  • Based on the region, the market has been studied in the Americas, Asia-Pacific and Europe, Middle East and Africa. The Americas are studied in more detail in Argentina, Brazil, Canada, Mexico and the United States. The United States is studied in more detail in California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. Asia-Pacific is further explored in Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, the Middle East and Africa are studied in more detail in France, Germany, Italy, the Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates and United Kingdom.

Companies mentioned

  • Allergan plc

  • Altaire Pharmaceuticals inc.

  • Beximco Pharmaceuticals Ltd.

  • Catalent Pharma Solutions

  • Cipla Limited

  • Hikma Pharmaceuticals PLC

  • Mylan NV

  • Navajo Manufacturing Company Inc.

  • Pharmaceutical company Nephron

  • Perrigo Company plc

  • Preferred Pharmaceuticals Inc.

  • Sandoz International GmbH

  • Sheffield Pharmaceuticals LLC

  • Sun Pharmaceutical Industries Ltd.

  • Teva Pharmaceutical Industries Ltd.

Cumulative impact of COVID-19

COVID-19 is an incomparable global public health emergency that has affected nearly all industries, and the long-term effects are expected to impact the growth of the industry during the forecast period. The analyst’s ongoing research is amplifying their research framework to ensure the inclusion of the underlying issues of COVID-19 and potential avenues to follow. The report provides insight on COVID-19 given changes in consumer behavior and demand, purchasing patterns, supply chain diversion, dynamics of current market forces, and significant government interventions. . The updated study provides information, analysis, estimates and forecasts, considering the impact of COVID-19 on the market.

Competitive strategic window

The Competitive Strategy Window analyzes the competitive landscape in terms of markets, applications and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for suppliers to adopt successive strategies of merger and acquisition, geographic expansion, research and development, and new product introduction strategies to continue the expansion and growth of the business during a forecast period.

FPNV positioning matrix

The FPNV Positioning Matrix assesses and ranks vendors in the Generic Inhalation and Nasal Spray market based on business strategy (company growth, industry coverage, financial viability, and channel support) and product satisfaction (value for money, ease of use, product features) and customer support) which helps businesses make better decisions and better understand the competitive landscape.

Market share analysis

The market share analysis offers the analysis of the suppliers considering their contribution to the overall market. It provides the idea of ​​its revenue generation in the overall market compared to other space providers. It provides insight into the performance of vendors in terms of revenue generation and customer base compared to others. Knowing the market share gives an idea of ​​the size and competitiveness of the suppliers for the base year. It reveals the characteristics of the market in terms of traits of accumulation, fragmentation, dominance and fusion.

Competitive scenario

The competitive scenario provides a outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section delivers valuable insights at different stages while staying up to date with the business and engaging stakeholders in the economic debate. The competitive scenario represents press releases or news from companies categorized as M&A, Agreement, Collaboration and Partnership, New Product Launch and Improvement, Investment and Funding, and Reward, Recognition and Expansion. All the news gathered helps the supplier understand the market gaps and the strengths and weaknesses of the competitors, thus providing information to improve products and services.

Main topics covered:

1. Preface

1.1. Objectives of the study

1.2. Market segmentation and coverage

1.3. Years taken into account for the study

1.4. Currency and price

1.5. Language

1.6. Limits

1.7. Hypotheses

1.8. Stakeholders

2. Research methodology

3. Executive summary

4. Market overview

4.1. introduction

4.2. Cumulative impact of COVID-19

5. Market dynamics

5.1. introduction

5.2. Conductors

5.2.1. Low cost associated with generic prescription drugs

5.2.2. Increased prevalence of asthma and COPD disorders

5.2.3. High cost of health care in developed regions

5.3. Constraints

5.3.1. Strict regulations for generic drugs

5.4. Opportunities

5.4.1. Successful drug patents expire and FDA approvals increased

5.4.2. Trend towards generic drugs in developed countries due to rising cost of health care

5.5. Challenges

5.5.1. Pressure on prices due to the presence of several players in the segment

6. Generic Inhalation and Nasal Sprays Market, by Indication

6.1. introduction

6.2. Allergic rhinitis

6.3. Asthma

6.4. COPD

7. Generic Inhalation Nasal Spray Drugs Market, By Age Group

7.1. introduction

7.2. Adults

7.3. Children 2 to 5

7.4. Children 6 to 12

8. Generic Inhalation and Nasal Spray Drugs Market, By Class

8.1. introduction

8.2. Allergy blocker

8.3. Anticholinergic

8.4. Antihistamine

8.5. decongestant

8.6. Mast cell inhibitor

8.7. Nasal steroid

9. Generic inhalation and nasal sprays market, by road

9.1. introduction

9.2. Inhalation

9.3. Nasal spray

9.4. Tropical Lotion

10. Generic inhalation and nasal sprays market, by distribution channel

10.1. introduction

10.2. Hospital medical store

10.3. Online pharmacy

10.4. Retail pharmacy

11. America Generic Inhalation and Nasal Spray Market

12. Asia-Pacific Generic Inhalation and Nasal Spray Market

13. Europe, Middle East & Africa Generic Inhalation Drugs and Nasal Sprays Market

14. Competitive landscape

14.1. FPNV positioning matrix

14.1.1. Quadrants

14.1.2. Business strategy

14.1.3. Product satisfaction

14.2. Market ranking analysis

14.3. Market share analysis, by key player

14.4. Competitive scenario

14.4.1. Merger & Acquisition

14.4.2. Agreement, collaboration and partnership

14.4.3. New product launch and improvement

14.4.4. Investment and financing

14.4.5. Awards, recognition and expansion

15. Company usability profiles

For more information on this report, visit https://www.researchandmarkets.com/r/1lry5e

read more
Generic drugs

The global market for generic inhalants and nasal sprays is expected to reach over $10 billion by 2026

DUBLIN, December 16, 2021–(BUSINESS WIRE)–The report “Inhalation & Nasal Sprays Generic Drugs Market Research Report by Indication, Age Group, Class, Route, Distribution Channel, and Region – Global Forecast to 2026 – Cumulative Impact of COVID-19” has been added to from ResearchAndMarkets.com offer.

The global Generic Inhalation Drugs and Nasal Sprays Market size was estimated at USD 6,392.52 million in 2020, is projected to reach USD 6,879.55 million in 2021 and is projected to grow at a CAGR of 7.95% to reach 10 USD 119.95 million by 2026.

Market statistics

The report provides market size analysis and forecasts for five major currencies – USD, EUR GBP, JPY and AUD. It helps organizational leaders make better decisions when currency data is readily available. In this report, the years 2018 and 2019 are considered as historical years, 2020 as the base year, 2021 as the estimated year and the years from 2022 to 2026 as the forecast period.

Market segmentation and coverage

This research report categorizes generic inhalants and nasal sprays to forecast revenues and analyze trends in each of the following submarkets:

  • On the basis of indication, the market has been studied for allergic rhinitis, asthma, and COPD.

  • On the basis of age group, the market has been studied on adults, 2-5 year olds, and 6-12 year olds.

  • Based on class, the market has been studied on Allergy Blockers, Anticholinergics, Antihistamines, Decongestants, Mast Cell Inhibitors, and Nasal Steroids.

  • Based on Route, the market has been studied for Inhalation, Nasal Spray, and Tropical Lotion.

  • Based on the distribution channel, the market has been studied in hospital medical stores, online pharmacies and retail pharmacies.

  • Based on region, the market has been studied in Americas, Asia-Pacific and Europe, Middle East & Africa. The Americas are studied in more detail through Argentina, Brazil, Canada, Mexico and the United States. The United States is studied in more detail through California, Florida, Illinois, New York, Ohio, Pennsylvania and Texas. Asia-Pacific is studied in more detail through Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand. Europe, the Middle East and Africa are studied in more detail in France, Germany, Italy, the Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, the United Arab Emirates and the United Kingdom.

Companies cited

  • Allergan AG

  • Altaire Pharmaceuticals Inc.

  • Beximco Pharmaceuticals Ltd

  • Catalent Pharmaceutical Solutions

  • Cipla Limited

  • Hikma Pharmaceuticals PLC

  • Mylan AG

  • Navajo Manufacturing Company Inc.

  • Nephron Pharmaceutical Company

  • Perrigo Company plc

  • Favorite Pharmaceuticals Inc.

  • Sandoz International GmbH

  • Sheffield Pharmaceuticals LLC

  • Sun Pharmaceutical Industries Ltd.

  • Teva Pharmaceutical Industries Ltd.

Cumulative impact of COVID-19

COVID-19 is an unparalleled global public health emergency that has affected almost every industry, and the long-term effects are expected to impact industry growth over the forecast period. The analyst’s ongoing research amplifies its research framework to ensure inclusion of the underlying issues of COVID-19 and potential pathways forward. The report provides insights into COVID-19 considering shifts in consumer behavior and demand, shopping patterns, supply chain rerouting, current market force dynamics, and significant interventions governments. The updated study provides insights, analysis, estimates, and forecasts considering the impact of COVID-19 on the market.

Competitive Strategy Window

The strategic competitive window analyzes the competitive landscape in terms of markets, applications and geographies to help the vendor define an alignment or match between its capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for vendors to adopt successive strategies of merger and acquisition, geographic expansion, research and development, and new product introduction strategies to execute further business expansion and growth. during a forecast period.

FPNV positioning matrix

The FPNV Positioning Matrix evaluates and ranks vendors in the Generic Inhalation and Nasal Sprays Market based on business strategy (business growth, industry coverage, financial viability, and channel support) and product satisfaction (value for money, ease of use, product features, and customer support) that helps businesses make better decisions and better understand the competitive landscape.

Market share analysis

The market share analysis offers the analysis of the vendors considering their contribution to the overall market. It gives the idea of ​​its revenue generation in the overall market compared to other providers in the space. It provides information on the performance of vendors in terms of revenue generation and customer base compared to others. Knowing the market share gives an idea of ​​the size and competitiveness of suppliers for the reference year. It reveals the characteristics of the market in terms of accumulation, fragmentation, dominance and merger.

Competitive scenario

The competitive scenario provides an analysis of the prospects of the various business growth strategies adopted by the vendors. The news covered in this section provides valuable insights at various stages while keeping abreast of activity and engaging stakeholders in the economic debate. The competitive scenario represents press releases or company news categorized into merger and acquisition, agreement, collaboration and partnership, new product launch and improvement, investment and funding, and awards, recognition and expansion. All the news gathered helps the vendor to understand the gaps in the market and the strength and weakness of the competitors, thus providing insights to improve the product and service.

Main topics covered:

1. Preface

1.1. Study objectives

1.2. Market segmentation and coverage

1.3. Years Considered for Study

1.4. Currency and price

1.5. Language

1.6. Limits

1.7. Hypotheses

1.8. Stakeholders

2. Research methodology

3. Executive Summary

4. Market Overview

4.1. introduction

4.2. Cumulative impact of COVID-19

5. Market dynamics

5.1. introduction

5.2. Drivers

5.2.1. Low cost associated with generic prescription drugs

5.2.2. Increased prevalence of asthma and COPD disorders

5.2.3. High cost of health care in developed regions

5.3. Constraints

5.3.1. Strict regulations for generic drugs

5.4. Opportunities

5.4.1. Blockbuster drug patents expiring and FDA approvals rising

5.4.2. Inclination towards generic drugs in developed countries due to rising cost of healthcare

5.5. Challenges

5.5.1. Pressure on prices due to the presence of several players in the segment

6. Generic Inhalation and Nasal Spray Market, By Indication

6.1. introduction

6.2. Allergic rhinitis

6.3. Asthma

6.4. COPD

7. Generic Inhalation and Nasal Spray Market, By Age Group

7.1. introduction

7.2. Adults

7.3. Children 2 to 5

7.4. Children from 6 to 12 years old

8. Generic Drugs for Inhalation and Nasal Sprays Market, By Class

8.1. introduction

8.2. allergy blocker

8.3. Anticholinergic

8.4. Antihistamine

8.5. Decongestant

8.6. mast cell inhibitor

8.7. nasal steroid

9. Generic Inhalation and Nasal Spray Drugs Market, By Way

9.1. introduction

9.2. Inhalation

9.3. nasal spray

9.4. Tropical Lotion

10. Generic Drugs for Inhalation and Nasal Sprays Market, By Distribution Channel

10.1. introduction

10.2. Hospital medical store

10.3. Online pharmacy

10.4. Pharmacy retail

11. Americas Generic Inhalation and Nasal Sprays Market

12. Asia-Pacific Generic Inhalation and Nasal Spray Market

13. Europe, Middle East and Africa Generic Inhalation and Nasal Spray Drugs Market

14. Competitive landscape

14.1. FPNV positioning matrix

14.1.1. Quadrants

14.1.2. Business strategy

14.1.3. Product Satisfaction

14.2. Market Ranking Analysis

14.3. Market share analysis, by key player

14.4. Competitive scenario

14.4.1. Merger & Acquisition

14.4.2. Agreement, collaboration and partnership

14.4.3. Launching and improving new products

14.4.4. Investment & Financing

14.4.5. Reward, recognition and expansion

15. Enterprise Usability Profiles

For more information about this report visit https://www.researchandmarkets.com/r/1lry5e

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211216005562/en/

contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Officer
[email protected]
For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900

read more
Prescription drugs

Hyperlipidemia Prescription Drug Market Outlook to 2026 by Application, End User and Geography

The latest research report on Prescription Drug Market for Hyperlipidemia Informs the reader of all the important aspects that influence the behavior of the industry, such as the main growth drivers and challenges, to enable stakeholders to make informed decisions for the future. It also includes a comparison of past and current business scenarios to support the study’s forecast. In addition, the document offers a detailed account of the various market segments and recognizes the key areas that promise solid revenues in the years to come.

According to industry experts, the hyperlipidemia prescription drug market size is expected to yield high profits over the period 2021-2026, registering a XX% CAGR throughout.

Research literature uncovers the impact of the COVID-19 pandemic on this area, with a focus on barriers such as changes in customer behavior, supply chain flows, and imbalances in business operations . It also recommends various approaches that will ensure an upward growth trajectory in the years to come.

Request a copy of this report @ https://www.nwdiamondnotes.com/request-sample/100872

ImportantPointers of the Hyperlipidemia Prescription Drugs Market report:

  • COVID-19 Status and Its Impact on Industry Compensation
  • Market and submarkets growth rate approximations
  • Predominant trends in the vertical
  • Business expansion opportunities
  • Advantages and disadvantages of the indirect and direct sales channel
  • Main traders, suppliers and resellers

Hyperlipidemia Drugs Market Segments Covered in Report:

Geographic bifurcation: North America, Europe, Asia-Pacific, South America and Middle East & Africa

  • Review of the business landscape for each regional market at country level
  • Aggregate sales and revenue data for each area
  • Share of industry captured by major regional contributors
  • Estimates of the growth rate of each regional market over the evaluation period

Product Types: HMG COA Reductase Inhibitors, Fibric Acid Derivatives, Nicotinic Acid, Bile Acid Sequestering Agents, Cholesterol Absorption Inhibitors, and Combination Drug Therapy

  • Sales, revenue and market share of each product segment
  • The pricing model for each product category

Application spectrum: Hospital and Clinic

  • Global turnover and sales secured by each application segment
  • Product pricing according to scope

Competitive dashboard:

  • Amgen
  • Eli lilly
  • GlaxoSmithKline Pharmaceuticals
  • Isis Pharma
  • Merck
  • Dr Reddy’s laboratories
  • Immuron Limited
  • Esperion Therapeutics
  • Pfizer and Formac Pharma

  • Products and services offered by the best companies
  • Leading organizations manufacturing facilities in the geographies served
  • Annals of price models, gross margins, sales, market share and cumulative revenue of major players
  • SWOT analysis of the main organizations
  • New emerging competitors in the market
  • Review of well-known trading tactics
  • Conclusive overview of market concentration rate and commercialization rate

Purpose of Prescription Drugs for Hyperlipidemia: –

To assess the value, market share, sales margin, hyperlipidemia drugs industry status (2016-2020) and forecast scenario (2021-2026).

To study the main players of the drug Hyperlipidemia and their company profiles, their statistics of production, consumption and import-export

To analyze the growth, opportunity, development, and risk of the Hyperlipidemia Drugs industry in various regions.

To understand the competitive view of the market, SWOT and gross margin statistics.

To present, describe, analyze, and define the Hyperlipidemia Drugs industry on the basis of product type, applications, and regions.

To examine development plans, industry policies, market size, value, and sales of major players in Hyperlipidemia Prescription Drugs.

Investigate crucial factors such as market risks, drivers, maturity analysis of prescription hyperlipidemia drugs.

Table of contents overview:

  1. Hyperlipidemia Prescription Drug Market Overview
  2. Hyperlipidemia Prescription Drug Market Company Profiles
  3. Competition in the market, by players
  4. Market Size Segment by Type
  5. Market Size Segment by Application
  6. North America by Country, Type and Application
  7. Europe by country, type and application
  8. Asia-Pacific by Region, Type and Application
  9. South America by Country, Type and Application
  10. Middle East & Africa by Country, Type and Application
  11. Research results and conclusion.

Request customization on this report @ https://www.nwdiamondnotes.com/request-for-customization/100872

read more
Medical supplies

How Medpick simplifies the process of purchasing medical supplies

In 2016, when Dr Ranjit Makam’s father survived a stroke, he realized that although he lives in one of the main cities with the latest medical facilities, it often becomes difficult for caregivers. to obtain medical supplies. Medpick was originally formed as a Bengaluru-based healthcare startup that worked as a B2C supplier of drugs and medical equipment.

Digging deeper, Ranjit realized that the loopholes created – procurement processes leading to lost revenue and inefficient patient care – were for B2B players like retail pharmacies and medical stores. Thus, Medpick decided to tackle the problem of providing appropriate medical supplies to retail stores and now operates as a B2B platform to simplify the procurement of drugs in healthcare companies.

Facilitate easy pharmaceutical delivery

Since there were only a few names in the business when Medpick started, it was easier to create the startup where a group of like-minded people with the same medical background came together to solve the problem on the platform.

Commenting on his current services, Chethan KS, Co-Founder and Biomedical Engineer at Medpick, said, “As a B2B platform, we face customers from both sides. While on the one hand, Medpick helps hospitals, small clinics, government projects, and laboratories automate procurement, maintain medical supplies, and acquire products overseas, it also lends a helping hand. white-level medical suppliers and distributors in marketing their products to achieve a uniform sales flow, when regional marketing can be a major obstacle. In addition, Medpick also serves as a platform to organize its supply chain, while reaching out to new hospitals across the country. In conclusion, Medpick is the meeting point for hospitals and medical providers, which ultimately benefits customers.

Solarix deserves special mention here, especially at a time when the world is gripped by the pandemic. Chethan adds, “Solarix is ​​a portable disinfectant device that appears to be tailor-made for the Indian market. Originally designed and manufactured in Canada, Solarix was introduced to Medpick by one of its vendors. Perhaps Solarix was also the means of opening the doors to the supply of drugs from Canada to Indian hospitals, thus increasing the visibility of the market. So, Medpick enabled Solarix on its app, and apart from medical organizations, it also reached end users from whom taxi drivers have greatly benefited, helping them disinfect the surface, decreasing fear of contamination.

Medpick deals with a wide variety of health insurance businesses. The most important thing for Chethan is to help hospitals / medical organizations obtain imaging equipment, whether for MRIs, X-rays or ultrasounds. Often times, it becomes difficult for hospitals to pay for imaging machines. Medpick helps them get refurbished equipment from the United States.

Recent statistics show that hospitals that source through Medpick have already reduced their procurement costs by 10-15%. Additionally, all of the large slides and medical equipment that have been parked in warehouses due to lack of proper maintenance have been made operational by Medpick based on their excellent biomedical network spread across the country.

The e-commerce platform allows doctors to instantly decide on the purchase of a product with detailed specifications, as well as import equipment for hospitals around the world, use improved medical technologies for the India, and also to help healthcare startups follow the right marketing strategies for their products.

Ease and affordability of a .in domain

Considering their potential customers, Medpick generally works offline. So, to educate them on the benefits of buying online, the .in domain has served well. Catering to hospitals and manufacturers across India was our main focus when we launched the e-commerce store. The .in domain seemed like a natural way to scale up, ”says Chethan.

The National Internet Exchange for India (NIXI) helps many businesses across the country obtain a .in or .Bharat domain. Businesses of any scale and size can benefit from a .in domain with the help of NIXI. It is affordable and can be used in over 22 languages ​​for businesses from all parts of the country.

Growth and turnover

Medpick realized that their true calling was to refurbish, operate, and supply medical devices to hospitals. Tracing the history of growth, Medpick began by integrating a single multi-specialty hospital, from which it reached over 100 hospitals, contacting the platform daily through their app or website. In addition, they have successfully partnered over 150 manufacturers and distributors across India, expanding to a wider space regardless of location.

With the restrictions brought about by the pandemic, most hospitals are restricting the entry of medical representatives, increasing the difficulties for manufacturers and distributors to market their products. Chethan sees this as a golden opportunity for Medpick as they can help hospitals move their medical shopping online while helping suppliers and manufacturers move their supply chain online.

Commenting on the future roadmap, Chethan said, “We see a good market opportunity through our GPO-based purchases, leading to at least 500 hospital purchases by next fiscal year, as well as the projection. from 500 to 600 manufacturers. “

The series “Shaping India Inc’s Online Growth” chronicles the journeys of startups and SMEs in India and how the creation of an online presence in the .in or .Bharat domain has fueled their successes.


read more
Prescription drugs

Pet Prescription Drug Market size, increasing diversity of trends, analysis, future scope analysis with major key industry players by 2026

The primary objective of the Animal Drugs market report is to determine the performance of the industry over the anticipated time frame to help stakeholders to make informed decisions and action plans that will ensure long term success . The document highlights all the factors that favor the growth of this vertical, followed by counter-approaches to the major challenges facing companies. In addition, it includes the changes in this vertical due to the Covid-19 pandemic and highlights the best opportunities for the future.

Key points of the impact assessment of Covid-19:

  • Impact of Covid-19 on the economic scenario on a global scale.
  • Changes in the share of supply and demand.
  • Predictions of the long-term effects of the Covid-19 pandemic on the growth matrix.

An overview of the regional landscape:

  • Geographically, the pet prescription drug market is divided into North America, Europe, Asia-Pacific, South America, Middle East & Africa, Southeast Asia.
  • The contribution of each region to the overall growth of the industry is measured in the study.
  • An analysis of the revenue, sales and growth rate for key regions during the forecast period is also provided.

Request a copy of this report @ https://www.nwdiamondnotes.com/request-sample/96766

Other important takeaways from the Pet Prescription Drugs Market report:

  • The report categorizes the pet prescription drug market product landscape into oral type, smear type, injection type and spray type.
  • Sales and volume share estimates for each product category are provided.
  • The study also highlights the market share, growth rate and production pattern of each type of product over the forecast period.
  • In terms of the scope, the Animal Prescription Drugs market is fragmented into Pets, Livestock, geographically, the detailed production and trade analysis of the following countries is covered in Chapter 4.2, 5: United States, Europe, China, Japan and India.
  • The market share guaranteed by each application segment along with their growth rate forecast is discussed in detail in the report.
  • The main companies that are setting trends in the pet prescription drug market are Ceva Sante Animale, MSD Animal Health, Ourofino Saude Animal, Dechra, Virbac, Boehringer Ingelheim, Vetoquinol, Zoetis, Animalcare Group and Elanco Animal Health.
  • Listed companies are analyzed on the basis of their gross margins, production models, product and service portfolio, pricing model, market compensation and market share.
  • Major competitive trends and their implications for businesses are comprehensively elaborated.
  • Granular industry supply chain analysis, with details of key manufacturers, suppliers and consumers is included.
  • The feasibility study of a new project using several methodologies such as SWOT analysis and Porter’s five forces analysis is provided in the document.

Reasons to access this report:

  • Know the opportunities and plan strategies by having a solid understanding of the investment opportunities in the Animal Prescription Drugs market
  • Identification of key parameters driving investment opportunities in the prescription animal drugs market
  • Facilitate decision making based on solid historical and forecast data
  • Position yourself to make the most of the industry’s growth potential
  • Develop strategies based on the latest reports.
  • Identify key partners and avenues for commercial development
  • Respond to your competitor’s business structure, strategy and outlook
  • Identify the main strengths and weaknesses of important market players

The key questions answered by this report:

  • What will the market size and growth rate be during the forecast year?
  • What are the key factors driving the global pet prescription drugs market?
  • What are the risks and challenges facing the market?
  • Who are the major vendors in the global pet prescription drugs market?
  • What are the trend factors influencing market shares?
  • What are the main results of Porter’s five forces model?
  • What are the global opportunities for expanding the global pet prescription drugs market?

Important point mentioned in the Research report:

  • Market overview, market dynamics, market growth etc. are cited in the report.
  • The power and commercial output of major manufacturers have been mentioned along with the technical data.
  • The study provides historical market data with revenue forecast and forecast from 2020 to 2025.
  • This report is a valuable asset for existing players, new entrants and future investors.

Table of Contents for Market Share by Application, Research Objectives, Market Sections by Type, and Forecast Years Considered:

Pet Prescription Drugs Market Share by Major Players: Here, the analysis of capital, revenues and prices by the company is included along with other sections such as development plans, areas served, products offered by major players, alliance and acquisition. and seat distribution.

Global growth trends: Industry trends, growth rate of major producers, and production analysis are the segments included in this chapter.

Market Size By Application: This segment comprises an analysis of the Animal Prescription Drugs market consumption by Application.

Pet Prescription Drugs Market Size By Type: It includes analysis of product value, utility, market percentage and production market share by type.

Manufacturer profiles: Here, the major players of the global Animal Prescription Drugs Market are studied on the basis of sales area, key products, gross margin, revenue, price, and production.

Animal Medicines Market Value Chain Analysis and Sales Channels: It includes analysis of customers, distributors, market value chain and sales channels.

Market Forecast: This section focuses on production and production value forecast, forecast of key producers by type, application and regions

Request customization on this report @ https://www.nwdiamondnotes.com/request-for-customization/96766

read more
Medical products

3 actions to capitalize on the dynamism of the medical products industry

This story originally appeared on Zacks

The COVID-19 pandemic, which has proven to be a biological crisis of an unprecedented nature, has changed the very nature and dynamics of the healthcare industry. Zacks’ medical products industry has also not been immune to the pandemic, and has been hit hard by widespread supply chain disruptions and postponement of elective proceedings. However, the medical products space has seen a substantial recovery, mainly due to the easing of previous restrictions and the acceleration of vaccinations. Apart from this, the slow resumption of elective procedures, the growing demand for in vitro diagnostics (IVD) and the growing reliance on artificial intelligence (AI) and robotics are expected to favor industry participants. in the coming days. Despite a pandemic-induced disruption triggered by the Delta variant, particularly during August and September, industry players have yet to show signs of slowing down. Industry participants love Abbott Laboratories ABT, Bio-Rad Laboratories, Inc. BIO and Hill Rom Holdings, Inc. HRC are likely to take advantage of the factors mentioned above.

– Zack

5 actions in the process of doubling

Each has been handpicked by a Zacks expert as the # 1 favorite stock to earn + 100% or more in 2021. Previous recommendations have climbed + 143.0%, + 175.9%, +498 , 3% and + 673.0%.

Most of the stock in this report is flying under Wall Street’s radar, which provides a great opportunity to get into the ground floor.

Today, discover these 5 potential circuits >>

Want the latest recommendations from Zacks Investment Research? Today you can download 7 best stocks for the next 30 days. Click to get this free report

Abbott Laboratories (ABT): Free Stock Analysis Report

BioRad Laboratories, Inc. (BIO): Free Inventory Analysis Report

HillRom Holdings, Inc. (HRC): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks investment research

read more
Prescription drugs

ASHP wants to stop white bags on prescription drugs

The American Society of Health-System Pharmacists (ASHP) is working to end a practice known as “white bagging,” officials said.

White bagging is when a payer demands that providers can only source drugs from a limited selection of specialty pharmacies affiliated with the payer. In white sachets, pharmacies in the health system receive these drugs from specialized pharmacies which they must then dispense to patients. Typically, as part of the purchasing and billing system, pharmacies in the health system maintain their own inventories and prepare medications based on physicians’ electronic health records.

“We believe ASHP is compromising patient care,” said Kyle Robb, PharmD, state policy and advocacy associate at ASHP, during a presentation at the company’s virtual meeting in mid-year. White bags blind clinicians and hospitals to drug supply chains, can lead to delays in care and compromise electronic medical records, he added.

“White bagging has really emerged and gained momentum over the past couple of years,” noted Tom Kraus, MHS, vice president of government relations at ASHP.

In March, the ASHP and the American Hospital Association co-signed a letter to the FDA asking the agency to enforce the Drug Supply Chain Security Act (DSCSA) – which required that electronic chain histories supplies are maintained for all prescription drugs. until this drug is delivered to the patient – with the aim of ending the white bags.

“Our main argument with the FDA is that white bagging fundamentally bypasses the DSCSA,” Robb said. The DSCSA was adopted in 2013 in response to a meningitis outbreak in several states caused by contaminated steroids made at a compounding pharmacy in Massachusetts.

As part of white bagging, specialty pharmacies do not share transaction information with vendors, which means hospitals do not know the supply chain history of white bagged drugs. he explained.

However, the FDA has yet to take regulatory action regarding the white bags, Robb said.

The ASHP saw more state-level action for the first time this year, he noted. Prior to 2021, no state had white bag legislation, and only one state had introduced a bill in 2020. So far this year, 11 states have introduced white bag bills. Three states – Louisiana, Arkansas, and Virginia – have passed laws.

Louisiana’s law was passed in June and ensures that plans cannot refuse to pay a provider for the provision of clinician-administered drugs and cannot punish patients with additional fees, according to Robb. The law also requires that drugs in white sachets from specialized pharmacies be accompanied by a history of transactions.

In Arkansas, the new legislation takes a different approach to preventing white bags: it only applies to hematology and oncology patients, although the Arkansas Insurance Commissioner may extend the covered conditions. This law states that payers must cover both medical and pharmaceutical benefit channels, and that patients and providers can choose the billing channel that works best for them.

In Virginia, plans must allow unprivileged pharmacies to dispense drugs covered at network rates and cannot increase costs for patients who use unprivileged pharmacies. The Virginia Board of Pharmacy has also passed regulations on the storage and tracking of white bagged medications.

  • Lei Lei Wu is a news intern for Medpage Today. She is based in New Jersey. To follow

Disclosures

Robb and Kraus did not report any financial disclosures.

read more
Generic drugs

Corporate Rx for Distressed Healthcare System: Affordable Generics Made in USA

Nexus Pharmaceuticals founder Mariam Darsot believes in altruistic acts like funding a labor and delivery ward in Sierra Leone, the country with the highest maternal mortality rate in the world. Photograph of Evan Jenkins

Nexus Pharmaceuticals is a 2021 Inc. Best in Business winner. With the second annual Best in Business, Inc. award recognizes companies that have made an exceptional impact on their industries, communities, the environment and society as a whole.

Meet the Illinois-based family-owned pharmaceutical company investing in nationwide manufacturing of drugs as treatment for the struggling healthcare industry.

Nexus Pharmaceuticals unveiled a state-of-the-art manufacturing facility in Pleasant Prairie, Wisconsin in June, doubling down on its mission to make high-quality generic drugs more affordable and accessible to patients in the U.S. The company’s three-story building, an investment of $ 250 million that will eventually employ more than 400, is the first national project of its kind in three decades. Meanwhile, production of US pharmaceuticals has largely shifted overseas so companies can take advantage of reduced environmental regulations and a lower-cost workforce. Today, only 28 percent of the active pharmaceutical ingredients supplied to the United States are produced here.

This over-reliance on foreign manufacturers has resulted in supply chain issues, quality-related recalls, and reduced export availability. All of this has contributed to rising pharmaceutical prices and national shortages, according to Mariam Darsot, CEO and founder of Nexus. And that, she says, prevents people from getting the timely treatment they might need. Also at the start of the pandemic, Indian manufacturers reduced exports of more than 20 essential pharmaceuticals and active ingredients to meet patient demand in their own country, which only added to the already heavy burden. of American health. the care industry, explains Darsot.

“I think it’s fair to say that the pharmaceutical industry has damaged its reputation a lot through price fixing allegations, substandard products from overseas or price increases. essential drugs, ”Darsot said. And she is committed to changing the industry, from the inside out. Since its inception in 2003, Nexus has prioritized the production of injectable drugs with historically rare critical needs. It has a long history of working with contract manufacturers to produce its FDA-approved generic pharmaceuticals, and now, with its own manufacturing facility, it can scale up its production even further to have a serious impact on the overall drug supply of consumers. United States. (Especially considering the fact that most of the drug shortages in the country are in generic drugs, Nexus’ specialty, the promise is clear.)

Over the past year, the company has already increased the US supply of two rare and life-saving pharmaceuticals: an injection of succinylcholine chloride, a drug in high demand to treat Covid patients, and an injection of potassium chloride, an IV solution with historically few manufacturers (including the one damaged in Hurricane Maria, resulting in a lasting shortage).

Darsot says she’s not interested in profit for profit – the company explicitly produces drugs that are needed in an attempt to lower healthcare costs for consumers. Nexus avoids private equity so as not to be influenced by shareholders. His altruism also extends beyond his core business. In 2020, for example, Nexus funded a labor and delivery unit at the Tanihanun health center in Sierra Leone, the country with the highest maternal mortality rate in the world. In 2021, the company also donated $ 176,000 to charitable organizations through employee matchmaking and community partnerships.

“Being a family business allows us to give back to a community that has given so much to our business and our family,” said Darsot. “This brings us back to our core mission of helping deliver affordable medicines to those who need them most.”

EXPLORE MORE Best in business COMPANIESRectangle

Extract from the Winter 2021/2022 issue of Inc. Magazine

read more
Medical products

Intensify actions to fight substandard and falsified medical products. Urgent appeal to “false breakers”

“Health is not a hoax – Fight the fakes” is the slogan for this year’s Fight the Fakes week. The aim is to highlight how substandard and falsified medicines pose serious risks to human health and have disastrous consequences for the well-being of communities and the socio-economic stability of each country. They deserve much more attention in international fora.

Fight the Fakes Alliance invites organizations and individuals around the world to become fake busters for this year’s Fight the Fakes week, December 6-12, and to help raise awareness of the dangers involved.

Sometimes substandard and falsified drugs can have tragic consequences. They are contributing to the development of the second global health emergency after COVID-19: antimicrobial resistance and drug-resistant infections. They create mistrust in drugs, health professionals and health systems and block the socio-economic development of a country. The problem is most acute in low- and middle-income countries, with estimates suggesting that up to 1 in 10 medical products are either substandard or falsified.

Since the start of the COVID-19 pandemic, diagnostic tests, personal protective equipment (PPE), potential therapies and vaccines have been found to be falsified across the world. The World Health Organization (WHO) has issued several medical product alerts related to COVID-19 vaccines and treatments over the past two years, while the Infectious Disease Data Observatory collects hundreds of reports from the field public on substandard and falsified COVID-19 medical products. and COVID-19 vaccines.

As the rollout of COVID-19 vaccination accelerates, criminals are capitalizing on shortages or barriers to access, but also waves of vaccine hesitation. It may also accelerate the spread of counterfeit products that are unrelated to COVID-19, proving a flourishing global business of substandard and falsified medical products, without regard for the health impacts.

About Fight the Fake Alliance

The Fight the Fakes Alliance (aka “Fight the Fakes”) is a non-profit, multi-party association that aims to raise awareness of the dangers of falsified and substandard medicines. He gives voice to those who have been personally affected and shares the stories of those working to end this threat to public health. He seeks to build a global movement of organizations and individuals who will shed light on the threat these so-called drugs pose to patient safety and health systems and to achieving universal health coverage. The diverse members of Fight the Fakes share the belief that coordination among all stakeholders working along the medical supply chain is essential if we are to tackle this threat to global health.




read more
Generic drugs

Medkart: Generic Medkart Retail Chain Raises Rs 40 Crore In Series A Cycle

Medkart, the Ahmedabad-based generic drug retail pharmacy chain, said on Tuesday it had raised Rs 40 crore in its Series A cycle from Alkemi Growth Capital and Insitor Partners with the participation of angel investors , including Prashant Poddar and other UAE professionals and former CEOs of IIFL Asset Management.

Medkart, founded by Ankur Agarwal and Parsharan Chari, is an omnichannel pharmacy that helps people lower their medical bills through access to the best quality generic drugs at the most affordable rates.

Founded in 2014, Medkart provides generic medicines certified by WHO GMP in its network of more than 75 stores in more than 22 cities.

Medkart says it cuts medical costs by up to 85% and has saved more than Rs 200 crore for its clients to date.

The company said it has a loyal base of over 600,000 chronic disease patients and derives 80% of its revenue from loyal customers.

The company has so far focused on building a robust supply chain and improving final delivery to customers.

During its founding years the company was started up, quickly achieved a positive unity economy, and gradually expanded its operations across Gujarat and Rajasthan. More recently, she has embarked on building online channels to add a more personalized experience to the customer.

Speaking about fundraising, Ankur Agarwal, Co-Founder, said, “Every year 6 crores of Indians are plunged into poverty due to medical expenses. Considering that drugs are a basic need especially for chronic patients, we aim to disrupt the way drugs are consumed in India. As a technology company, we always aim to serve our customers no matter which channel they are comfortable with. ”

Mumbai-based investment bank Radix Capital Advisors acted as exclusive financial advisor to Medkart.

read more
Medical products

Medical Products Supply Chain Weekly Review – FDA Approves Pfizer and Moderna Booster for All Adults | Alston & Bird

Over the past week, the FDA cleared the Pfizer and Moderna booster injections for all adult age groups, while the CDC’s Advisory Committee on Immunization Practices (ACIP) also recommended the Moderna vaccine booster. for all adults. Pfizer has submitted an Emergency Use Authorization (EUA) application for its oral treatment with COVID-19. President Biden signed the Infrastructure Investments and Jobs Act and the Executive Order for its implementation. The FDA has issued updated guidelines for manufacturers of SARS-CoV-2 tests. Please see details of these and other supply chain developments below:

  • On November 15, the President signed the Law on Investment in Infrastructure and Employment (IIJA) and a decree to facilitate its implementation. IIJA Amends Homeland Security Act 2002 to Allow Secretaries of Homeland Security, Health and Human Services (HHS) Departments, and Veterans to Transfer Personal Protective Equipment (PPE) and Equipment medically necessary for the national stock under a production contract during a public health emergency declared by the secretary of the HHS. In general, the Secretary of Homeland Security, at the request of the Secretary of HHS, is authorized to transfer to HHS, for reimbursement, excess PPE or medically necessary equipment possessed by the Department of Homeland Security (DHS). The DHS Secretary must determine whether the requested personal or medically necessary protective equipment is surplus equipment and certify that the transfer of such equipment will not have a negative impact on the health or safety of officers, employees or subordinates. treating DHS. The IIJA is also amending the Public Health Services Act to allow the Secretary of HHS, in coordination with the Secretary of DHS, to sell drugs, vaccines (and other biologicals), medical devices, or supplies. within the national stock to a federal agency, nonprofit, state, or local, tribal, or territorial entity. Products sold must be within one year of expiration or determined to be no longer needed in inventory due to advances in medical or technical capacity. The IIJA also includes a subtitle “Make PPE in America Act” which requires the development of a short-term (three-year) and long-term strategy for the national production of PPE. An Infrastructure Implementation Working Group has been established to oversee the implementation of the law. The working group will be co-chaired by Mitch Landrieu, White House Infrastructure Implementation Coordinator, and Brian Deese, Director of the National Economic Council.
  • On November 15, the FDA updated its policies regarding COVID-19 test review expectations and released several policies that provide guidance to manufacturers. The FDA’s goal is to ensure that the tests are reliable and accurate. The update included the following:
    • The FDA has re-issued the “Policy for Testing for Coronavirus-2019 Disease During Public Health Emergency (Revised),” which applies to tests that use diagnostic and serological methodology. Manufacturers can submit EUA requests for home and point-of-care testing, high-volume laboratory molecular diagnostic testing, high-volume laboratory and point-of-care antibody testing, and funded testing by the US government agency. All other types must use traditional pre-market channels.
    • The FDA has published the “Umbrella EUA for SARS-CoV-2 Molecular Diagnostic Tests for Serial Testing”. This EUA applies to certain SARS-CoV-2 serial use nasal swab tests, which are used in testing programs by schools, workplaces or community groups. Testing should be performed in a single CLIA certified laboratory.
    • The FDA reissued the EUA, “Laboratories that have developed a molecular test (LDT) for coronavirus disease 2019 (COVID-19)”. In its review of current policies and the changing needs of the pandemic, the agency is prioritizing serial use testing and has updated its conditions for authorizing molecular-based laboratory-developed tests. Additional tests may be permitted.
    • The FDA has issued guidance on its “Viral Transport Media Enforcement Policy During Coronavirus Disease 2019 (COVID-19) Public Health Emergency.” Due to the increase in serial testing, there is a need to increase the availability of transport media for clinical specimens. The FDA created this guide to support this effort and provide a standard for media manufacturers. The guide specifically provides criteria for commercial manufacturers on validation, agency notification and labeling expectations. Additional guidance and expectations are included for manufacturers of alternative media types and saline transport media.
  • On November 16, Pfizer announced the submission of an EUA application for its COVID-19 oral antiviral drug, Paxlovid (ritonavir). The medicine is intended for home use in high-risk patients to prevent hospitalization and death. According to an interim review from the Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) trial, a phase 2/3 study, Paxlovid demonstrated a relative risk reduction of 89% (risk reduction absolute 6.2%) of hospitalization and death in participants 18 years and older at high risk for disease progression. Recruitment for the trial was discontinued upon recommendation of the Data Oversight Committee based on interim analysis data. Trials for standard risk patients and post-exposure prophylaxis are still ongoing. On the same day, Pfizer agreed to license Paxlovid to the Medicines Patent Pool, a United Nations-backed entity, to provide access to the drug to low- and middle-income countries. On November 18, Pfizer announced an agreement with the US government to supply 10 million courses of Paxlovid, subject to regulatory clearance from the FDA.
  • On November 16, the Center for Devices and Radiological Health (CDRH) updated the Medical Device Development Tools program documents landing page. The program is voluntary and supports sponsors in the development and evaluation of their medical devices with the aim of facilitating the review of CDRH. The program’s tools are evaluated and approved by the FDA and must be capable of producing scientifically plausible results.
  • On November 17, the White House COVID-19 response team announced that the administration was planning to provide funding to increase vaccine production. The Department of Health and Human Services is in contact with manufacturing companies that can increase their vaccine production. The goal is to add at least one billion doses to the national supply through investments in infrastructure and training.
  • On November 19, the FDA cleared the Pfizer and Moderna vaccines for use as a booster dose in all age groups 18 years and older. The agency based its decision on data from ongoing clinical trials and real-time results from vaccine use. The authorizations relate to a booster dose at least six months after the end of the initial series. The CDC ACIP then met and unanimously recommended that the Moderna vaccine be allowed for people 18 years of age and older. The committee’s decision has been forwarded for approval to CDC director Dr. Walensky and the FDA.

[View source.]

read more
Medical supplies

New UPS Healthcare facility to help distribute temperature-controlled medical supplies

New UPS Healthcare facility to help distribute temperature-controlled medical supplies

UPS Healthcare is opening a new facility in Louisville with cold chain capabilities to expand the global delivery of temperature-controlled healthcare supplies, according to Louisville Business First. The new distribution center, 6204 New Cut Rd., Is located near UPS Worldport. “We strive to make sure that all of our buildings are truly the same in terms of process quality,” said Warren Olson, vice president of UPS Supply Chain Solutions. “We have a global quality system, so when you walk into a facility in Louisville, Ky., Or walk into a facility in Singapore, the only thing you should notice that is different is the accent of the people who take you on a visit. “The building will be used to house and distribute health products, including pharmaceuticals, medical devices and biologicals at room temperature, said Olson. Cold chain refers to supply chains to temperature controlled, which means that a product is produced, stored and distributed at the same time low temperature range. The cold chain capabilities of the center allow it to store temperature controlled devices in coolers and freezer, with temperatures of 20 to 25 degrees Celsius and -20 degrees Celsius, respectively. The total number of employees at the facility is undecided, but UPS Healthcare is currently hiring 400 positions, including entry and management levels. Olson said facilities of this size typically house 250 employees. The cold chain packaging center is now operational, but the rest of the facility is expected to begin operations by the first quarter of 2022. You can read more about the details in the full Louisville Business First file. . article here.

UPS Healthcare is opening a new facility in Louisville with cold chain capabilities to expand the global delivery of temperature-controlled healthcare supplies, according to Louisville Business First.

The new distribution center, 6204 New Cut Rd., Is located near UPS Worldport.

“We strive to make sure that all of our buildings are truly the same in terms of process quality,” said Warren Olson, vice president of UPS Supply Chain Solutions. “We have a global quality system, so when you walk into a facility in Louisville, Ky., Or walk into a facility in Singapore, the only thing you should notice that is different is the accent of the people who take you on a tour. “

The building will be used to house and distribute health products including pharmaceuticals, medical devices and room temperature biologicals, Olson said.

The cold chain refers to temperature-controlled supply chains, which means that a product is manufactured, stored and distributed in the same range of low temperatures. The centre’s cold chain capabilities allow it to store temperature-controlled devices in coolers and a freezer, with temperatures of 20 to 25 degrees Celsius and -20 degrees Celsius, respectively.

The total number of employees at the facility is undecided, but UPS Healthcare is currently recruiting 400 positions, including entry and management levels. Olson said facilities of this size typically house 250 employees.

The cold chain packaging center is now operational, but the rest of the facility is expected to start operating by the first quarter of 2022.

You can read more about the details in the full Louisville Business First article here.

read more
Medical supplies

Over $ 1 million in medical supplies to be delivered to rural African villages by Denver organizations

COVID has only made the problem worse and made it more difficult for rural areas to obtain medical supplies. From personal protective devices (PPE) to life-saving supplies to basic durable health goods, global demand has caused serious supply chain problems and rising prices. For rural and poor communities that already suffer from a lack of resources, this often means going without significant medical care and supplies.

“Our medical staff is at the service of patients in Denver every day “, said Shay kerman, COO of Emergency Care Solutions at Denver. “It’s easy to take for granted access to high-quality medical care like we have here, while other places suffer from lack of access to basic medical supplies and life-saving equipment. “

To help meet this need, Urgent Care Solutions and Project CURE have teamed up to send two containers of durable medical goods to Ghana and Senegal. Urgent Care Solutions pays the cost and their team members help collect the supplies and ship them to Africa.

“I saw the need firsthand,” Kerman said. “During my work in Ghana with groups of volunteers providing medical assistance, I saw tiny villages that had limited access to water, let alone medical supplies. “

At November 10e, Dairus and Shay Kerman, along with staff from AFC Urgent Care Denver, helped sort, assemble, pack and ship medical supplies to Project CURE’s nonprofit headquarters in Centenary, CO.

Medical supplies worth millions will be distributed by local health care providers.

“I am very excited about this partnership. Our head office is here in Denver and donations from a local organization like Urgent Care Solutions help us fulfill our mission, ”said Dr. Douglas jackson, President and CEO of Project CURE “Due to COVID, there is an even greater need for medical services and supplies in underserved countries. “

The CURE project provided more than $ 48 million in medical supplies donated in the United States and abroad. Donated medical supplies and equipment are provided free of charge to local health care providers serving remote areas.

About emergency care solutions

Urgent Care Solutions dba AFC Urgent Care has 9 sites serving more than 150,000 patients each year in Denver and Aurore, Colorado. AFC Urgent Care provides prompt and comprehensive medical care with short wait times and reasonable rates.

About the CURE project

Project CURE is the world’s largest distributor of donated medical equipment and supplies. They deliver these supplies to resource-limited communities around the world in more than 135 countries. Project CURE accepts donations from medical supply companies, hospitals, healthcare providers, and consumers.

Linked in the publication

Emergency care solutions in Denver is partnering with Project CURE to send millions of dollars in medical supplies to rural African villages in desperate need. Yesterday, the medical staff and management of Urgent Care sorted, assembled, packed and shipped much-needed medical supplies.

SOURCE Emergency Care Solutions

read more
Medical supplies

Medline Canada opens distribution center for essential medical supplies and equipment in Guelph, Ontario

600,000 square foot center enables rapid delivery of thousands of medical products to Canadian acute, long-term and primary care facilities

GUELPH, ON, November 12, 2021 / CNW / – Medline Canada today officially opened its new state-of-the-art distribution center in Guelph, Ontario, to meet the health care needs of Canadians with rapid delivery of essential medical supplies and equipment.

From left to right: Cam Guthrie, Mayor of Guelph; Lloyd Longfield, MP for Guelph; Doug Ford, Premier of Ontario; Mike Schreiner, MPP for Guelph; Ernie Philip, President of Medline Canada Mike Harris, MPP for Kitchener — Conestoga; and Kaveh Razzaghi, Chief Operating Officer of Medline Canada, mark the grand opening of Medline Canada’s new 600,000 square foot distribution center in Guelph, Ontario (CNW Group / Medline)

Medline Canada opens 600,000 square foot medical supplies distribution center in Guelph, Ontario.

“Medline’s investment in this new distribution center demonstrates our commitment to respond effectively from Canada medical supply needs and help improve the health and lives of Canadians, ”said Ernie Philippe, President, Medline Canada. “Our choice to set up our Canadian hub in Guelph gives us quick access to transportation to serve our Canadian customers. We are proud to contribute to from Guelph vibrant business community, economic and employment growth and supporting local environmental stewardship. “

The new 600,000 square foot facility employs 140 people and has approximately 25,000 different medical products in stock. This includes not only the products that everyone is familiar with – masks, gloves and gowns – but also personalized procedure kits, operating room instruments and incontinence care products, as well as many others that are essential to the functioning of our health care institutions and systems.

“We are delighted that Medline Canada has chosen Guelph as the location for this new state-of-the-art distribution center. This investment strengthens their presence here by Ontario and is a critical part of our mission to strengthen our provincial and national medical supply chain, ”said Doug Ford, prime minister of Ontario. “Medline’s commitment to Ontario is yet another demonstration that this is the best place in Canada doing business and we are delighted that they are rooting more deeply in this community. “

Medline has one of from Canada the largest inventory capabilities to help ensure the availability of medical supplies and equipment to a wide range of hospitals, clinics, retirement homes, pharmacies and retail stores.

“I am honored to welcome Medline and its employees to Guelph,” noted Cam Guthrie, Mayor of Guelph. “This state-of-the-art facility and the people who work there represent a major boost for from Guelph the local economy. Guelph is proud to house Medline, and we look forward to being a part of its continued growth and success in the years to come. “

The COVID-19 pandemic has shown the important role medical supplies play in ensuring the safety and health of frontline workers and patients. Medline Canada Guelph’s distribution center is certified by Health Canada and features state-of-the-art logistics technology, including a self-contained, temperature-controlled environment for safe storage of medical supplies. As a partner in from Canada A medical supply distribution system, Medline continues to work closely with key provincial government institutions to meet their medical supply needs.

Medline Canada

Medline is one of the world’s leading manufacturers and suppliers of high quality medical products and services for the healthcare industry. Our expertise in healthcare solutions across the continuum of care, coupled with the scale and agility of our supply chain, allows us to partner with our customers to improve patient care, improve clinical results, ensure effective cost management and provide rapid access to quality products.

By applying our CARES values ​​every day, in everything we do, Medline Canada is deeply committed to the health and well-being of our customers, employees, partners and communities. With over 550 employees, including 125 dedicated sales and clinic professionals, and nine distribution centers located across Canada, we are a trusted partner in meeting the health care needs of Canadians from coast to coast – Together, let’s improve lives. For more information visit www.medline.ca

Medline Logo (CNW Group / Medline)

Medline Logo (CNW Group / Medline)

SOURCE Medline

Cision

Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2021/12/c7039.html

read more
Medical products

Medical Products Supply Chain Week Review – November 2021 # 2 | Alston & Bird

Last week, the president chose Dr. Robert Califf to be the commissioner of the FDA. Congress passed the Infrastructure Investment and Jobs Act. New vaccination requirements have been issued by OSHA and CMS for some employers. In addition, the State Department has updated its rules for passengers entering the United States. Please see details of these and other supply chain developments below:

  • On November 4, the Department of Labor’s Occupational Safety and Health Administration (OSHA) announced a new Temporary Emergency Standard (ETS) that requires companies with 100 or more employees to develop a vaccination policy. against COVID-19. Requirements include that companies check the immunization status of each employee, require proof of vaccination, and keep records. Additionally, unvaccinated employees would be subject to weekly testing, early notification of a positive COVID-19 diagnosis, and a quarantine strategy. Employers have 60 days to comply with all of the requirements. In the meantime, lawsuits have been filed with the United States’ Courts of Appeals for the Fifth, Sixth, Seventh, Eighth, Eleventh and DC Circuits to review the legality of the order. While the Fifth Circuit has granted an emergency motion to suspend the OSHA HTA, cases will be consolidated and transferred to one circuit through a lottery system. The complainants argue that OSHA does not have the specific legislative authority to establish this rule and is in violation of the doctrine of non-delegation. For more information, see Alston & Bird’s Labor and Employment / Healthcare advisory, “What You Need to Know About OSHA’s ETS for Employee Vaccination Requirements” .
  • On November 4, the Centers for Medicare & Medicaid Services (CMS) issued emergency regulations requiring the full immunization of some health facility staff by January 4, 2022. The agency’s data collection determined that these requirements have not led to a critical shortage of personnel from the widespread resignation of essential personnel. For any non-compliant entity, CMS has committed to use its executing authority to take further action.
  • On November 6, Congress passed the Infrastructure Investment and Jobs Act. The law will provide funding for large infrastructure projects to “strengthen our supply chains and avoid the disruptions that have caused inflation.” The 10-year plan provides for $ 17 billion in funding for the modernization of port infrastructure and $ 25 billion in funding for US airports. The bill awaits the president’s signature.
  • On November 9, Pfizer and BioNTech submitted a request to change their Emergency Use Authorization (EUA) for the booster dose of the COVID-19 vaccine. The amendment would allow the booster dose to be authorized for all persons 18 years of age and over. The claim is based on data from a Phase 3 clinical trial which demonstrated the booster to be 95% safe and effective.
  • On November 10, the Administration announced action plans to improve the flow of goods through the supply chain and the progress made so far. The amount of cargo that passed through the ports of Los Angeles and Long Beach reached an all-time high. The Administration plans to facilitate the movement of goods by working with key stakeholders to operate the ports 24/7, including removing fees for truckers who collect cargo overnight and on weekends. , reducing rail rates for shipping to ports on weekends and encouraging retailers to use off-peak weekend hours for supply chain activities.
  • On November 12, President Biden will appoint Dr. Robert Califf as FDA commissioner. Califf previously served as commissioner during the Obama administration and is expected to receive bipartisan support. The announcement is expected today.
  • The FDA has issued “Product Specific, Interim and Revised Guidelines” to help manufacturers develop bioequivalence studies to use in their Abbreviated New Drug Application (ANDA) submissions. The guidelines and draft guidelines will apply to the products explicitly listed. The deadline for submitting comments is January 2, 2022.

[View source.]

read more
Medical products

Medical Products Supply Chain Weekly Review – November 2021 # 1 | Alston & Bird

Last week, the FDA granted EUA for the Pfizer-BioNTech vaccine for children aged 5 to 11. The agency also participated in the launch of the Bespoke Gene Therapy Consortium. The administration organized a global supply chain summit to strengthen cooperation and advocate for the diversification of supply chains. Please see details of these and other supply chain developments below:

  • On October 27, the FDA, the National Institutes of Health, 10 pharmaceutical companies and five nonprofits launched the Bespoke Gene Therapy Consortium (BGTC) to optimize and streamline the gene therapy development process. In particular, the BGTC will streamline regulatory requirements and processes for FDA approval of gene therapies, including the development of standardized approaches for preclinical testing (eg, toxicology studies).
  • On October 29, the FDA cleared the emergency use of the Pfizer-BioNTech vaccine for children aged 5 to 11. The authorization is for a two-dose regimen, and each dose is less than the prescribed dose for persons 12 years of age and older. The vaccine has been shown to be 90.7% effective in preventing COVID-19 in children 5 to 11 years old. Following the decision, the CDC approved the vaccine for use in this population.
  • On October 31, President Biden convened a summit with the European Union and 14 other countries to discuss transnational cooperation to strengthen supply chains. The conversation focused specifically on the diversification of the supply chain ecosystem, covering raw materials, manufacturing of intermediate and finished products, shipping, logistics, warehousing and distribution. President Biden also announced initiatives to address supply chain disruptions, including releasing stocks, funding technical assistance in Mexico and Central America, and a commitment to host future summits on the Supply Chain.
  • On November 3, the administration announced it would release a dashboard to show metrics that track progress and activity at the ports of Los Angeles and Long Beach. The dashboard will provide data on ships at berth awaiting docking, import volume in port and retail stocks. The Administration’s goal is to use the data to help stakeholders assess the health of the supply chain and foster future collaborations.
  • On November 4, the FDA released a draft guideline for industry, Content of Premarket Submissions for Device Software Functions. The guide aims to provide industry with the required information that should be included in a pre-market submission that will help the FDA assess the safety and effectiveness of software functions included in a medical device (SiMD), as well as software that functions as a medical device (SaMD). The guidelines will apply to all types of pre-market submissions, including PMA, 510 (k) and De Novo classification requests. Comments are due in 90 days.
  • The Center for Devices and Radiological Health has released its proposed list of guidance documents to be released in fiscal year 2022. The list includes its priorities (A-List) and guidance documents to be released if resources require it. allow (B-List). The CDRH will also carry out a retrospective review of the guidance documents for the years 1982, 1992, 2002 and 2012.

[View source.]

read more
Medical products

Medical Product Supply Chain Week in Review – November 4, 2021 – Food, Drugs, Healthcare, Life Sciences

United States: Medical Product Supply Chain Week in Review – November 4, 2021

To print this article, all you need to do is be registered or log in to Mondaq.com.

Last week, the FDA granted an EUA for the Pfizer-BioNTech vaccine for use in children ages 5 to 11. The agency also participated in the launch of the Bespoke Gene Therapy Consortium. The Administration hosted a global supply chain summit to strengthen cooperation and advocate for the diversification of supply chains. Please see details of these and other supply chain developments below:

  • On October 27, the FDA, the National Institutes of Health, 10 pharmaceutical companies and five nonprofit organizations spear the Bespoke Gene Therapy Consortium (BGTC) to optimize and streamline the gene therapy development process. In particular, the BGTC will streamline regulatory requirements and FDA approval processes for gene therapies, including the development of standardized approaches for preclinical testing (eg, toxicology studies).
  • On October 29, the FDA authorized emergency use of the Pfizer-BioNTech vaccine for children 5-11 years old. The clearance is for a two-dose regimen, and each dose is lower than the dose prescribed for people 12 years of age and older. The vaccine has been shown to be 90.7% effective in preventing COVID-19 in children 5 to 11 years old. Following the decision, the CDC approved the use of the vaccine in this population.
  • On October 31, President Biden tenuous a summit with the European Union and 14 additional countries to discuss transnational cooperation to strengthen supply chains. The conversation focused specifically on diversifying the supply chain ecosystem, covering raw materials, manufacturing of intermediate and finished goods, shipping, logistics, warehousing and distribution. President Biden also announced initiatives to address supply chain disruptions, including the release of inventory, funding for technical assistance to Mexico and Central America, and a commitment to host future summits. of the supply chain.
  • On November 3, the administration announcement that it will publish a dashboard to show metrics that track progress and activity at the Ports of Los Angeles and Long Beach. The dashboard will provide data on vessels in berth waiting to berth, import volume in port and retail stocks. The administration’s goal is to use the data to help stakeholders gauge the health of the supply chain and foster collaborations going forward.
  • On November 4, the FDA published Draft Industry Guidelines, Content of Pre-Release Submissions for Device Software Features. The guidelines are intended to provide industry with the required information that must be included in a premarket submission that will help the FDA evaluate the safety and effectiveness of software functions included in a medical device (SiMD), as well as software that operate as a medical device (SaMD). The guidelines will apply to all types of premarket submissions, including PMAs, 510(k), and De Novo filings. Feedback is due in 90 days.
  • Center for Devices and Radiation Health Center for Devices and Radiation Health published its proposed list of guidance documents to be released in fiscal year 2022. The list includes its priorities (A list) and guidance documents to be published as resources permit (List B). The CDRH will also conduct a retrospective review of policy documents for the years 1982, 1992, 2002 and 2012.

The content of this article is intended to provide a general guide on the subject. Specialist advice should be sought regarding your particular situation.

POPULAR ARTICLES ON: US Food, Drugs, Healthcare, Life Sciences

read more
Medical products

‘Huge economic blow’ as South Ayrshire medical products sites close with 75 jobs cut

Two sites of surgical wholesalers in South Ayrshire will close next year, putting 75 hardworking employees out of work.

Guardian Surgical’s facilities in Girvan and Ayr will close in 2022 with 75 jobs lost over the next four months.

The company – which produces single-use surgical drapes, gowns and tray wraps – announced this week that an internal process is underway as the company grapples with its future.

Now a spokesperson for the company has confirmed that an “extremely difficult decision” has been made due to a loss of key customers, “obstacles in the supply chain and an overall reduction in procedures. routine surgical procedures “.

Girvan’s site at Grangestone Industrial Estate on Ladywell Avenue will see 71 jobs cut while four jobs will be cut at the warehouse at Ayr’s Heathfield Industrial Estate on Whitfield Drive.

Girvan advisor Alec Clark said the news was “a real economic blow”.



Guardian Surgical sites in Girvan and Ayr to close, resulting in 75 job cuts

He said: “It’s not just people’s jobs, it’s a whole skill base that you are losing.

“What I cannot understand is that this is a profitable factory with a skilled workforce, providing quality medical items such as PPE, gowns and masks.

“For me it’s like equating it to McVitie’s factory in Glasgow when the Turkish owners closed it, even though it was a profitable factory and had its roots in Scotland.

“I think we’re in a situation here where this is where you find yourself facing the dangers of having external property and unfortunately that’s the position we find ourselves in.”

Guardian Surgical ran into trouble in April 2016, when staff received an internal memo revealing plans to cut costs by moving operations to China.

However, after a long period of consultation, the company announced in March 2017 that the jobs had been saved.



The Ayrshire Live app is available for download now.

Get all the local news in your area – plus features, football news and the latest information on the coronavirus crisis – right at your fingertips 24/7.

The free download features the latest breaking news and exclusive stories, while you can customize your page with the sections that interest you.

The Ayrshire Live app is available for download now on iOS and Android.

Cllr Clark said the South Ayrshire Council’s Economics and Regeneration team are “working in the background” and will be joining Scottish Enterprise, while he also raised the issue with Elena Whitham MSP’s office.

He said: “There was a joint approach before when there was some danger; therefore it is to be reviewed.

“I think we need the direct support of the relevant Scottish government minister here.

“We have been in contact with all the relevant agencies to make sure that we are exploring any alternatives.

“Is there an alternative to continue production here under different auspices? Is there a connection with someone else? Is there a skill set that can relate to another industry – whatever that can retain the workforce, the skills. and plant assets.

“We don’t want to let a skilled workforce be abandoned. We have an asset here and that asset needs to be nurtured and developed and hopefully retained.



Councilor Alec Clark
Councilor Alec Clark

“It is a real economic blow if this is lost, not just for Girvan but the whole region.”

A spokesperson for Rocialle Healthcare said: “After a six-week consultation period, we announced today, with heavy hearts, the closure of our two Scottish sites (responsible for the Guardian Surgical product) in 2022.

“This extremely difficult decision was made due to the continued downturn in site construction and the loss of key customers the company relied on to make the site operation commercially viable.

“With supply chain obstacles and an overall reduction in routine surgical procedures, there has been a significant impact on our order intake and forecasting models.

“As a result, we unfortunately confirm the loss of exactly 75 jobs over the next four months.

“This is a very emotional time for a group of longtime, loyal and committed staff and we will continue to do our utmost to provide support and assistance as we go through this difficult transition. “

Don’t miss the latest Ayrshire titles – sign up for our free daily newsletter here

read more
Medical products

Medical Products Supply Chain Week Review – October 28, 2021 – Food, Medicines, Healthcare, Life Sciences

United States: Medical Products Supply Chain Weekly Review – October 28, 2021

To print this article, simply register or connect to Mondaq.com.

Over the past week, the FDA’s Vaccines and Related Biologics Advisory Committee recommended authorization of the Pfizer-BioNTech vaccine for use in children 5 to 11 years of age. The CDC has officially approved the booster dose for Moderna and J&J vaccines. President Biden met with Dr. Robert Califf for the top FDA post. Please see details of these and other supply chain developments below:

  • On October 21, the CDC director approved the Advisory Committee on Immunization Practices (ACIP) recommendations for Moderna and J&J booster doses. The move comes after both vaccines received Emergency Use Clearance (EUA) from the FDA. The indication for the Moderna booster is administration six months after the end of the initial vaccination schedule at two doses for people aged 65 years and over, people aged 18 to 64 years with risk factors for serious disease and those whose profession puts them at risk. risk of exposure. For the J&J booster, the indication is administration two months after a first vaccination for all individuals aged 18 and over. The CDC has also approved FDA clearance to mix and match dosing from different manufacturers.
  • On October 22, President Biden met with Dr. Robert Califf to discuss the possibility of leading the FDA. Califf previously served as FDA Commissioner from February 2016 to January 2017. Califf is the Donald F. Fortin MD Distinguished Professor of Cardiology at Duke University School of Medicine. He is also the founding director of the Duke Clinical Research Institute and a member of the National Academy of Medicine. No official announcement was made.
  • On October 22, the administration announced that investments had been made in the manufacturing supply chain to expand the availability and use of home COVID-19 tests, including rapid tests. More recently, the FDA cleared the Celltrion DiaTrust COVID-19 Ag Home test, which is intended for use as a home test that can be used without a prescription. The FDA has also reissued the EUA for the Quidel QuickVue At-Home OTC COVID-19 test to include home use without a prescription. The Department of Health and Social Services and the Department of Defense have awarded more than $ 500 million in contracts to companies dedicated to this effort. The Authority has pledged to invest $ 3 billion by the end of the year. To date, 419 tests and specimen collection devices have received an EUA; however, only 15 home tests were authorized.
  • On October 26, the FDA’s Vaccines and Related Biologics Advisory Committee recommended granting an EUA for Pfizer-BioNTech’s COVID-19 vaccine for children ages 5 to 11. The two-dose regimen would be a lower dose (10 micrograms per vaccine) than vaccines used in people 12 years of age and older. If the FDA changes the EUA for the vaccine, ACIP will vote on the recommendations at its meeting on November 2-3, 2021.
  • On October 27, the FDA, Health Canada and the UK Medicines and Health Products Regulatory Agency jointly published 10 Guiding Principles for the Development of Good Machine Learning Practices (GMLP). The principles are intended to lay the foundation for international collaborative organizations (such as the International Forum of Medical Device Regulators) to advance the maturation of GMLPs.

The content of this article is intended to provide a general guide on the subject. Specialist advice should be sought regarding your particular situation.

POPULAR ARTICLES ON: Food, Medicines, Health Care, Life Sciences of the United States

read more
Medical products

Results of medical products actions on November 2: IDXX, STE and more

The latest earnings forecast reflects a stable quarterly performance for the medical industry so far this reporting cycle. According to the industry scorecard, 25.5% of companies in the medical sector, constituting nearly 47.6% of the industry’s market capitalization, reported profits until October 27. Of these, 78.6% exceeded profit estimates and 85.7% exceeded the same for income. Profits increased 19.6% year-on-year to revenues up 12.1%.

This scoreboard reflects the stability in the United States over the gradual reopening of the economy even amid the rise of the Delta variant. However, supply chain disruptions are still significant due to international restrictions in many geographies. In addition, many parts of the international market affected by COVID are still suffering due to declining cash flow and difficult economic conditions.

Overall, the medical sector’s third-quarter profits are expected to rise 19.5% on a sales increase of 12.6%. This compares to second quarter reported profit growth of 32.1% and revenue growth of 21.3%.

Quarterly synopsis of medical products

The dynamic nature of the COVID-19 crisis is rapidly transforming the landscape of the medical products industry. Growth in the collective operations of medical product companies (within the broader medical sector) improved significantly in the second quarter, with the phasing out of restrictions. But the third quarter reporting cycle has so far shown a steep sequential decline in the core business inherited from the companies.

However, thanks to fiscal and monetary stimulus measures and the mass vaccination campaign inside and outside the country, the process of reopening the economy has never stopped. The current reporting cycle shows that hospital visits and core hospital activities slowed temporarily in July and August, but picked up sharply in September.

On the other hand, with the increase in the number of cases, manufacturers of tests, vaccines and therapeutics have seen massive market adoption of their COVID-related health care support products and services in the third quarter. trimester.

Specifically, the third quarter results for medical product inventories so far have shown a temporary decline in baseline activity compared to the second quarter. At the same time, inventories of diagnostic tests, which had seen a slowdown in demand for COVID-19 tests in the second quarter, picked up momentum in the third quarter, in line with industry trends.

Zacks’ medical products business is currently ranked in the bottom 38% (156 out of 254 industries).

Let’s take a look at four medics players who are expected to report their results on November 2.

IDEXX Laboratories, Inc. IDXX: In the third quarter, IDEXX’s Companion Animal Group (CAG) business is expected to have benefited from consistent and healthy organic revenue growth, supported by strong organic growth in recurring CAG diagnostics revenue in the United States. United and internationally. Robust growth in clinical activities in the United States is likely to have contributed to CAG Diagnostic’s recurring revenue gains in the United States. When releasing its second quarter results, the company noted 13% growth in clinical visits to the United States, with strength in the “non-wellness” and “wellness” visit categories. The CAG branch likely benefited from organic growth in revenues from CAG diagnostic instruments, as it did in the previous quarter. (Learn more: IDEXX to Report Third Quarter Revenue: What’s in the Cards?)

Zacks’ consensus estimate for third quarter earnings per share is set at $ 1.88. Revenue is expected to be $ 793.3 million.

IDEXX has the right combination of two key ingredients – a positive winning ESP and a Zacks # 3 (Hold) or better ranking – which increases the odds of a winning winning streak.

The company has + 2.77% ESP revenue and Zacks # 3 rank.

You can discover the best stocks to buy or sell before they are flagged with our ESP Earnings Filter.

You can see The full list of Zacks # 1 Rank (Strong Buy) stocks today here.

IDEXX Laboratories, Inc. Price and EPS Surprise

IDEXX Laboratories, Inc. price-eps-surprise | Quote IDEXX Laboratories, Inc.

STERIS plc STE: The Applied Sterilization Technologies (AST) arm of the company likely benefited from increased customer demand for medical devices in the second quarter of fiscal 2022, as it did in the previous quarter. The company expects this branch to remain strong as its major medical device customers continue to benefit from the rebound in procedures and some inventory replenishment. Additionally, demand for COVID-related products and vaccines as well as disposables for bioprocess manufacturing is expected to remain strong, which will benefit the AST arm. (Read More: STERIS to Announce Q2 Revenue: What’s in the Cards?)

Zacks’ consensus estimate for the second quarter of fiscal 2022 is set at earnings per share of $ 1.83. Revenue is expected to reach $ 1.16 billion.

The company has ESP income of 0.00% and Zacks Rank 2 (buy).

STERIS plc Price and EPS Surprise

STERIS plc Price and EPS Surprise

STERIS plc price-eps-surprise | STERIS plc quote

Henry Schein, Inc. HSIC: According to Henry Schein’s August 2021 update, the company has seen increased demand in the global dental and medical markets for the gradual reopening of practices and stable patient traffic around the world over the course of recent months, even in countries with stricter foreclosure rules. This recovery trend is expected to continue throughout the third quarter of 2021, thus increasing the company’s turnover. (Read more: What’s next for Henry Schein in third quarter results?)

Zacks’ consensus estimate for the third quarter is set at 94 cents per share. Revenue is expected to reach $ 2.94 billion.

The company has an ESP on earnings of +1.06% and a Zacks # 2 rank.

Henry Schein, Inc. Awards and EPS Surprise

Henry Schein, Inc. Awards and EPS Surprise

Henry Schein, Inc. price-eps-surprise | Quote from Henry Schein, Inc.

Omnicell OMCL: In recent months, Omnicell has benefited from the strength of its business model and its strategic positioning in the market. In the midst of the pandemic, the corporate healthcare system and retail pharmacy customers have shown greater acceptance of the fully self-contained pharmacy. As a result, demand for Omnicell’s end-to-end automation solutions has grown. The company, in August, said it was on track to meet its five-year target company goal initiated earlier this year. All of these developments are expected to have contributed significantly to the company’s revenue in the third quarter of 2021.

Zacks’ consensus estimate for third quarter earnings per share is set at 91 cents. Revenue is expected to be $ 283.8 million.

The company has an ESP on earnings of 0.00% and a Zacks # 2 rank.

Omnicell, Inc. Awards and EPS Surprise

Omnicell, Inc. Awards and EPS Surprise

Omnicell, Inc. price-eps-surprise | Omnicell Quote, Inc.

Boom in infrastructure stocks will sweep America

A massive push to rebuild crumbling American infrastructure will soon be underway. It is bipartisan, urgent and inevitable. Billions will be spent. Fortunes will be made.

The only question is, “Are you going to jump into good stocks early when they have the greatest potential for growth?” “

Zacks published a special report to help you do just that, and today it’s free. Discover 7 special companies looking to make the most of the construction and repair of roads, bridges and buildings, as well as transporting goods and transforming energy on an almost unimaginable scale.

Download FREE: How to Profit from Billions of Dollars in Infrastructure Spending >>

Click to get this free report

Omnicell, Inc. (OMCL): Free Stock Analysis Report

Henry Schein, Inc. (HSIC): Free Stock Analysis Report

IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report

STERIS plc (STE): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks investment research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

read more
Generic drugs

Generic Drugs Authorized “Insufficient” to Improve Affordability of Medicare Part D

20 October 2021

2 minutes to read

Source / Disclosures

Disclosures: The authors do not report any relevant financial disclosures.


We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact [email protected]

Generic drugs licensed for insulin and direct-acting antiviral agents may reduce out-of-pocket expenses for patients, but are unlikely to save money for Part D plans or Medicare, according to the data.

“Compared to brand name drugs, authorized generic versions of direct-acting antiviral agents for hepatitis C and insulin are said to have resulted in lower out-of-pocket expenses for Medicare beneficiaries.” Stacie B. Dusetzina, PhD, associate professor of health policy and Ingram associate professor of cancer research at Vanderbilt University School of Medicine in Nashville, Tennessee, and colleagues wrote in JAMA Internal Medicine. “However, coverage for authorized generic drugs was limited for some Part D beneficiaries, with many beneficiaries covered by plans covering only brand name drugs. For Part D plan sponsors, this decision likely reflects rational economic behavior, as the net prices (after rebates) of brand name drugs in these classes may be similar to or lower than the net prices of authorized generic drugs.

Various colorful pills
Source: Adobe Stock

As Healio previously reported, manufacturers of insulin and direct-acting antiviral agents for the treatment of hepatitis C have recently introduced authorized generic alternatives to their patented branded products at a time when brand name drugs faced no immediate threat of generic competition. Authorized generic drugs have list prices at least 50% below the list price of brand name drugs; the announcements followed close scrutiny in Congress on high drug prices.

In a cross-sectional study, Dusetzina and colleagues analyzed data from the Medicare Prescription Drug Plan form and third quarter 2020 pricing information files and Medicare Part D enrollment for September 2020. Researchers assessed the coverage of four branded formulations of direct-acting insulin and antivirals and their authorized generic formulations: sofosbuvir and velpatasvir fixed-combination tablets (Epclusa, Gilead), ledipasvir and sofosbuvir tablets (Harvoni, Gilead), insulin lispro (Humalog, Eli Lilly) and insulin aspart (Novolog, Novo Nordisk).

“We selected these drugs because we believe they are the only ones to have launched generic formulations authorized more than a year before the expected expiration of the patent and have faced no traditional generic competition in the third quarter of 2020. “the researchers wrote.

The main results were the weighted coverage of the formulary by beneficiaries of branded products and authorized generics; disbursements by the beneficiary; and the prepayment plan, manufacturer and Medicare expenses on branded products and authorized generics.

As of the third quarter of 2020, 97% of beneficiaries were on plans that covered only brand name drugs or both brand name drugs and authorized generics. About 3% of beneficiaries were on plans that covered only authorized generic drugs.

The researchers found that the list prices of authorized generic drugs were 67%, 62% and 50% lower than the list prices of Epclusa, Harvoni and each branded insulin product, respectively. “Medicare beneficiaries using licensed generics could save $ 270 per year for 12 vials of Humalog and $ 2,974 for a full treatment of Harvoni,” the researchers wrote.

The plans, however, have limited incentives to encourage the use of authorized generics; discounts for brands likely exceed savings available with authorized generics, especially for beneficiaries whose spending reaches the Medicare Part D coverage gap.

“Ultimately, the availability of licensed generic options for products that do not face traditional generic competition is insufficient to improve affordability for Medicare beneficiaries,” the researchers wrote. “The results of this study suggest that efforts to change Medicare Part D benefits should also ensure that incentives for plans and beneficiaries are properly aligned and that beneficiaries are not paying too much for drugs that are better.” value for their health plan and Medicare program. “

read more
Medical products

Medical Products Supply Chain Weekly Review – October 2021 # 1 | Alston & Bird

Last week, AstraZeneca and Merck filed Emergency Use Authorization (EUA) applications for their COVID-19 drugs. The FDA has provided information to the public on a database repository of genetic variants and associated conditions. The United States, along with 135 other countries, have agreed to an overall minimum tax of 15%. Please see details of these and other supply chain developments below:

  • On October 5, AstraZeneca filed an EUA application for its COVID-19 long-acting antibody (LAAB) prophylaxis, AZD7442, composed of tixagevimab and cilgavimab. Although the LAAB combination is under investigation for prophylactic and therapeutic purposes, the EUA’s request was for its prophylactic use against symptomatic COVID-19. Two phase III trials have shown a reduction in the relative risk of symptomatic COVID-19 by 77% and 33%. The data suggests that the drug is also effective against variant strains. On October 11, AstraZeneca also released a press release revealing high-level results from another Phase III trial. The trial showed a reduction in the rates of severe COVID-19 or death in the treatment group, compared to the placebo group, in out-of-hospital participants with mild to moderate symptoms.
  • On October 5, the FDA released a final rule on the De Novo medical device classification process. The rule establishes procedures and criteria for submitting and withdrawing a De Novo application and how the FDA will assess the application. Based on the new rule, the agency updated the following guidance documents:
    • The final guidelines “FDA and Industry Actions on De Novo Classification Requests: Effect on FDA Review Clock and Goals” provide sponsors with information on decision points and deadlines that the FDA will meet when reviewing a De Novo application. .
    • The final guide “De Novo Classification Process (Evaluation of Automatic Class III Designation)” provides guidance to sponsors whose device is automatically classified as Type III based on a determination that the device was not substantially equivalent to a predicate device via process 510 (k).
    • The final guide “Usage Fees and Refunds for De Novo Classification Requests” provides sponsors with information on De Novo classification requests requiring a fee, requests that are exceptions, and the refund process.
  • On October 7, the FDA’s Center for Devices and Radiological Health released a Description of Public Human Genetic Variant Databases, a repository of genetic variants and related diseases or conditions. The FDA’s goal is to help manufacturers develop tests for these diseases or conditions by providing FDA-recognized databases that contain data and claims, which can be used to support regulatory review of the FDA. The FDA considers the available databases to be scientifically valid.
  • On October 8, the United States, along with 135 other countries, approved an overall minimum corporate tax rate of 15%. Multinational companies have transferred their business infrastructure and interests to foreign countries with the lowest tax requirements. Countries with a stricter tax code, such as the United States, may benefit. The goal is to keep business interests in their home country and boost local economies.
  • On October 11, Merck filed an EUA application for its COVID-19 oral antiviral drug, molnupiravir. The request comes after interim results from the Phase III clinical trial demonstrated a positive benefit: severe hospitalization and death rates were reduced in the treatment group. If approved, the drug would be the first oral antiviral drug to treat COVID-19 that patients can take at home.
  • On October 12, the FDA announced it was withdrawing three guidance documents: “Temporary Policy for the Preparation of Certain Alcohol-Based Hand Sanitizers During Public Health Emergency (COVID-19)”, “Policy for the temporary composition of certain alcohol-based products for the hands Disinfectant products during a public health emergency” and “Temporary policy for the manufacture of alcohol to be incorporated into disinfectant products for the hands based on alcohol during the public health emergency (COVID-19). ”The manufacture of affected products must cease by December 31, 2021 and distribution by March 31, 2022. The agency determined that the urgent need to temporary orders no longer exist as the supply of alcohol-based disinfectants by “traditional” manufacturers can meet demand.

[View source.]

read more
Generic drugs

Generic drugs are cheaper in the US, but quality control can be a problem, says professor | WFAE 90.7

Every week through October, we examine the medical, business, and cultural systems that contribute to the dichotomy that is America’s healthcare system — a system that benefits some but costs us all.

Today we are looking at generic drugs. You may have heard that they are cheaper than brand name drugs and they are just as good, right? Well, changes are afoot in the industry that are testing this long held theory. Dr. Kevin Schulman is a professor of medicine at Stanford University and has studied this question extensively.

Marshal Terry: Welcome.

Kevin Schulman: Thank you very much for inviting me.

Terri: Conventional wisdom has long held that generic drugs are the same as brand name drugs. Is this assumption wrong?

Schulman: They are the same chemical entity. What we learn is that over time, the question we ask ourselves is the quality of the drugs. How are they made? Are they made to the same standards as the original brand name drug?

Terri: And what is the answer to that?

Schulman: Unfortunately, we find that often they fail. There are large classes of drugs — generic drugs — that have been recalled in the past two years because they contain carcinogens that were not suitable for drugs. And that just opens up the question: what’s going on in the generic drug market? How do we understand both the price and the quality of the drugs we receive?

Terri: Well, what’s going on with the generic drug market? What leads to this?

Schulman: Thus, the idea of ​​generic drugs dates back to 1984 with what is called the Hatch-Waxman Act. At the time, the idea was to allow generic drugs into the US market to drive down the price of drugs, and it was mostly a price-driven set of issues. And it worked very well. In 1984, the generic drugs we got in the United States were mostly made in the United States and Europe. Today, these drugs are made overseas – maybe in India, maybe in China.

Our ability to regulate these manufacturers is very different, and the market itself has really changed dramatically. We had a huge concentration of intermediaries in the market — the drug distributors. And this puts enormous pressure on manufacturers’ prices. So today, yes, generic drugs are the cheapest ever. Sometimes the really important drugs are pennies. But this is purely a price market. There is no quality assessment. It’s like going to Amazon and saying, “Give me the cheapest good in any category without the quality rating.” And we all know what that leads to.

Terri: You said more of these generic drugs are now being made outside the United States — overseas, in places like China and India. How much more common is that?

Schulman: Around 2005, 2007, about 50% of all generic drugs in the United States were made overseas. And I think now…the majority of them are made overseas. There are different parts of the drug. The chemicals that go into the drug are almost all made overseas. And then whoever packages the drug and takes those active pharmaceutical ingredients and makes it into a pill or a tablet or a capsule—that’s also usually overseas.

“Yes, generic drugs are the cheapest they’ve ever been. Sometimes the really important drugs cost pennies. But it’s purely a price bargain. There’s no quality assessment. “

— Dr. Kevin Schulman, Professor of Medicine at Stanford University

Terri: Now, you mentioned that one of the concerns with this shift to more of these foreign-made drugs was a quality control issue. And the countries you mentioned—two of the biggest countries where these drugs are made, India and China. What is the scope of the FDA in regulating these drugs manufactured in these countries?

Schulman: Our FDA has the ability to audit US factories. What he needs to do is ask governments for permission to audit factories in India and China. In the United States we have secret inspections. The FDA shows up right at your doorstep and wants to inspect the plant. In India and China, he must ask permission and notify manufacturers that he is coming.

But more broadly… The FDA only inspects every two years. Meanwhile, the FDA has no idea what’s going on at an individual manufacturing plant. I mean, it’s no different than what we’ve seen in other industries that have outsourced. The idea of ​​the FDA monitoring all potential sources of molecules for the US market is really, really hard to imagine.

Terri: Do these countries themselves have organizations equivalent to the FDA? Do they have their own version? And if they do, do they meet the same standards as our FDA?

Schulman: They have nascent institutions that are not at the same level as the United States. I don’t know how big the Chinese FDA was, but a few years ago it was 100 people. The problem here is the supply chain.

You would think that you would test some of these drugs — the suppliers would test or the distributors would test the drugs to make sure that the ones they dispense say what is on the label and that they are of good quality. Unfortunately, what we have seen is that this is not true. And the recalls that happened with these carcinogens in metformin and ranitidine – metformin is a first-line treatment for diabetes, and the FDA eventually recalled 40% of all drugs on the market because of these carcinogens. But the only way we found out about this was actually through a third-party testing organization looking into the issue.

So what’s happening today is that every new manufacturer of a generic drug has to offer a lower price to enter the market. And so prices have dropped, which is a good thing. But again, there is no quality consideration. And so, at a certain point, the market price is lower than the price that a high-quality producer can produce, and people leave the market. And so now we have this market where it’s basically the cheaper manufacturers that are supplying the drugs to the United States.

Terri: What can Americans do now to verify the quality of their generic drugs? Is there anything they can do?

Schulman: Unfortunately, at the moment there is really nothing they can do. But we can go back and say, “We don’t want to tolerate this. If we are paying for a medicine at a pharmacy, we want that pharmacy to assure us that it is a medicine that is made safely and of the highest quality, not the cheapest medicine available that they could find .

Terri: You support a generic drug rating system, similar to the ratings you see on Amazon.com. Even if we had a rating system that assigns, you know, one star, two stars, etc., can you really rate a pill the way you would, say, a vacuum cleaner or a toaster?

Schulman: Absoutely. I mean, there are very specific parameters. Is the dose on the label the actual dose? The quality of the pill, in terms of contaminants, is the quality of the pill there? And then are there other chemicals in the pill that you don’t want in the pill, like those carcinogens that have been found? So I think we can assess it. We can rate it as yes/no. Does it match the label? Is it within the standards? Or we can rate it 1-5. I think it is possible to do one or the other.

It’s really important not to scare off the American public. It is very important to take your medications. But if for a month your high blood pressure pill doesn’t work or you feel really bad when you take your medicine that you’ve been taking for a long time and you wonder if there’s something wrong with the pill, the only thing that I would say that it is quite possible these days that there is something wrong. You can go back to the pharmacy, get another manufacturer, and you can also ask the pharmacy, “Why don’t you give me a quality rating on this drug and a price?” »

Terri: Thank you for taking the time.

Schulman: Thank you very much.

Terri: Dr. Kevin Schulman is a professor of medicine at Stanford University and has extensively studied the changes affecting the generic drug industry.

read more
Medical products

Operations | Medtech | Pharmaceutical and medical products

We offer a suite of proprietary tools and methodologies to optimize technical systems, develop management infrastructures and promote good behavior and mentality. Here are examples of some of these tools we use to complement our work:

Comparative analysis of medical devicesMT: Diagnostic and transformation tool for manufacturing, supply chain, quality, purchasing and organization, with over 50 customizable metrics per module that give insightful recommendations for actionable opportunities.

Model factories: A global network of nine Capacity Centers that provide over 150 online and in-person leadership and skills development training in product development, procurement, supply chain management, service operations and performance management. Learn more about model factories.

Suite of complexity management solutions: A diagnostic suite using advanced analytics to assess the complexity of a medical technology firm’s portfolio and the in-game value of optimizing and improving management, and provide actionable recommendations. It includes tools like Complexity Fingerprint, Wallet X-ray, Complexity Cost Calculator, Wallet Setup, and Complexity Cockpit.

Design to Value (DtV) and Cleansheet Solution ™ Laboratories: Our engineering centers of expertise where competitive product teardowns and cost modeling are performed to strengthen customer focus and help reduce time to market and product costs. Our Cleansheet Solution ™ helps establish cost transparency, analyze cost drivers, calculate target cost and reap those benefits. Learn more about Design to Value and Cleansheet Solution.

Purchasing centers: Our global sourcing centers located in Brazil, China, Eastern Europe, India and Mexico using our Global Sourcing Information Exchange (GSIE) database help identify suppliers in low cost countries. Learn about innovation, design and development, productivity, agility and automation, and quality, compliance and remediation.

read more
Generic drugs

The generic drug market is witnessing the emergence of Amgen Inc. and Dr. Reddys Laboratories Ltd. as major market contributors | 17000 + Technavio


Understand the driving forces of the Generic Drugs market and target potential customers here.

Get a free sample report!

Technavio analysts curated the reports thoroughly through qualitative and quantitative research methodologies to yield the most relevant industry and business results.

Businesses around the world are focused on creating a resilient business model in the face of COVID-19. Suppliers are continuing their ongoing operations while building resilient business models as the path to recovery from the pandemic is being charted.

The recovery process involves different phases including:-

  • Recognize the existing business model
  • Focus on agile execution of proposed and approved changes.
  • Conceptualize scenario-based planning to mitigate future crisis situations.

Download the post-pandemic activity planning structure

Key Considerations for Market Forecast:

  • Impact of lockdowns, supply chain disruptions, demand destruction and changing customer behavior
  • Optimistic, probable and pessimistic scenarios for all markets as the impact of the pandemic unfolds
  • Market estimates before and after COVID-19
  • Quarterly impact analysis and updates on market estimates

Access in-depth syndicated research reports on demand using Technavio’s subscription platform

The Technavio SUBSCRIPTION platform

Related reports:

Human Microbiome Therapeutics Market Report – The human microbiome therapeutics market has the potential to grow USD 516.08 million during the period 2021-2025, and the growth momentum of the market will accelerate at a CAGR of 47.79%.Download a free sample report now!

Human Combination Vaccines Market Report – The human combination vaccines market has the potential to grow in $7.16 billion during the period 2021-2025, and the growth momentum of the market will accelerate at a CAGR of 8.80%. Download a free sample report now!

Analysis of the main players in the market

  • Amgen Inc. – The company offers a wide range of generic drugs like Aimovig, Corlanor, Epogen, Xgeva and others.
  • Dr.Reddys Laboratories Ltd. – The company offers affordable generic formulations such as Omez (Omeprazole), Nise (Nimesulide), Ketorol (Ketorolac Thromethamine) and others
  • Fresenius SE and Co. KGaA – The company offers generic drugs for areas such as anesthesia, maldigestion and oncology

If you purchase an updated report within the next 60 days, we’ll send you the new edition and data extract FREE! Get a preview of the report here to get a detailed market share analysis of market players during the COVID-19 lockdown:

https://www.technavio.com/report/generic-drugs-market-industry-analysis

Generic Drugs Market 2021-2025: Segmentation

The generic drugs market is segmented as follows:

  • Type
    • Small Molecule Generics
    • Biosimilars
  • Geography
    • North America
    • Europe
    • Asia
    • LINE


The generic drug market is driven by increased outsourcing of drug discovery and development and increasing drug patent expirations. Additionally, other factors such as the advent of RPA, increase in mergers and acquisitions, and hospital-owned generics are expected to drive the generic drugs market.

Plan and reinforce your sales and marketing strategies: https://www.technavio.com/talk-to-us?report=IRTNTR44584

Market factors
Market challenges
Market trends
Supplier Landscape

  • Suppliers Covered
  • Ranking of suppliers
  • Positioning on the supplier market
  • Competitive scenario

About Us
Technavio is a global leader in technology research and consulting. Their research and analysis focuses on emerging market trends and provides actionable insights to help companies identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialist analysts, Technavio’s reporting library consists of over 17,000 reports and counts, spanning 800 technologies, spanning 50 countries. Their customer base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing customer base relies on Technavio’s comprehensive coverage, in-depth research, and actionable market intelligence to identify opportunities in existing markets and potentials and assess their competitive positions in changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Manager
USA: +1 844 364 1100
UK: +44 203 893 3200
E-mail: [email protected]
Website: www.technavio.com/

SOURCETechnavio

read more
Generic drugs

OP-ED: Americans deserve public generic drugs – Orange Leader

Bold policies could have saved America’s largest generic drug factory, but it’s never too late to start putting communities first.

It’s an all-too-familiar story. A company with some of the highest paying jobs and a vital community anchor decides to engage in “restructuring” to “maximize long-term value creation”.

In other words, it closes its doors and lays off its workers in search of bigger profits.

But the late July closure of the Viatris pharmaceutical plant in Morgantown, West Virginia – which employed nearly 1,500 people and was the largest remaining generic pharmaceutical plant in the United States – is particularly infuriating.

West Virginia Governor Jim Justice echoed a sentiment across the political spectrum when he said Aug. 4, “I think it’s pitiful, pitiful, absolutely pitiful that our federal government right now, with something as critical as pharmaceuticals are to our citizens, either just decide to sit on the sidelines and let this disaster happen.

The shutdown was only preventable – if there had been federal or state action based on prioritizing protecting public health and economic well-being over short-term shareholder returns. We had the tools. All that was needed was the audacity and the political will to use them.

The chain of events began in 2020 when factory owner Mylan (led by Heather Bresch, daughter of West Virginia Senator Joe Manchin) merged with Upjohn to form a new company, Viatris, creating the largest generics company in the world. Shortly after, Viatris announced a “restructuring initiative” which included closing some of its plants, including the Morgantown plant.

The local Steelworkers representing many workers at the plant began calling on both the new Biden administration and state officials to keep the plant open. Their key argument was its role in the country’s pharmaceutical supply chain, especially in the context of the COVID-19 pandemic. The plant produced 18 billion doses of low-cost generics a year, including many essential drugs paid for through various federal programs.

A letter to the Biden administration signed by the Steelworkers and about 40 other healthcare and advocacy groups (including The Democracy Collaborative, where I work) called for using the Defense Production Act to stop the plant shutdown .

One of President Biden’s first executive orders called for using the law if necessary to “acquire additional inventory, improve distribution systems, build market capacity, or expand the industrial base.” But the Biden administration, like the Trump administration before it, did none of that in Morgantown.

Keeping the Morgantown plant open would have been a clear case of ensuring local distribution and manufacturing capacity for a critical good: medicine. The designation the plant has already received from the Department of Homeland Security as critical infrastructure underscores this.

The opportunity to explore a public ownership option in pharmaceuticals has been overlooked. Public enterprises are free from profit constraints and can instead define their bottom line by what they contribute to public health, scientific advancement, and local economic resilience.

The payoffs for our communities would be enormous: Reliable access to affordable generics helps keep people out of hospitals and into jobs, schools and community service roles. Generics significantly reduce our overall health care costs. Additionally, manufacturing plants are vital economic engines as well as centers of local intellectual capital.

It is encouraging that a public institution, West Virginia University, announced talks with Viatris to acquire the plant, but that was after hundreds of highly skilled workers were unnecessarily laid off, most of whom are eager to see if an agreement is reached before looking for New work.

What we really need in the face of continued outsourcing and offshoring is a genuine industrial strategy that includes public ownership and puts community health above the demands of absentee shareholders.

Dana Brown is director of the Next System Project of The Democracy Collaborative, “a research and development laboratory for the democratic economy”. This editorial was distributed by OtherWords.org.

read more
Medical products

Advancing next-generation medical products

Photos courtesy of Avient Corporation, © 2021

An aging population and the growing threat of emerging infectious viral diseases, such as COVID-19, mean that global healthcare is an extremely important problem and is changing dramatically and dynamically. To respond to these changes, a new generation of specialized and sustainable medical equipment solutions is emerging. Read on to learn more about the evolution of this industry and to explore an example of medical device innovation.

If you haven’t seen a doctor in person since the onset of the coronavirus pandemic, you are not alone. Telemedicine and on-demand care have exploded over the past 12 months and are two of many growing trends in global healthcare. Another trend in the era of increasing personalized medicine is the development of biologic pharmaceuticals. A rapidly growing market, the revenues of biologic pharmaceutical companies have increased by 70% over the past five years, to more than US $ 232 billion.[i]. Yet the high doses required by patients for biologic therapies can present very real challenges for drug delivery.[ii]. Whatever the trend and in all directions in which healthcare develops, the goal is always to protect and improve the lives of patients.

Plastics in medical devices and pharmaceutical packaging increasingly play a vital role in providing safe treatments and their use is expected to increase further. This can be attributed to the fact that they offer design freedom, protection, convenience and functionality that few other materials can match. Globally in 2020, approximately 7.6 million tonnes of plastics were used in healthcare applications[iii] and this is expected to grow by around 8.6% from 2020 to 2027. Companies supplying plastics to the healthcare market must have in-depth knowledge of the industry, as well as advanced technical and design capabilities, to develop innovative solutions that truly respond to their customers. challenges.

Let’s take a look at an example of an innovative solution – a conceptual auto-injector, where the new generation meets industry trends for the functionality and aesthetics of surfaces.

Auto-injectors are a great example of innovation, bringing more convenience and control to the lives of patients. Playing on trends in telemedicine, on-demand care and biologics, they offer self-management and drug administration, technology-driven monitoring and diagnostics, as well as the ability to deliver increased volumes of drugs. and large molecule biologics.

This study example describes a conceptual auto-injector developed by Avient – a new materials company born from two historical leaders, PolyOne and Clariant Masterbatch. It will illustrate how Avient has used innovative materials, design and technological services to accelerate the development of next generation products.

Photos courtesy of Avient Corporation, © 2021

The injection window and cap of an autoinjector require excellent clarity, scratch resistance, and exceptional toughness for visualizing drug levels. In this study, an anti-UV additive was used to protect the drug contents from harmful UV rays without sacrificing clarity or transparency. Next, a dynamic masterbatch formulation (MEVOPUR ™ medical grade dyes) was used to enable product differentiation, better drug identification and consistent branding. MEVOPUR colors highlight the cap, button, lot ID / SKU, trigger and plunger. The raw materials were tested against common pharmaceutical standards to ensure that the devices would be safe and compliant from a regulatory point of view.

On the body of the autoinjector, a laser marking additive has been used to enable inkless marking, with no surface pretreatment required, thus avoiding solvent residue. The additive provided reliability and process improvement over traditional marking technologies and improved design possibilities due to the absence of physical contact with the marking system. This type of laser marking functionality can be combined with other functions or dyes to meet performance and aesthetic needs. In addition, to combat the increase in counterfeit drugs and devices in the healthcare industry, Avient has also developed a comprehensive plastic solution that protects against counterfeiting, while enabling medical device companies to ensure the integrity. supply chain with low impact on productivity and operations.

For the integrated rigid needle guard and device cap, biocompatibility, durability and overmolding are essential. A medical grade TPE (Versaflex ™ HC TPE) replaced rubber, with sealing properties to prevent needle contamination and oxygen contact with drugs in pre-filled syringes. These TPEs are USP VI tested and chemical resistant with low extractability and no tearing.

The viscosity of the drug has a direct impact on the pain of patients during drug administration. Therefore, the device’s heating system and heat exchanger used thermally conductive formulations to help heat and reduce the viscosity of biologic drugs.

Technology is transforming the way care is delivered by making it simpler, easier, more collaborative and more data-driven. This conceptual auto-injector is a demonstration of how next-generation materials and design expertise can truly improve a finished device.

If you would like more information on this application study, or on Avient materials and colorant / additive technologies, please visit avient-help.com.


[i] https://www.iqvia.com/-/media/iqvia/pdfs/nemea/uk/disruption_and_maturity_the_next
_phase_des_biologics.pdf
[ii] https://pubmed.ncbi.nlm.nih.gov/26277263/
[iii] https://www.grandviewresearch.com/industry-analysis/medical-plastics-market

Content sponsored by Avient Corporation

read more
Medical products

Aptar Reaches Agreement with Weihai Hengyu Medical Products to Add Elastomeric and Plastic Component Manufacturing Capabilities in China for Injectable Drug Delivery

CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product delivery and active materials science solutions, today announced that it has entered into an agreement to acquire 80% stake in Weihai Hengyu Medical Products Co., Ltd., one of China’s leading manufacturers of elastomeric and plastic components used in the delivery of injectable drugs.

This acquisition supports Aptar’s strategic priority of building its capabilities in high-growth economies such as China, and enhances the company’s ability to meet changing local market needs, which include regional manufacturing, a well-integrated supply chain and proximity to customers and their patients. . By adding local manufacturing capability, this acquisition allows Aptar to capitalize on the growth potential of the Asian region, while strengthening the company’s ability to serve local and global customers in the injectable drug market with the best products and services in their category, a competitive lead in time and technical support, while relying on Aptar’s global network.

Commenting on the transaction, Stephan B. Tanda, President and CEO of Aptar, said:This acquisition of a majority stake is a strategic step that strengthens our competitive position in Asia and in the fast-growing market for the administration of injectable drugs. This transaction will respond to our disciplined investment approach and Hengyu’s capabilities are complementary to our growing portfolio of injectable solutions.

Xiangwei Gong, President of Aptar Asia, added:The acquisition of Hengyu will be another critical step in executing Aptar’s strategy in Asia, which targets growth in all of our core markets, including the injectable drug delivery market. We foresee strong and sustainable long-term growth in this critical application area in Asia, as more patients are prescribed drugs in injectable form for their safety, efficacy, availability and affordability.

Wang Yingye, co-founder of Hengyu, said, “Aptar is a global leader in drug delivery solutions. Hengyu shares the same vision as Aptar – to be an expert in drug delivery, providing unique, high quality products to the healthcare industry. We are delighted to have Hengyu join Aptar’s large manufacturing footprint in China and Asia.

Gaël Touya, President of Aptar Pharma, said: “We look forward to adding Hengyu’s manufacturing capacity, capabilities and expertise to our global manufacturing network to continue to be close to customers and their patients as they deliver life-saving and essential treatments every day. improve life. With the expertise of the Aptar Pharma and Hengyu teams, we will set up a new center of excellence in the region.

Located in Weihai, a coastal city in Shandong province in eastern China, Hengyu designs and manufactures elastomer and plastic components used in the delivery of injectable drugs. Hengyu was founded in 1998 and has approximately 150 employees at its factory in Weihai.

Under the terms of the agreement, Aptar will have the option to acquire the remaining 20% ​​stake in Hengyu on the fifth anniversary of the closing of the initial majority investment. The transaction is subject to customary regulatory approvals and is expected to close by the end of the third quarter of 2021. The transaction is not expected to have a material impact on adjusted earnings per share in 2021 or 2022.1. The purchase will be financed with available cash.

1Adjusted earnings per share is a non-GAAP financial measure. Additional information regarding this measure is available on the Company’s website at aptar.com on the Investors page (click Events and Presentations for a reconciliation of non-GAAP financial measures).

About Aptar

Aptar is a global leader in the design and manufacture of a wide range of drug delivery, consumer product delivery and active materials science solutions. Aptar’s innovative solutions and services serve a variety of end markets, including pharmacy, beauty, personal care, home, food and beverage. By using proprietary knowledge, design, engineering and science to create dispensing, dosing and protection technologies for many of the world’s leading brands, Aptar is in turn making a meaningful difference in the life, look, health and the homes of millions of patients and consumers around the world. . Aptar is headquartered in Crystal Lake, Illinois, and has 13,000 dedicated employees in 20 countries. For more information, visit aptar.com.

This press release contains forward-looking statements, including with respect to the potential acquisition of Hengyu and the anticipated effects of the acquisition. Future or conditional expressions or verbs such as “will”, “would” and “expect” are intended to identify these forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information we currently have. Accordingly, our actual results may differ materially from those expressed or implied by such forward-looking statements due to known and unknown risks and uncertainties that exist in our operations and business environment, including, but not limited to : the satisfaction of the closing conditions of the acquisition; the expected benefits of the acquisition; the successful integration of Hengyu; the regulatory environment; and competition, including technological advances. For more information about these and other risks and uncertainties, please see Aptar’s filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Aptar’s Forms 10-K and 10-Q. Aptar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

read more